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ABSTRACT

Locally advanced breast cancer (LABC) represents 15% of all non-metastatic
breast cancers, with an overall poor prognosis, despite current guidelines that
recommend neoadjuvant chemotherapy followed by surgery and adjuvant
radiation. Therefore, a novel treatment paradigm using concurrent neoadjuvant
chemoradiotherapy was proposed. A clinical trial was designed, where 32 LABC
patients

were

treated

with

q3

weekly

5-fluorouracil,

epirubicin

and

cyclophosphamide for three cycles, followed by weekly docetaxel for 9 weeks
with concurrent regional radiation (45+5.4Gy) for the first 6 weeks. Patients
subsequently underwent modified radical mastectomies. Pathological complete
responses (pCR) and 3 year overall survival rates were compared to a matched
concurrent control cohort. The concurrent chemoradiation cohort saw a
significant increase in pCR rate and a trend toward 15% improvement in overall
survival that failed to reach statistical significance. This regimen was not without
toxicity, and 25% of patients experienced grade 3 or greater dermatitis and 25%
experienced grade 3 or greater pneumonitis, resulting in one death. Tumour
biomarker, plasma osteopontin, prior to chemotherapy was found to significantly
predict for overall survival. In conclusion, LABC is an aggressive subset of breast
cancer for which novel regimens must continue to be developed, taking
advantage of the improved response to treatment with radiosensitivity seen in

ii

this concurrent chemoradiation regimen, but using alternative radiosensitizing
agents to minimize toxicity.
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CHAPTER 1

General Introduction and Literature Review

Portions of this chapter were adapted from a published manuscript in which M.
Brackstone was a co-author: Mandilaras V, Bourginam N, Spayne J, Dent R,
Aranaout A, Boileau FJ, Brackstone M, Meterissian S, Clemons M. Current
Oncology 2015, vol. 22(1): 25–32. Reproduced with permission.
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CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW

1.1 BREAST CANCER
Breast cancer is the most common non-cutaneous cancer diagnosis for
women in Canada, with an anticipated 24,400 Canadian women diagnosed in
2014, and 5,000 women dying of the disease [1]. Although newer treatments
have improved both overall survival and progression-free survival for early and
metastatic cancer patients respectively [2], there remains a subgroup of women
with Locally Advanced Breast Cancer (LABC) who do poorly.

1.2 PATHOPHYSIOLOGY OF CANCER
Cancer is a multi-step process that occurs because of an interaction
between an environmental factor(s) and a host that is genetically susceptible
[3,4]. Cell division is a physiological process that occurs in almost every tissue
type in the body. Under normal circumstances, the balance between proliferation
and programmed cell death (usually in the form of apoptosis) is maintained by
regulation of both of these processes, to ensure the integrity of tissues and
organs. Any alteration by mutation of the genes responsible for the control of
either of these leads to cancer. Cancer cells, therefore, behave as cells that have
lost the control over their growth rate, spreading to other tissue types and
invading other areas of the body, as well as interfering with their function. This
can lead to death if not treated or removed.
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DNA damage is considered to be the primary cause of any cancer. Normal
damage to DNA is common, but inherent repair machinery is available and able
to fix it. Thus, a deficiency in DNA repair would cause more DNA damage to
accumulate and increase the risk of cancer. There are two main types of genes
that regulate cancerous cell growth and differentiation: oncogenes (normal genes
that regulate cellular growth are called proto-oncogenes, while mutation of these
genes results in constitutive activation; these genes are then called oncogenes,
which are either present in inappropriately high numbers, or altered, to then
exhibit new tumour promoting properties as a result of their alteration) and
tumour suppressor genes (genes that inhibit cell division or survival of cancer
cells; mutations in these genes result in a loss of function and resultant cancer
[3,4].
Breast cancer refers to several types of neoplasm arising from breast
tissue. The most common one is adenocarcinoma, originating from the epithelial
cells lining the terminal duct lobular unit. Over 80% of breast adenocarcinomas
are derived from the epithelial cells lining the ducts specifically, termed mammary
ductal carcinoma. Carcinoma in situ (DCIS) is proliferation of cancer cells within
the duct itself but without invasion through the myoepithelial and basement
membrane lining of the ducts; invasive carcinoma (IDC) is composed of cancer
cells that have invaded through the myoepithelial lining of the ducts into the
surrounding stromal tissue of the breast. Lymphovascular space invasion is
usually associated with a more aggressive phenotype. Although DCIS is believed
to be a non-obligate precursor of IDC in most instances, approximately 40% of

4
DCIS will progress to IDC if left untreated, evidenced by DCIS and IDC having
very similar gene expression patterns, although both display intra-tumoural
heterogeneity [5]. The drivers of invasion, or epithelial-to-mesenchymal transition,
remain unknown, but epigenetic (DNA methylation) or histone modification
events have been implicated [5]. The breast microenvironment, as well as
genetic and epigenetic factors have been also implicated in driving tumour
progression from invasive to metastatic breast cancer.

1.2.1 Risk Factors for Developing Breast Cancer
There are many risk factors associated with the development of this
disease; these include gender (females are more prone than males), age (the
risk of developing breast cancer increases with age, particularly after
menopause), reproductive history (risk increases with higher number of ovulatory
cycles and nulliparity), lactation (lactational changes related to breast feeding
reduces risk of developing breast cancer), exposure history (ionizing radiation
exposure, alcohol intake and hormone replacement therapy all increase the risk
of having breast cancer), height and weight (taller women and those of higher
BMI have a higher chance of developing breast cancer), family history and
Breast Related Cancer (BRCA-1/BRCA-2) gene mutation (these significantly
increase the chance of breast cancer) [6,7].
A number of inherited tumour suppressor gene mutations can lead to
breast cancer, the most common of which are within the BRCA1 and BRCA2
genes. BRCA gene mutations significantly increase the risk of breast cancer
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development from a 1 in 9 risk for average women to 65% lifetime risk for BRCA
gene mutation carriers [8]. BRCA genes are DNA repair genes, responsible for
identifying and repairing erroneous double-stranded DNA breaks. BRCA gene
mutation carriers have inherited a defective copy of this gene from one parent
and therefore rely on the other functioning inherited copy. A secondary somatic
mutation in this gene leads to cancer development, consistent with the 2-hit
hypothesis [9]. As a result, these gene mutation carriers develop breast and/or
ovarian cancer (tissues where BRCA proteins are most responsible for DNA
damage repair) at an earlier age than is seen in women who develop somatic
mutations in each of their normal genes as a result of exposure or other unknown
factors. Mutation carriers can develop cancer in their early 20s, are much more
likely to be pre-menopausal at diagnosis, and develop more aggressive cancers
(typically estrogen negative in 80% of cases) [10].
Hormones appear to have an important influence over the development of
breast

cancer,

particularly

estrogen

and

progesterone.

Estrogen

and

progesterone are steroidal sex hormones that are produced by the ovaries in
premenopausal women, whereas in postmenopausal women, they are derived
from the conversion of androgens to estrogen by aromatase in the adrenal
glands and to a lesser degree in peripheral tissues such as adipose tissue [11].
Progesterone is derived from pregnenolone that is itself derived from cholesterol
[11]. Circulating estrogen (estradiol or its weaker counterpart, estriol) promotes
the upregulation of progesterone receptors, particularly in breast tissue [11]. Both
estrogen and progesterone have a number of roles, including female sexual
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development, maintenance of sex characteristics and fertility. Two different types
of estrogen receptors (ER) exist: alpha (α) and beta (β) (ERα and ERβ
respectively). Various tissues express ER (breast, ovaries and the endometrium
express ERα, while the kidneys, brain, lungs and several other organs express
ERβ). The role of ERβ in carcinogenesis remains controversial, whereas, a clear
link between ERα protein and breast cancer has been established [12]. Both ER
subtypes carry a DNA binding domain and exist in the nucleus and the
cytosol. When estradiol enters the cell, it binds the ER, and the complex
migrates into the nucleus, where it functions as a transcriptional activator and
promoter of cell growth. Most breast cancers (at least 80%) are ER positive
and/or PR positive, meaning that these cancer cells proliferate in the presence of
circulating estradiol, and are, therefore, inhibited by ER antagonists or aromatase
inhibitors [11].

1.2.2 Prognostic Factors or Markers
A number of tumour and patient factors determine the risk of recurrence or
death from recurrence of breast cancer [13]. These include tumour stage
(outlined below, in section 1.4.1), menopausal status (worse prognosis with premenopausal status), tumour grade (worse prognosis with higher grade), and
histological subtype (some breast cancer subtypes exhibit more favourable
prognoses as a function of slower tumour growth and lower risk of developing
metastases; favourable types include mucinous, medullary and tubular
carcinomas) [14].
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Another poor prognostic factor is HER2/neu (HER2) status. HER2 is a
receptor that belongs to the human epidermal growth factor receptor (HER)
family of proto-oncogenes including epidermal growth factor receptor (EGFR,
HER1), one of four plasma membrane-bound receptor tyrosine kinases. HER
family proteins have an extracellular ligand binding domain, a transmembrane
domain and an intracellular domain that can bind and activate signaling
molecules through its tyrosine kinase as a result of, or independent of, ligand
binding [15]. HER2 can heterodimerize or homodimerize for activation and is,
therefore, the preferred partner in dimerizing of the HER family receptors. Its
constitutive activation by dimerization results in it functioning as an oncogene by
autophosphorylating tyrosine residues, thus activating those signaling pathways
[15]. Up to 30% of all breast cancers are comprised of tumour cells that
overexpress HER2, and this overexpression allows for homodimerization and
activation of HER2, promoting oncogenic features such as rapid tumour growth
as well as an increased risk of locoregional and distant recurrence after surgery.
As a result, HER2 overexpression is an independent poor prognostic marker and
these breast cancers are associated with worse survival than HER2 normal
tumours.
Overall, the integration of ER, PR and HER2 status, as well as
proliferation markers such as Ki67, allow for the prognostication of tumours
based on a rough molecular subtype [16,17]. The molecular classification was
first described as a genomic DNA classification of tumours into 5 main subtypes,
roughly defined by the following: Luminal A (low grade, ER positive, HER2
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negative); Luminal B (ER positive, Ki67 high, usually high grade, HER2 positive
or negative); HER2 positive (typically ER negative and HER2 positive); Triple
negative (ER negative, PR negative and HER
2 negative) and Basal-like (high grade, poorly differentiated) [16]. Since
then, a number of other classification systems have been reported, some using
DNA expression patterns, others using mRNA expression, others still with
molecular phenotype as a surrogate for gene expression profiling. This
differentiation remains the most clinically relevant prognostic marker for breast
cancer.

1.3 CLASSIFICATION
Breast cancers can be classified and substratified using a number of
clinically relevant features. The purpose of classification is to select the best
therapy and treatment algorithms, as well as to prognosticate. The major
classification features include histopathological type, the grade of the tumour, the
stage of the tumour, and the molecular (ER/PR/HER2) subtype (a surrogate for
gene expression profile classification).
Histopathological classification involves the differentiation between in situ
and invasive breast cancers, as well as their histologic type and grade.
Histological features roughly stratify the invasive cancers as either no special
type (infiltrating ductal) or special type (medullary, mucinous, lobular, tubular,
cribriform), although there are also other more rare forms (e.g. metaplastic,
apocrine, adenosquamous, etc.) [18]. Tumours showing mixed ‘no special type’
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and ‘special type’ features usually behave and are classed as a ‘no special type’
tumour of the same histologic type and grade.
Grading focuses on the differentiation of the breast cancer cells compared
to that of the normal breast cells. As the cell division becomes uncontrolled,
nuclei become less uniform and cell arrangement more disorganized. The grade
of an invasive carcinoma is assessed using the Scarff-Bloom-Richardson grading
system, which involves three criteria: tubule formation (the percentage of tumour
made up of tubular structures (1 point for >75% tubules; 2 points for 10-75%
tubules and 3 points for <10% tubules)); nuclear pleomorphism (the degree of
change in the shape and size of the cells’ nuclei (1 point for small and uniform
nuclei; 2 points for medium to large nuclei but they remain consistent in shape);
and 3 points for large and varied nuclei)); and mitotic count (number of cells
under microscope that are actively dividing (1 point for slow mitotic rate; 2 points
for medium mitotic rate and 3 points for rapid mitotic rate)) [19]. Thus every
tumour is graded out of a possible 9 points. This is then further collapsed into a
score for grade out of three (grade 1=1-5 points; grade 2=6-7; grade 3=8-9
points). These could also be described as well differentiated (low-grade),
moderately differentiated (intermediate-grade) and poorly differentiated (highgrade) as the cells progressively lose the features and arrangement of normal
breast cells. The poorer the differentiation is (or the higher the grade), the worse
the prognosis for the patient [19].
Staging of breast cancer is based on the size where it originally started,
and the locations to which it has travelled. The tumour, lymph nodes, metastasis
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(TNM) staging system from the American Joint Committee on Cancer is used
(see section 1.4.1 on Staging) [20].
Receptor status (ER, PR, HER2) is also a clinically-relevant classification
stage, given that it determines treatment with hormonal therapy (selective
estrogen receptor modulator, for premenopausal women to function as an ER
antagonist (such as anastrazole, letrozole or aromasin drugs) breast cells
including cancer cells, or an aromatase inhibitor (to block the conversion of
steroidal molecules into estrogen for postmenopausal women to virtually
eliminate any estrogen which could otherwise bind to ERs in cancer cells). HER2
overexpressing tumours are treated with a targeted monoclonal antibody called
trastuzumab following chemotherapy, with other anti-HER2 targeted therapies
currently under investigation.

1.4 DIAGNOSIS
Patients present with cancer in one of two ways: a palpable breast mass
or change in breast appearance, or an abnormality such as a mass or
microcalcifications seen on screening mammogram. Appropriate diagnostic
imaging for any suspicious finding requires both a mammogram and an
ultrasound [21]. If the finding persists on imaging, then an image-guided core
needle biopsy is performed. If the clinical finding persists but the mammogram
and ultrasound are negative, a surgical consultation is obtained to determine
whether this is an abnormal finding requiring an excisional biopsy procedure, or
whether further imaging (such as magnetic resonance imaging (MRI)) would be
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warranted for the few cancers which present as mammogram and/or ultrasound
occult [21].
Once a biopsy is done using image guidance, the specimen is processed
by the pathology team, using formalin fixation and paraffin embedding for
microscopic examination, with hematoxylin and eosin staining. The pathologist
determines whether the cancer is in situ or invasive, and if invasive, its histologic
type and grade, as described above. Immunohistochemical staining is done to
determine whether the cancer cells are ER and/or PR positive and whether the
cells are HER2 overexpressing [22]. If the tumour is HER2 equivocal by
immunohistochemistry, testing for the HER2 gene may be performed by
fluorescent in situ hybridization (FISH), to determine whether or not the HER2
gene is amplified.
Distant staging investigations (searching for distant metastases using
imaging tests) are not recommended for early breast cancers; however, as the
risk of distant metastases rises, then staging investigations are recommended
prior to any systemic therapies. These standardly include a computerized
tomography (CT) scan of the chest, abdomen and pelvis, and a full body bone
scan. Imaging of the brain is not indicated in the absence of symptoms, as the
yield for detecting metastases is otherwise low [21].

1.4.1 Staging
There are two different staging methods that can be applied to breast
cancer. These are the Roman numeral staging system, as well as TNM staging,
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which is most clinically utilized [20]. The TNM staging system can be collapsed
into the Roman numeral staging system for ease of use prognostically.
The TNM system [20] is used for staging breast cancer in order to roughly
prognosticate survival and determine need for adjuvant therapies based on
statistical likelihood of distant recurrence.
Tumour: tumour classification (TX, T0, Tis, T1, T2, T3 or T4) depends on
the cancer site. TX refers to an inability to assess that site; Tis refers to ductal in
situ carcinoma, lobular in situ carcinoma or Paget’s disease of the nipple; T1
represents tumours up to 2cm in size; T2 represents tumours more than 2cm but
less than 5cm; T3 represents tumours 5cm or greater; T4 represents tumours
invading surrounding structures including chest wall, skin, both or infiltrating
dermal lymphatics resulting in a clinical diagnosis of inflammatory breast cancer.
Lymph Node: lymph node involvement with cancer (NX, N0, N1, N2 or
N3) depends on the number and location of the involved lymph nodes, whether
axillary lymph nodes, the infra or supraclavicular lymph nodes, or the internal
mammary lymph nodes are affected. The axilla is designated as having three
levels: lateral, deep and medial to the pectoralis muscle. In the axilla, NX
designation means the lymph nodes have not been assessed; N0 signifies no
lymph node metastases; N1 means 1-3 lymph nodes are involved with cancer
(either microscopic or macroscopic nodal involvement); N2 means 4-9 nodes are
involved and N3 means 10 or more nodes are involved. Clinically, all nodal
basins are examined and any positive nodes identified clinically are classed
based on their location: N1 means palpable but mobile axillary nodes; N2
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represents matted nodes in the axilla or infraclavicular or internal mammary
nodes; N3 represents nodes found in the supraclavicular nodal basin.
Metastases: The clinically relevant classification for distant metastases
for breast cancer are M0 and M1, which refers to distant detectable metastases
or absence thereof. The most likely areas for breast cancer cells to harbour
clinically visible or relevant metastases are bone, lung, liver and brain.
Roman numeral staging involves assigning a number to describe the
progression of cancer. The following stages are recognized:
•

Stage 0: carcinoma in situ.

•

Stage I: T1 tumours that are lymph node negative.

•

Stage II: tumours up to T2 in size, with up to N1 nodal metastases, or T3
in size but no nodal metastases. This is the most common stage at
diagnosis for breast cancer, and typically involves the addition of systemic
therapies such as chemotherapy, and hormonal or antibody-based
therapies if indicated. Distant staging is indicated from this stage forward.

•

Stage III: This stage is considered locally advanced. These cancers are all
lymph node positive (N1-N3) or invading surrounding structures (T4). The
patients all benefit from systemic therapy and are usually given
neoadjuvant chemotherapy prior to surgery, in order to cytoreduce the
tumour burden and increase the likelihood of successful resectability.

•

Stage IV: cancer has metastasized to other organs or throughout the
body. Management of stage IV cancers is palliative, and treatments are
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aimed at lengthening quality of life and reducing negative symptoms of the
disease.

1.4.2 LABC
Locally advanced breast cancer (LABC) is a mix of neglected and
aggressive cancers [23]. In developing nations, most patients present with LABC,
but it appears that the majority of these are neglected due to patient, societal and
care access factors, allowing the tumour to grow and advance in stage. LABC in
North America can present as a neglected cancer in patients with denial and/or
fear of the diagnosis, but more commonly represents an aggressive subset of
breast cancer which can present as a large burden of disease that arises within a
year from an otherwise normal screening mammogram (called an interval
cancer). Neglected tumours tend to be seen in older patients, with the tumours
displaying lower grade, and are more commonly ER positive, while interval LABC
cancers tend to present in younger patients, with the tumours displaying high
grade features and ER negativity. LABC is most commonly defined as stage IIB
(T3N0) and Stage IIIA/B/C from the TNM classification (AJCC 2009) [20,24-26];
clinically, these tumours being greater than 5cm in size and/or extend beyond the
breast tissue into the surrounding skin or muscle, with/without matted axillary
lymph nodes (N2), internal mammary nodes or ipsilateral supraclavicular lymph
node involvement (N3). LABC represents approximately 10-15% of all breast
cancer cases, and the overall survival has historically been estimated at 30-42%
at 5 years [27] a significant portion of whom will be living with metastatic disease.
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However, a small subset of women receiving neoadjuvant chemotherapy who
achieve a complete pathological response, or pCR, (defined as no residual
invasive breast cancer pathologically following neoadjuvant treatment) to
treatment are projected to have a vastly improved 5 year disease free survival
rate of 87% [27] with 5 year overall survival rates of 89% to 90% [28]. As such,
pCR rates have become the surrogate measure for favorable long-term
outcomes in trials involving neoadjuvant treatment [29], particularly since the
efficacy of systemic therapy can only readily be evaluated with the tumour in vivo.
Historically, pCR was defined as no residual invasive breast cancer within
the breast [30], but has since been more commonly used to denote the absence
of residual invasive breast cancer either within the breast or axillary nodes [31].
More recently, it has also been demonstrated that pCR is significantly associated
with tumour subtype (also termed intrinsic subtype, roughly classified by a
combination of estrogen receptor (ER) or progesterone receptor (PR) positivity,
tumour

grade

and

epidermal

growth

factor

receptor

HER2

over-

expression/amplification as described above), based on a meta-analysis of 30
trials [32]. A review of 7 German neoadjuvant trials also showed that pCR rates
rose with increasing number of chemotherapy cycles, increasing anthracycline
dose, cumulative taxane dose and capecitabine-containing regimens [33]. The
most significant predictor of response to neoadjuvant chemotherapy (as
measured by pCR) was found to be molecular subtype status [33]. Based on this,
pCR is being increasingly considered a suitable surrogate for all tumour subtypes
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except Luminal A (clinical proxy for genotypic classification of Luminal A is made
using ER positive, HER2 negative, absence of high grade) [34].

1.5 THERAPEUTIC APPROACH TO LABC
1.5.1 Systemic Chemotherapy
Systemic chemotherapy can be delivered in two main regimens:
neoadjuvant (prior to surgery) and adjuvant (following surgery). Multiple
chemotherapeutic agents may be used in combination. Determining the
appropriate regimen depends on the character of the tumour (i.e. its hormonal
status), lymph node status, and the age/health of the patient. Many regimens
have been clinically evaluated and proposed, but for the majority of breast
cancers, the regimens typically contain an anthracycline and a taxane, as these
have demonstrated superior survival to regimens not containing these classes of
drugs [26]. Six international randomized controlled trials (RCTs) that have
compared neoadjuvant versus adjuvant chemotherapy have included patients
diagnosed with breast cancer from stages T1-T4 [35-40]. All failed to
demonstrate a survival advantage with neoadjuvant chemotherapy, although an
individual level pooled analysis of the LABC subset of these trials is currently
underway (Brackstone, unpublished). For more detailed discussion regarding
specific regimens, see the neoadjuvant chemotherapy section below. Tumours
that are HER2 overexpressing benefit from the addition of trastuzumab to reduce
recurrence and improve survival. Its use was validated in the adjuvant setting
concurrently with the taxane component of chemotherapy [26]. As a
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monotherapy, it is less efficacious in improving survival, therefore is not delivered
to patients not also receiving cytotoxic chemotherapy [41]. Since trastuzumab is
a monoclonal antibody-targeted therapy, it is delivered intravenously, with an
initial loading dose of 18mg/m2, followed by a maintenance dose of 9mg/m2 every
3 weeks for 18 doses (one year) [26]. Therefore, it overlaps with the
administration of adjuvant radiation. It was tried as a concurrent regimen with
anthracyclines, but this was found not only not to improve pCR rates, but also an
increase in cardiac toxicity (in the metastatic setting) [41]; therefore, most
regimens are designed to deliver the antracyclines first, followed by taxane with
trastuzumab and radiation.
The most common regimens used to treat breast cancer include: AC-T
(anthracycline and cyclophosphamide IV, q3 weekly x 4 or dose-dense as q2
weekly x 4) followed by taxane (paclitaxel or docetaxel, either q3 weekly x 4 or qweekly x 9-12); FEC-D (5-fluorouracil, epirubicin and cyclophosphamide IV q3
weekly x 3) followed by docetaxel IV q3 weekly x 3. The dosages and more
specific details regarding these regimens can be found below (Section 1.6).
Systemic hormonal therapy is recommended for all ER and/or PR positive
breast cancers where there is a significant risk of distant relapse, balanced
against the toxicity profile of these agents for each individual patient. Current
recommendations support the use of a selective estrogen receptor modulator for
10 years in premenopausal patients, and an aromatase inhibitor for 5 years (10
year versus 5 year RCT, NCIC-MA17R, results still pending).
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1.5.2 Surgery
The goal of surgery is to remove all of the cancerous tissue (tumour), plus
some of the margins. The extent of surgery is dictated by the staging and the
type of tumour, and may include lumpectomy (removal of the lump) or
mastectomy (removal of the whole breast). Most early breast cancers (stage I
and II) consist of small primary breast cancers that are, therefore, easily
resectable by lumpectomy (termed ‘breast conserving surgery’), whereas stage
III advanced cancers tend to occupy a larger portion of the breast and, therefore,
require a mastectomy for successful removal of the entire involved area.
Standard practice requires the surgeon to establish margins clear of cancer,
indicating that the cancer has been completely excised. If the removed tissue
does not have clear margins, further operations to remove more tissue may be
necessary. Therefore, in an effort to minimize the risk of margin positivity while
reducing the amount of normal breast tissue that needs to be resected,
neoadjuvant chemotherapy has increasingly been used to downsize the primary
breast cancer, in order to render operable breast cancers amenable to breast
conserving surgery [40]. These tumours would otherwise require a mastectomy
for complete removal if chemotherapy were to be delivered in the adjuvant
setting.
For larger breast cancers that remain extensive despite neoadjuvant
chemotherapy, or which are multicentric in nature (separate tumours distributed
throughout different quadrants of the breast), a mastectomy remains the
standard of care. This involves removing the glandular breast tissue from the
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pectoralis fascia, resecting overlying skin and nipple-areolar complex and
achieving primary skin closure over the chest. A drain is left beneath these large
skin flaps, as seromas tend to accumulate over the ensuing 1-2 weeks, until the
wound heals.
During the operation, the lymph nodes in the axilla must be sampled or
removed entirely, in order to stage the patient for regional metastases. Until the
early 2000s, the standard of care for staging the axilla involved resection of all
axillary lymph nodes in the level I and II zones, resulting in reduced arm mobility,
dysesthaesias of the upper arm and a 10-20% risk of permanent lymphoedema
of the arm (lymphatic drainage was severely affected by the removal of so many
lymph nodes, resulting in a swollen upper extremity). More recently, the
technique of sentinel lymph node (SLN) dissection has become popular, as it
requires the removal of far fewer lymph nodes (i.e. fewer side effects) [26,42].
The SLN dissection involves resection of the first tier of axillary lymph nodes that
drain the breast, mapped functionally using dual tracer modality (blue dye
injected into breast parenchyma preoperatively and technetium 99-m (99-mTc)
radiocolloid bound to sulphur protein injected intradermally preoperatively). SLN
mapping can spare 65-70% of patients with breast cancer from having a
complete lymph node dissection, for what could turn out to be a negative nodal
basin, but is indicated for early breast cancers felt clinically to be lymph node
negative. In LABC, the vast majority of these patients are lymph node positive
(either clinically or pathologically) and, therefore, the standard of care remains an
axillary lymph node dissection [26], although this is a rapidly evolving field.
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Removal of the breast with the axillary lymph nodes is called a modified radical
mastectomy (radical mastectomy refers to removal of the breast, axillary lymph
nodes and pectoralis muscle, a surgical technique that is no longer performed).
Patients with Stage IV breast cancer are deemed incurable and, therefore,
goals of care are shifted to extension of quality life years. As a result, there is
great debate whether the patient should undergo surgery to remove the primary
cancer if it has already metastasized, particularly if the primary tumour appears
to be well-controlled by the systemic therapies being given to control the distant
disease. This is being addressed by a current clinical trial, the results of which
remain outstanding (NCIC MAC14). Certainly there is a tendency to treat distant
disease with monotherapies rather than combined regimens of chemotherapies
and hormonal therapies, in an effort to maximize the duration of treatment
response from each.

1.5.3 Radiation Therapy
Radiation therapy (RT) is used to reduce the risk of locoregional
recurrence, and is almost always delivered in the adjuvant setting to the surgical
field. It is the standard of care for reducing by more than 50% the risk of local
recurrence in the breast following lumpectomy, or following mastectomy for
lymph node positive breast cancers [43].
RT involves the delivery of high-energy X-rays that target the tumour, or
post-surgery tumour site. It can be delivered in the form of external beam
radiotherapy (linear accelerator), or brachytherapy (radiation source is placed
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directly at the treatment site, which for breast remains largely confined to select
subspecialty cancer centers or through clinical trials). This high energy therapy
results in double-stranded DNA breaks for rapidly dividing cells, felt to target any
residual cancer cells which might be present in the surrounding normal tissues or
pre-invasive cancer cells at risk of progressing to invasive and resulting in a local
recurrence.
RT delivered by tangents (or 2-field) refers to radiation to the breast alone,
although the radiation beams do overlap and, therefore, treat approximately 80%
of the lower axilla. Four-field or regional radiation refers to additional fields or
radiation to the upper axilla (level III nodes, clavicular and internal mammary
nodal basins).
The dose of radiation must be strong enough to be cytotoxic to
proliferating cancer cells, but tolerable by surrounding normal cells, since all
tissue types are susceptible to this damage. Therefore, the radiation delivery is
planned using a 3-dimensional conformal CT scan where radiation oncologists
and physicists calculate dosage to deliver even radiation to the area in question
while constraining doses to critical structures. Damage is then minimized by
delivering the treatment over many fractions at a low dose per fraction (typically
2Gy per fraction).
For LABC, the standard post-mastectomy dosage of 50Gy in 25 fractions
is typically delivered, plus a boost of up to 9Gy in 5 fractions to regional nodes or
surgical site for margin positivity or heavy nodal involvement [26]. Radiation is
standardly delivered 5 days per week, excluding weekends, for administrative
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convenience rather than for therapeutic reasons. It remains controversial whether
patients who have achieved a pCR with neoadjuvant chemotherapy still require
regional radiation after surgery, given the vastly improved survival rates in this
subset, but at present it remains the standard recommendation [26].

1.6 NEOADJUVANT TREATMENT
1.6.1 Neoadjuvant Chemotherapy
Regardless of differential sensitivities between breast cancer subtypes,
and despite an absence of survival benefit, neoadjuvant chemotherapy has
become a standard of care for locally advanced breast cancer. The NSABP-18
trial was the first large randomized study to demonstrate the efficacy of
neoadjuvant chemotherapy. In the study, 1523 patients with T1-3, N0-1 were
randomized to four cycles of AC (adriamycin 60mg/m2 and cyclophosphamide
600mg/m2) intravenously every 3 weeks either pre- or post- operatively [44].
There was a significant improvement in clinical complete response (cCR),
pathologic complete response (pCR) and the rate of breast conserving surgery
with neoadjuvant treatment, but no difference in disease-free (DFS) or overall
survival (OS) across the study population. However, in analyzing the 13% of
patients who achieved a pCR, there was a significant improvement in DFS
(p=0.014), distant DFS (p=0.0004) and a trend to OS (p=0.06) when compared to
patients who did not achieve a pCR. At sixteen years of follow-up, these patients
continued to show a significant improvement in DFS (Hazard Ratio (HR) 0.47,
p<0.0001) with OS (HR 0.32, p<0.0001) now reaching statistical significance [45].
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The correlation between improved survival from locally advanced breast cancer
and pCR has been identified in other studies, mainly using anthracyclines [46-48].
In order to improve survival from breast cancer, novel cytotoxic agents
such as taxanes were evaluated. Docetaxel is a microtubule-stabilizing agent
that induces cell-cycle arrest and apoptosis [49,50].

It has demonstrated

response rates up to 50% in anthracycline-resistant metastatic breast cancer [5153], and superior survival when used first-line in randomized studies in the
metastatic setting [54,55].

Docetaxel is most commonly given intravenously

every 3 weeks. However, a randomized phase III study in the metastatic setting
compared docetaxel 100mg/m2 every 3 weeks, to 35mg/m2 weekly for 3 of every
4 weeks [56]. Although response rates were lower on the weekly arm, there was
no difference in progression-free survival (5.7 months vs 5.5 months; p=0.46) or
OS (18.3 months versus 18.6 months; p=0.34).

There were higher rates of

clinically significant toxicity in the q 3-weekly arm, (88.1% versus 55.9%;
p=0.0001).
Based on its activity in the metastatic setting, docetaxel has been tested in
randomized trials in early stage breast cancer, and demonstrated superior
survival when added to anthracycline-based regimens compared to the regimens
alone [57,58]. FEC-D, (fluorouracil 500mg/m2 IV, epirubicin 100mg/m2,
cyclophosphamide 500mg/m2 IV every 3 weeks x 3 cycles, followed by docetaxel
100mg/m2 IV every 3 weeks x3) is currently one of the more commonly employed
regimens in the adjuvant post-operative setting.

In the PACS-01 study, this

regimen was compared to 6 cycles of FEC in 1999 women with node-positive
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operable breast cancer. With a median follow-up of 60 months, there was a
trend toward improvement in DFS (73.2% versus 78.4% p=0.12) and overall
survival (86.7% versus 90.7%, p=0.17) favouring the docetaxel arm [57]. Toxicity
was considered favourable, with more grade 3 and 4 neutropenia in the FEC arm
(33.6% versus 28.1%, p=0.008), as well as higher use of colony-stimulating
factors to maintain blood counts (27% versus 22%, p=0.01). There was a slightly
higher incidence of febrile neutropenia in cycle number 4 with docetaxel
compared to FEC (1.0% versus 4.6%, p=0.005), as well as significantly more
edema and nail changes with the docetaxel. Similar improvements in DFS and
OS were also found in the Breast Cancer International Study Group 001 which
compared 6 cycles of TAC (docetaxel 75mg/m2, adriamycin 50mg/m2,
cyclophosphamide 500mg/m2 IV every 3 weeks) to FAC (5-FU 500mg/m2,
adriamycin 50mg/m2, cyclophosphamide 500mg/m2 IV every 3 weeks) in a
similar population of women [58].
Several nonrandomized studies of docetaxel have also shown activity in
the locally advanced setting either as a single agent, concurrent, or sequentially
with other agents [59-63].

In order to determine whether the addition of

docetaxel improves outcomes in the pre-operative setting, several randomized
studies have been conducted. The largest, the NSABP-27, randomized 2411
women with T1c – T3 N0-N1 disease to receive 4 cycles of adriamycin and
cyclophosphamide (AC) pre-operatively, versus 4 cycles of AC followed by 4
cycles of docetaxel preoperatively, or 4 cycles of AC preoperatively followed by
surgery and 4 cycles of post-operative docetaxel. Compared to preoperative AC
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alone, the addition of docetaxel significantly improved cCR (40.1% versus 63.6%;
p<0.001), pCR (13.7% versus 26.1%; p<0.001) and proportion of patients with
negative nodes (50.8% versus 58.2%; p<0.001) [64]. With 8.5 years of follow-up,
across all 3 groups, there was no difference in DFS or OS (2). However, in the
patients achieving a pCR, there was a significant improvement in DFS (HR=0.49,
p<0.0001) and OS (HR=0.36, p<0.0001).
The Aberdeen Breast Group also tested the efficacy of the addition of
docetaxel to an anthracycline-based regimen in the preoperative setting [65].
One hundred and forty-five women with newly diagnosed T3, T4 or TxN2 disease
received 4 cycles of CVAP (cyclophosphamide 1,000mg/m2, doxorubicin
50mg/m2, vincristine 1.5mg/m2 and prednisone 40mg). Those who achieved a
pCR or cCR were then randomized to either 4 more cycles of CVAP or 4 cycles
of docetaxel (100mg/m2). Those who did not respond to the initial 4 cycles of
chemotherapy were treated with docetaxel in a nonrandomized fashion.
Intention-to-treat analysis demonstrated a higher clinical cCR (94% versus 66%,
p=0.03) and pCR (31% versus 16%, p=0.04) with the addition of docetaxel
compared to 4 more cycles of CVAP. At 38 months median follow-up, docetaxel
significantly improved DFS (90% versus 77%, p=0.03) and OS (97% versus 84%,
p=0.05) [66]. A third study, the GEPARDUO, compared AC for 4 cycles followed
by docetaxel for 4 cycles (AC-DOC) to dose-dense doxorubicin 50mg/m2 plus
docetaxel 75mg/m2 every 14 days for 4 cycles, with filgastrim support (ADOC)
preoperatively in 913 women with T1-3 N0-2 breast cancer [67]. All endpoints,
including pCR (22.4% versus 11%) and breast-conserving surgery rates (75%
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versus 66%) were significantly improved with the sequential AC-T over the dosedense arm [67]. Survival endpoints have not yet been reported. Based on these
findings, the use of taxanes in the neoadjuvant setting has been recommended
for non-metastatic advanced breast cancer [68]. For HER2 overexpressing
tumours, the GerparQuattro trial (combining trastuzumab with anthracyclinebased neoadjuvant chemotherapy regimens) demonstrated a significant increase
in pCR with the addition of trastuzumab and recommended it also be initiated in
the neoadjuvant setting [69].
In spite of the improved outcomes with neoadjuvant use of chemotherapy,
the gains are modest in terms of impact on overall survival. Furthermore, the
only patient groups experiencing a survival advantage are those who achieve a
pathologic complete response, which represent a small proportion of women
treated with a neoadjuvant approach (historically 10% in our institution as well as
in our provincial consortium database, unpublished data).

1.6.2 Concurrent Chemo-Radiotherapy (CCRT)
Concurrent chemoradiation is an increasing form of effective therapy for a
variety of cancers. The mechanisms by which various chemotherapeutic agents
interact with radiation effects to produce supra-additive or synergistic effects (i.e.
treatment response that is more than additive with what would have been seen
with either treatment alone) differ widely [70]. There remains no one universal
mechanism to explain the interaction between these drugs and radiation effects.
Rather,

the

molecular

class

of

drugs

determines

the

mechanism

of

27
radiosensitization; this can include modification of DNA damage by radiation,
interference with DNA repair processes, cytokinetic cooperation, inhibition of
proliferation, enhancing apoptosis, inhibition of angiogenesis, modifying hypoxia,
and interference with signal transduction pathways [70].
Some classes of drugs exhibit biological cooperation, where the
chemotherapy targets disease in one area, while radiation targets disease in
another area. Others exhibit kinetic cooperation, meaning that both the
chemotherapy and radiation modulate cell cycle and proliferation mechanisms
[70].
A common feature of radiosensitizing drugs is that the interaction is dose
and time dependent rather than tumour cell specific. For example, cisplatin must
be present prior to radiation to produce any radiosensitizing effects [70]. Wilson
and colleagues speculated that the presence of cisplatin molecules in the tissues
receiving radiation inhibits sub-lethal damage repair from occurring after
radiation-induced DNA damage [70]. 5-fluorouracil, on the other hand, inhibits
DNA synthesis. It is not currently known what the specific mechanism is by which
taxanes (docetaxel and paclitaxel) produce a supra-additive effect when present
during radiation.
For breast cancer, radiation is recommended in patients who undergo
breast conserving surgery for early disease, as well as for patients with advanced
or lymph node positive disease. The recommended timing for the delivery of
radiation for breast cancer is in the adjuvant setting; however, there is evidence
to suggest that neoadjuvant radiation may improve patient outcome and should
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be considered. The Stockholm Breast Cancer Trial, conducted between 19711976, randomized 960 early breast cancer patients to neoadjuvant radiation,
adjuvant radiation (both delivered as 4500Gy in 25 fractions, 4-field) or surgery
only (modified radical mastectomy for all patients) [71]. No systemic therapy was
given. The study demonstrated a significant improvement in survival among
patients treated in the preoperative setting, suggesting a potential benefit from
receiving radiation therapy with the tumour in vivo. Although this study was
completed a long time ago in what might be considered another era of care, it is
a pure investigation, in the sense that it was a RCT where no other treatments
were delivered (hormonal or systemic chemotherapy), thereby allowing the
effects of the radiation to be evaluated alone in terms of impact on recurrence
and survival.
In other cancers diagnosed elsewhere in the body, a combined modality
approach of local neoadjuvant radiation given concurrently with radiosensitizing
chemotherapy has been employed, in order to improve outcomes (both the
locoregional control and overall survival). This has become the standard of care
for the treatment of head and neck, rectum, lung, cervix and other cancer sites.
Furthermore, a significant improvement in pCR as a surrogate for DFS with
preoperative chemo/radiotherapy has also been reported [72]. The concurrent
approach has demonstrated improvements in organ preservation and survival
over radiation alone in multiple randomized trials [73-76].
Several randomized trials have demonstrated improved local control and
survival in non-small cell lung cancer with the use of concurrent versus
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sequential chemoradiation, most commonly with platinum-based chemotherapy
[77-80]. Multiple small studies have been done in this patient population adding
docetaxel as the radiosensitizer [81-86].

Doses have varied from 20mg/m2 -

40mg/m2 weekly as a single agent, or in combination with cisplatin. The studies
showed the feasibility of adding docetaxel, for favorable response rates and
survival, with manageable toxicity.
Limited published data exist for the use of neoadjuvant chemoradiotherapy in locally advanced breast cancer. The most common reported use
of concurrent chemo-radiotherapy is in the metastatic setting or in locally
advanced (inoperable) or inflammatory breast cancer patients who progress on
first line anthracycline-based chemotherapy [87-90], all of these using 5-FU or
capecitabine as the radiosensitizing agent. These trials all occurred prior to
standard incorporation of taxane into breast chemotherapy regimens.
Among early stage II breast cancer patients, the sandwich approach to
neaodjuvant chemotherapy was evaluated, with radiation delivered between
cycles 1,2 and 3,4 [91] in 14 patients. The regimen was considered feasible, with
a 7% pCR rate but no survival outcome data. For similar early breast cancer
patients treated in the adjuvant setting, sequential was later found to be similar to
concurrent chemo-radiotherapy (ARCOSEIN trial) in terms of overall and
disease-free survival, with the caveat of having used older, less effective
chemotherapy regimens [92]. Of note, among the higher risk patients (node
positive), there was an improved relapse-free survival.
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In high-risk breast cancer patients (LABC), a few studies were undertaken
to explore the potential use of concurrent neoadjuvant chemoradiotherapy. The
largest trial was a retrospective review of 1,117 LABC patients treated in South
India from 1990-1999 [93], who were treated with cyclophosphamide,
methotrexate and 5-fluorouracil (CMF) versus 5-fluorouracil, epirubicin and
cyclophosphamide (FEC) chemotherapy, with

60

Co delivered as 40Gy in 20

fractions, followed by surgery and oophorectomy. A pCR rate of 34% was
obtained with acceptable toxicity.
Prospectively, similar smaller trials were undertaken using CMF [94] and
50Gy in 25 fractions to breast, where a pCR rate of 44% was reported in 73
LABC patients but no survival data was available. Again, sandwich techniques
were explored, where radiation was delivered halfway through neoadjuvant
chemotherapy cycles in LABC patients, but did not seem to improve outcomes
[95,96].
Data supporting sequential treatment derives mostly from studies in early
stage breast cancer. From pooled data of 10 retrospective studies, delaying
radiotherapy in favour of chemotherapy increased the risk of local relapse from
6% to 16% [97]. Furthermore, radiotherapy given more than 8 weeks after
surgery has been shown to double the local recurrence rate [97]. The only
prospective trial designed to answer this question in early breast cancer
demonstrated that patients treated initially with radiotherapy had higher rates of
distant relapse; in contrast, patients treated with initial chemotherapy had higher
rates of local relapse [98]. These differences were no longer apparent at 10
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years of follow-up [99]. A major limitation of these sequential studies is the fact
that the systemic treatments used are not comparable to modern chemotherapy
regimens (which typically include taxanes, or targeted agents like trastuzumab).
It is, therefore, possible that the differences in local relapse rates seen in the
above studies may over-estimate the clinical reality today.
A number of cytotoxic chemotherapy drugs have been demonstrated to
have radiosensitizing features (through molecular mechanisms not fully
understood) as assessed through improved clinical outcomes with increased
locoregional toxicity, most notably fluoropyrimidines [93,95], mitoxantrones [100],
taxanes (docetaxel and paclitaxel) [101,102] and platinum [87] drugs.
Concurrent chemotherapy with radiation has the potential to offer patients
the combined benefits of improved local and distant disease control. In early
breast cancer, CMF-based concurrent adjuvant chemo-radiotherapy has been
studied in several trials. Although this treatment had an acceptable toxicity profile,
and shortened overall treatment time, clinical benefit in terms of overall or
disease free survival was not consistently shown [103-106]. Anthracycline-based
CCRT has been associated with serious skin toxicity, including recall reactions
and

cardiac

toxicities.

Mitoxantrone

(12mg/m2)

in

combination

with

cyclophosphamide (500mg/m2) and fluorouracil (500mg/m2) every 21 days for 6
cycles (CNF) and radiotherapy starting during the first cycle of CNF was shown
in the multicentre randomized Arcosein trial, to improve local control in lymph
node positive subgroup patients compared to sequential CNF and radiotherapy
[92,107]. Unfortunately, concurrent CNF and RT compared to sequential CNF
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and RT failed to show any benefit in 5-year DFS and OS. Similar results were
seen in a French multicentre trial comparing concomitant CNF and radiotherapy
to CEF (cyclophosphamide, epirubicin, and fluorouracil) and sequential RT [100].
A benefit in local control and decrease in local recurrence rate by 2.8 fold was
seen in the concurrent CNF and RT arm, compared to the sequential CEF and
RT arm, with no significance difference in OS and DFS. Unfortunately
mitoxantrone has been associated with high rates of leukemic transformation and,
therefore, is now rarely used.
In exploring the role of CCRT in breast cancer, using pCR as a surrogate
for increase in survival has its limitations. The correlation of pCR achieved with
systemic therapy and survival has been well established. This may be due to the
ability of systemic therapy to sterilize micrometatstases if capable of achieving a
complete response in the primary tumour and lymph nodes. Therefore, in this
setting pCR would be a reflection of the effect of the treatment on all cancer cells,
including disseminated disease. The value of achieving pCR with CCRT is not
known. In fact, if one views radiation therapy, in a minimalist fashion, as a
locoregional treatment, then achieving a pCR might not reflect the systemic
benefit. However, some authors have proposed an anti-tumour systemic effect of
local breast radiation [108].

1.6.3 Neoadjuvants: Taxanes as Radiosensitizers?
Anthracycline and taxanes are the backbone of most modern breast
chemotherapy regimens in North America. Since anthracycline-based CCRT has
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been associated with serious skin and cardiac toxicity, there has been an interest
in evaluating taxane chemotherapy use as a radiosensitizer in the neoadjuvant
setting currently with neoadjuvant radiation [109]. One retrospective review of 44
patients receiving concurrent chemoradiation with taxanes for stage I – IV breast
cancer as a second line regimen was reported [110]. The majority had stage IIIA
disease (31%). Seven patients had received prior radiation for breast cancer.
Twenty-nine patients received concurrent paclitaxel and 15 received concurrent
docetaxel, given on a q3 weekly schedule for the majority. Treatment was
generally well tolerated with no grade 4 toxicities.

Nine patients (20%)

experienced grade 3 skin toxicity (moist desquamation), leading to a delay in
chemotherapy in 11% of patients, until radiation was completed. Only one patient
experienced long-term toxicity with retraction and fibrosis of the breast. Overall,
this study demonstrated the safety and feasibility or concurrent chemoradiation
with taxanes in locally advanced breast cancer. Response rates and survival
outcomes were not reported.
A second study reported on 44 women with stage IIB to III locally
advanced breast cancer who received twice weekly intravenous paclitaxel 30
mg/m2 for 8 – 10 weeks concurrent with radiation to total dose of 45Gy to the
breast plus 14Gy in 7 fractions boost, followed by surgery [101]. For those who
responded to the initial chemoradiation, post-operative doxorubicin/paclitaxel was
given for 4 cycles, with 4 cycles of doxorubicin/cyclophosphamide given postoperatively to non-responders.

No grade 4 toxicities were observed in the

preoperative chemoradiation phase. In the postoperative phase, the only grade
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4 toxicity was leucopenia (10%).

Ninety percent of patients received the

prescribed concurrent treatment. Three patients (7%) experienced grade 3 skin
toxicity; other grade 3 toxicities noted in the preoperative treatment were
hypersensitivity to the paclitaxel, fatigue, stomatitis, and dyspnea limited to one
case each. Dose reductions in chemotherapy occurred in 20% of patients: 3 for
grade 3 neuropathy, 3 for grade 3 neutropenia, one for grade 3 stomatitis, and 1
for grade 3 esophagitis. No cases of radiation pneumonitis were reported. Postmastectomy complications occurred in 6 patients (14%).

These included 4

infections with delayed healing, one tram flap necrosis requiring revision and one
mastitis. A clinical response was achieved in 91% of patients, with 11% CR and
80% PR. Sixteen percent of patients achieved a pCR, with 18% a pPR. There
was no association between total dose of preoperative chemotherapy and pCR.
Overall survival with a median follow-up of 32 months is 93.9%.
A third phase I/II study in 33 inoperable LABC and metastatic patients
evaluated infusional paclitaxel with or without vinorelbine and concurrent 6070Gy radiation. A 50% rate of grade 3 dermatitis was reported, with a pCR in the
LABC subset of 46% [111].
Two studies have also been published in abstract form only. One reported
on 112 patients with stage IIB – IIIB breast cancer who received 4 cycles of
neoadjuvant FAC or AC given every 3 weeks followed by chemoradiation with
mitomycin C 5mg weekly, 5-FU weekly, or cisplatin 30mg, gemcitabine 100mg
weekly; 60Gy was delivered, but the fractionation schedule was not reported.
This was followed by surgery, and 2 additional courses of postoperative
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chemotherapy [112]. The pCR rate was 42% in breast, and 29.5% in breast and
axillary nodes. No relationship between pCR and RFS was found. The only
grade 3 toxicity reported was skin toxicity in 22.4%. The second study reported
on 23 patients receiving 50.4Gy over 6 weeks, with paclitaxel 175mg/m2 day 1,
and 5-FU 1000mg/m2/day continuous infusion day 1-3 for 3 cycles every 3 weeks
[113]. This was followed by 3 cycles of FEC every 3 weeks, then surgery. Grade
3 toxicities included 39% radiation dermatitis. The clinical complete response rate
was 82.6%, with a pCR rate of 52.2% and an overall 2-year survival rate of
80.7%.
In addition to the perceived improved response to chemoradiation when
delivered in the neoadjuvant setting, it may be that radiation planning with the
disease in vivo may improve dose delivery, with minimization of unwanted
dosage to critical structures, although that has not been studied.

1.7

THESIS RATIONALE
Locally advanced breast cancer remains a significant clinical challenge

with inferior survival in spite of improved systemic treatments. The cumulative
data across tumour sites demonstrates a clear association between pCR and
improved survival. Neoadjuvant therapy, when used in LABC, does not yield the
high response rates that are seen and frequently cited in patients with operable
tumours. Although pCR rates may be impressive in triple negative and HER2positive patients, for those who achieve less than a pCR, poor outcomes are
likely. Taxanes have improved OS in the metastatic and adjuvant setting, as well
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as pCR rates and survival in the neoadjuvant setting; however, the pCR rates still
remain disappointingly low. Concurrent administration of taxanes and radiation
have demonstrated improved outcomes including survival across different tumour
sites. In LABC, the concurrent approach has been shown to be feasible with
manageable toxicity. The current standard treatment for locally advanced breast
cancer is preoperative chemotherapy with an anthracycline and a taxane.
However, the ideal regimen and number of cycles remain under debate. Given
the improvement in local control, pCR and survival in other tumour sites the
current study is aiming to determine whether a concurrent approach will improve
pCR in locally advanced breast cancer.

1.7.1 Hypothesis
Our hypothesis was that concurrent neoadjuvant chemotherapy with
regional radiation would improve the pCR rate from the current provincial rate of
10-15%, when compared to matched LABC patients undergoing standard of care
(neoadjuvant systemic chemotherapy followed by surgery and adjuvant regional
radiation). The goal was to use current standard full regimen chemotherapy
(FEC-D) in order to avoid compromising on systemic efficacy for distant relapse
with dose reductions, avoiding sandwich techniques which were felt only to
create dose delays in the chemotherapy delivery, while delivering standard
adjuvant doses of regional radiation in the neoadjuvant setting for radiosensitivity,
while maintaining locoregional control in these high risk patients. The regimen
was modified to include weekly docetaxel instead of q3 weekly (for which funding
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for and approval of this modified regimen was secured from Ontario’s Ministry of
Health, Health Canada and Cancer Care Ontario), in order to provide maximal
overlap of radiosensitizing chemotherapy during radiation and to minimize
potential toxicity from the heightened effects of docetaxel as a result of the
concurrent radiation.
The secondary hypothesis was that response to concurrent chemotherapy
and radiation could be predicted by biological markers, such as imaging changes
seen on serial cross-sectional imaging, serial measurements of tissue RNA
concentration and integrity, and potentially predicted ex vivo using a 3D in vitro
invasion assay. The findings of the secondary hypothesis are described in
Appendix IV; they remain preliminary and hypothesis-generating at present.

1.7.2 Outline of this Thesis
We undertook a prospective Phase II Clinical Trial to test the effectiveness
of the new protocol, concurrent radiation during the weekly docetaxel portion of
neoadjuvant FEC-wD chemotherapy. As demonstrated in Chapter 2, we found
that the neoadjuvant chemoradiation therapy significantly improved the pCR
rates when compared to standardly treated LABC patients, with a trend toward
improved disease-free and overall survival.
This regimen was not without toxicity, and the increase in pneumonitis
seen as a result of combining docetaxel with radiation is evaluated and reported
in Chapter 3.
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Finally, we undertook to evaluate how effective the plasma levels of
biomarker osteopontin (OPN) would be, as a predictor of pCR or overall survival
with our novel neoadjuvant chemoradiotherapy protocol. This study and its
findings are described in Chapter 4.
Overall conclusions and recommendations for future directions are
outlined in Chapter 5.
The appendix chapters contain the full clinical trial protocol, the current
LABC guidelines (written by Muriel Brackstone for Cancer Care of Ontario), and
the preliminary findings of the biological correlative trials (secondary hypotheses).
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CHAPTER

2:

CLINICAL

TRIAL

EVALUATION

OF

CONCURRENT

NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN
LOCALLY ADVANCED BREAST CANCER.

2.1 INTRODUCTION
Breast cancer is the most common non-cutaneous cancer diagnosis for
women in Canada, with an anticipated 24,400 Canadian women diagnosed in
2014, and 5,000 women dying of the disease [1]. Although newer treatments
have improved both overall survival and progression-free survival for early and
metastatic cancer patients respectively [2], there remains a subgroup of women
with Locally Advanced Breast Cancer (LABC) who do poorly.
LABC is most commonly defined as stage IIB (T3N0) and Stage IIIA/B/C
from the TMN classification [3]. Clinically these tumours are greater than 5 cm in
size and/or extend beyond the breast tissue into the surrounding skin or muscle,
with/without matted axillary lymph nodes (N2), internal mammary nodes (N3) or
ipsilateral supraclavicular lymph node involvement [3]. LABC represents
approximately 10-15% of all breast cancer cases, and the overall survival has
historically been estimated at 30-42% at 5 years [4] a significant portion of whom
will be living with metastatic disease. However, a small subset of women
receiving neoadjuvant chemotherapy who achieve a complete pathological
response, or pCR, (defined as no residual invasive breast cancer following neoadjuvant treatment) to treatment are projected to have a vastly improved 5 year
disease free survival rate of 87% [4], with 5 year overall survival rates of 89% [4]
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and 90% [5]. As such, pCR rates have become the surrogate measure for
favorable long-term outcomes in trials involving neoadjuvant treatment [6],
particularly since the efficacy of systemic therapy can only readily be evaluated
with the tumour in vivo. Neoadjuvant, or pre-operative chemotherapy has
become a standard of care for locally advanced inoperable breast cancer or
operable LABC where breast-conserving surgery is being contemplated [7, 8].
A number of cytotoxic chemotherapy drugs have been shown in other
disease sites to have radiosensitizing features, as assessed through improved
clinical outcomes with increased locoregional toxicity, although the molecular
mechanisms are not fully understood. Of these, the most notable are
fluoropyrimidines [9, 10], mitoxantrones [11], taxanes (docetaxel and paclitaxel)
[12, 13] and platinum [14] drugs. However, limited published data exists for the
use of neoadjuvant chemo/radiotherapy in LABC. The most common reported
use of radiotherapy concurrent with radiosensitizing chemotherapy is in the
metastatic setting, locally advanced (inoperable) or inflammatory breast cancer
patients who progress on first line anthracycline-based chemotherapy [14-17],
where 5-fluorouracil (5-FU) or capecitabine were used as the radiosensitizing
agent.
Our

hypothesis

was

that

concurrent

neoadjuvant

radiosensitizing

chemotherapy with regional radiation would improve the pCR rate from the
current provincial rate of 10-15%. The goal was to use current standard full
regimen chemotherapy in order to avoid compromising on systemic efficacy for
distant relapse with dose reductions, avoiding sandwich techniques which could

50
create dose delays in the chemotherapy delivery, while delivering standard
adjuvant doses of regional radiation to provide optimal locoregional control in
these high risk patients.

2.2 METHODS
2.2.1 Rationale
At the time that the clinical trial was created, the only Ontario health care
funded chemotherapy regimen for breast cancer in the neoadjuvant setting was
AC-T (doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 IV q3 weekly x 4
cycles, followed by paclitaxel 175mg/m2 IV q3 weekly x 4 cycles). The choice of
FEC (5-fluorouracil 500mg/m2, epirubicin 100mg/m2 and cyclophosphamide
500mg/m2 IV q3 weekly x 3 cycles) and docetaxel was based on the superior
survival in high risk patients in the PACS-01 study [18]. Furthermore, epirubicin
is associated with a lower risk of cardiotoxicity than doxorubicin, which must be
considered in light of the concurrent radiation [19, 20]. Weekly docetaxel is as
effective as docetaxel given every 3 weeks in the metastatic setting [21], but is
associated with less toxicity; in particular, less myelosuppression, which should
reduce the chances of having to reduce or eliminate cycles of chemotherapy.
Therefore,

FEC-D

(5-fluorouracil

500mg/m2,

epirubicin

100mg/m2

and

cyclophosphamide 500mg/m2 IV q3 weekly x 3 cycles, then docetaxel 100mg/m2
IV q3 weekly x 3 cycles) was selected.
The weekly docetaxel regimen (35mg/m2) was selected in order to provide
constant radiosensitizing potential during chemotherapy [21, 22]. Special
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permission was obtained from Cancer Care Ontario to have this regimen funded
through Ministry of Health for this trial only. Standard regional intensitymodulated radiotherapy (IMRT) (45Gy in 25 fractions plus or minus boost for
gross residual disease) was selected in order to provide optimal regional therapy
for these patients at high risk of locoregional and distant relapse. Permission was
obtained from Health Canada for use of these chemotherapy and radiation
regimens concurrently in the neoadjuvant setting. This study was approved by
Western University’s Health Subjects Research Ethics Board (Appendix I).

2.2.2 Patient Description
Thirty-two patients presenting to the London Regional Cancer Program
with non-inflammatory LABC were offered participation in this single-arm
prospective Phase II clinical trial. Patients were deemed eligible if they had
biopsy-proven LABC (defined as any T3 or T4 tumour stage or any N2 or N3
nodal stage by American Joint Committee on Cancer [23] staging). Patients were
all female, at least 18 years of age and able to give informed consent, with a
negative serum pregnancy test, no prior history of invasive cancer and adequate
renal, hepatic, pulmonary and cardiac function. The clinical trial schedule is
outlined in the trial calendar (Table 2.1). Patients were staged using CT
chest/abdomen/pelvis and bone scan to rule out metastases (protocol details in
Appendix III).
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Table 2.1.

LABC clinical trial calendar.
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2.2.3 Treatment Regimen
Patients were treated with 3 cycles of FEC (intravenous 5-fluororuracil
500mg/m2, epirubicin 100mg/m2 and cyclophosphamide 500mg/m2) q3 weekly,
followed by docetaxel weekly x 9 weeks (dose adjusted to 35mg/m2) (Figure 2.1).
On the evening prior to docetaxel chemotherapy, dexamethasone 8mg oral was
taken by each patient. Concurrent radiation therapy was started during the first
day of docetaxel. Radiation therapy consisted of external beam IMRT therapy for
a total dose of 45Gy in 25 fractions over 5 weeks. A reduced volume boost of
5.4Gy in 3 fractions to 9Gy in 5 fractions was given to residual gross disease in
the breast and/or regional lymph nodes. All treatment planning was performed
on the Phillips Pinnacle workstation, and radiation treatment was delivered on
megavoltage machines using 6MV energy or greater. Chemotherapy with
radiation was followed by modified radical mastectomy (including standard level I
and II axillary node dissection) 5 weeks after the last dose of docetaxel, allowing
8 weeks of radiation recovery preoperatively.
Adverse events from chemotherapy and radiation therapy as well as
grading of any developed toxicity were assessed by the oncologist as per the
National Cancer Institute [24]. Patient tolerability was assessed every 3 patients,
and any grade 4 or higher toxicities or any treatment delays were reviewed by an
independent data safety monitoring committee (IDSMC). Mid-study, the protocol
was modified to include a normal pulmonary function test and non-smoker status
after the first three patients with pneumonitis were reviewed by the IDSMC.
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Locally Advanced Breast Cancer
(exclude inflammatory)
Baseline Imaging – MRI, CT CAP,
PFT, Bone Scan, Wall Motion
Chemo: FEC
Weeks 0, 3 & 6
Sesta MIBI
Weeks 0 &3

Chemo: Docetaxel
Weeks 9-14 & Regional
Daily Radiation (60 Gy)
Docetaxel Alone
Weeks 15-17
5 Weeks

Surgery –
Mod Radical Mastectomy

Figure 2.1. Schema for LABC clinical trial.
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Women with HER2/neu positive breast cancer received one year of
trastuzumab, initiated in the neoadjuvant setting concurrently with docetaxel as
per standard of care, given the absence of evidence to support increased
cardiotoxicity even when administered concurrently with radiation or taxanes [25,
26]. Monitoring for cardiac toxicity from trastuzumab included a wall motion study
performed every 3 months while on therapy. Dose modification was made as per
international and institutional guidelines for trastuzumab-associated cardiac
dysfunction [27]. Women with estrogen receptor positive breast cancer received
postoperative endocrine therapy according to their menopausal status.

2.2.4 Assessment of Pathological Response
Pathological response was subcategorized as follows [28]: pCR –
pathological complete response (no residual invasive breast cancer in the breast
tissue or axila); pSPR – pathological significant partial response (<10 foci of
microscopic invasive tumour within breast); pPR – pathological partial response
(<30% of original invasive breast tumour volume remaining); SD – stable disease
(30-80% of original invasive breast tumour volume remaining); NR – no response
(81-120% of original invasive breast tumour volume remaining).
Molecular subtype was categorized using tumour phenotype as a surrogate for
genotypic classification as follows:
•

Luminal A:

Estrogen receptor (ER) and/or Progesterone receptor (PR)

positive, epidermal growth factor receptor erb2 (HER2) negative, NOT
high grade

56
•

Luminal B:

ER and/or PR positive, high grade only (HER2 positive or

negative)
•

HER2+:

ER and PR negative, HER2 positive

•

Basal:

ER and PR negative, HER2 negative

The proliferation marker Ki67 is not measured at our institution.

2.2.5 Statistical Analysis
This study was designed to accrue 52 patients, based on a sample size
calculation powered to detect a doubling of pCR rate (26% to 52%) from
published clinical trials of neoadjuvant chemotherapy [8], but was closed
prematurely after a treatment-related death, with 32 patients accrued, at the
recommendation of the IDSMC. The treatment cohort (n=32) was compared to a
concurrent control cohort of LABC patients off-study treated at the same
institution, all of whom received neoadjuvant chemotherapy (FEC-D or AC-D),
modified radical mastectomy and equivalent locoregional radiation delivered in
the adjuvant setting (50Gy in 25 fractions using IMRT). Patients were matched
1:N by stage, age, and molecular subtype using greedy matching by propensity
score +/- 0.1 to minimize selection bias. Cox regression analysis was employed
using a robust sandwich estimator for paired comparison of pCR rates between
the concurrent chemoradiation cohort and the control cohort. Cox proportional
hazards analysis was used to compare disease-free and overall survival between
the two cohorts. SAS 9.3 was used for all statistical analyses (SAS Institute Inc.,
Cary NC).
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2.3 RESULTS
Of the 32 patients accrued to the study, one patient progressed during the
FEC portion of the treatment and was taken off study in favor of second line
chemotherapy. Another patient with inoperable bilateral LABC received bilateral
regional radiotherapy during the docetaxel/radiation portion of the study and
developed pneumonitis-induced acute respiratory distress syndrome shortly after
completion of radiation. This patient did not go on to surgery and died shortly
thereafter. From 30 remaining patients who all completed neoadjuvant therapy
and surgery, 27 were successfully matched to 81 concurrent control patients
using propensity score greedy matching to minimize selection bias, since
statistical power was optimized with a 1:3 matching.
No statistically significant difference in patient age, pre-treatment tumour
size, pre-treatment nodal status or molecular subtype was found using Cox
regression analysis (Table 2.2). A statistically significant difference in postchemotherapy tumour size was seen (mean residual tumour size in concurrent
chemoradiation cohort was 13.16mm versus 31.12mm in control cohort, p<0.001)
(Table 2.3).
The overall pCR rate was significantly higher in the concurrent
chemoradiation cohort (22.6% versus 14.9% in control cohort, p=0.019) (Table
2.3). The number of patients in each molecular subtype group was too small to
permit statistical comparisons of pCR rates by molecular subtype. None of the
concurrent chemoradiation cohort patients who achieved a pCR have had a
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Table 2.2.

Patient

demographics

comparing

LABC

neoadjuvant

concurrent chemotherapy and radiotherapy study patients to
matched control cohort.

LABC Chemotherapy
Matched Cohort (3:1)
(n=81)

Chemoradiation LABC
Study
(n=27)

51.2

49.3

42.0

43.2

Baseline clinical node (%)
N0
N1-N3c
NX

10.1%
65.9%
24.0%

28.1%
68.8%
3.1%

Luminal subgroup – N (%)
Luminal A
Luminal B
HER2+
Basal

29 (34.9)
33 (39.8)
8 (9.6)
13 (15.7)

9 (33.3)
10 (37.0)
3 (11.1)
5 (18.5)

Variable
Mean age at registration
(years)
Baseline mean tumour
size (mm) – pre-treatment
(baseline ultrasound)
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Table 2.3.

Clinical

response

to

neoadjuvant

therapy

(primary

chemotherapy for LABC chemotherapy matched cohort versus
concurrent chemotherapy with radiotherapy for LABC study
patients). *p<0.05

LABC Chemotherapy
Matched Cohort (3:1)
(n=81)

Chemoradiation
LABC Study
(n=27)

Mean tumour size (mm) – posttreatment (pathology)

31.12

13.16

Lymph nodes positive (%) posttreatment

60.9

53.3

Luminal subgroup with pCR (%)
Luminal A
Luminal B
HER2+
Basal

6.0
13.9
30.3
18.0

0 (33.3)
10 (37.0)
3 (11.1)
5 (18.5)

14.9

22.6*

18.9

20.0

Variable

TOTAL with pCR (%)
Follow-up – distant recurrence (%)
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Table 2.4.

Treatment related toxicity rates between LABC neoadjuvant
concurrent chemotherapy with radiotherapy and matched
control cohort.

Toxicity *

LABC Chemotherapy
Matched Cohort (3:1)
(n=81)

Chemoradiation
LABC Study
(n=27)

Dermatitis

0 (0%)

6 (22%)

Pneumonitis

1 (1%)

5 (19%)

Cardiomyopathy

2 (2%)

0 (0%)

Neuropathy/Arthralgia

3 (4%)

0 (0%)

Febrile Neutropenia

8 (10%)

0 (0%)

The numbers were too small for statistical comparison between groups.

* Only class 3 or higher toxicities causing treatment delays or interruptions were used; as most
radiation pneumonitis occurs at the end of treatment (hence it rarely interrupts treatment), it is,
therefore, likely that the effect is under-represented in the adjuvant treatment control cohort.
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recurrence, while 36% of patients who did not achieve a pCR recurred and died
of their disease within 36 months of treatment.
Although there was no significant difference in disease-free (DFS) or
overall survival (OS) between the treatment groups due to premature study
termination and resultant smaller sample size, there was a trend at 36 months in
DFS for the concurrent chemoradiation cohort of 79% versus 64% for the control
cohort (Figure 2.2). The Hazard Ratio (HR) for DFS in the concurrent
chemoradiation cohort was 0.51 (95% CI=0.16-1.4; p=0.185). A similar trend was
also seen for OS, where the OS for the concurrent chemoradiation cohort was
84% versus 69% in the matched control cohort (Figure 2.3). The HR for OS was
0.46 in favor of the concurrent chemoradiation cohort (95% CI=0.16-1.4;
p=0.161).

2.4 DISCUSSION
This study demonstrated that the addition of neoadjuvant radiation to
anthracycline and taxane-based chemotherapy significantly improved the pCR
rate in LABC patients, with a trend of 15% higher overall survival at 3 years as
well as disease-free survival that failed to reach statistical significance based on
sample size.
Since the trial was initiated, other trials using concurrent neoadjuvant
chemotherapy with radiation for breast cancer have been published. Follow-up
data from Formenti’s 2003 trial [12] was subsequently published [29],
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Figure 2.2. Disease

free

survival

(DFS)

comparing

chemoradiation cohort to matched control cohort.
HR, hazard ratio; Chemo/Rads, chemoradiation.

concurrent
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Figure 2.3. Overall survival (OS) in concurrent chemoradiation cohort
compared to matched control cohort.
HR, hazard ratio; Chemo/Rads, chemoradiation.
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demonstrating a combined pCR and pPR rate of 34% resulting in a significant
association with better DFS and OS (hazard ratio (HR)=0.35 for recurrence and
HR=4.27 for overall survival, both with p<0.01) when compared to nonresponders within the same treatment cohort. In that study, only the taxane was
given neoadjuvantly, with the remainder of the chemotherapy regimen being
given adjuvantly following a perioperative delay. Formenti’s study confirmed that
patients able to achieve a pCR with concurrent chemoradiation obtain a
significantly improved DFS and OS over non-responders treated the same way. It
does not compare concurrent versus sequential chemotherapy and radiation as
this trial does.
Trials of neoadjuvant chemoradiotherapy evaluating older regimens of
chemotherapy without taxane have since also been published [30-33], most
using 5-FU as the radiosensitizing agent, demonstrating feasibility and
reasonable toxicity and pCR rates of 10-29% and an overall survival of 84%.
These were mostly retrospective studies in highly selected patient cohorts.
Other trials evaluated neoadjuvant concurrent chemoradiotherapy as a
rescue for LABC patients who progressed on first line neoadjuvant chemotherapy,
using 5-FU as the radiosensitizer [34, 35] with reasonable pCR rates and
resultant operability. Long-term outcomes were not reported.
Ours represents the first clinical trial evaluating full dose concurrent
neoadjuvant chemotherapy including a radiosensitizing taxane as part of a
modern chemotherapy regimen (FEC-D), delivered with locoregional radiation in
LABC patients. Our findings support those of the Formenti group [29], where

65
pCR rates were significantly increased with concurrent delivery of radiation and
taxane chemotherapy, and goes further to show a trend in improved DFS and OS
at 3 years over standard sequential therapy.
This regimen was not without its toxicity, and while high rates (25%) of
grade 3 dermatitis (moist desquamation of chest wall skin) might be considered
clinically acceptable, the 25% rate of grade 3 or higher pneumonitis was
concerning. All patients who presented with clinical pneumonitis had the
diagnosis confirmed on CT scan and were treated with a 2-3 week tapering
regimen of high dose corticosteroids. One patient suffered ARDS shortly after
completion of preoperative therapy and died. None of the 30 patients proceeding
to surgery required a delay in surgery due to pneumonitis. The pneumonitis
experienced by the patients in this study behaved clinically like acute interstitial
pneumonitis and not radiation pneumonitis in that the symptoms resolved acutely
within weeks and did not lead to long-term impairment, however it is felt that the
radiation likely exacerbated its presentation [36].
Capillary leak and interstitial pneumonitis from taxane chemotherapy is
well known, although pre-treatment with 8mg of dexamethasone, as was used in
this trial, is felt to reduce this risk. The typical rate of pneumonitis (1-5% for q3
weekly docetaxel) [37] increases when administered q-weekly, reportedly to 27%,
which is comparable to our study [38]. Rates of pneumonitis are also elevated in
patients with pre-existing lung disease [39]. On the other hand, with the q-weekly
regimen, none of the patients suffered from other toxicity commonly associated
with docetaxel, such as febrile neutropenia or peripheral neuropathy. None of the
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study patients developed a postoperative wound infection or dehiscence,
although one patient had a protracted seroma that required multiple aspirations.
This study was not without its limitations. As a single arm phase II trial,
there was no randomization to a control arm to correct for unanticipated bias, and
a matched design to a control cohort may have inadvertently introduced selection
bias. Every effort was made to minimize this risk by having an independent
statistician do the matching to our comprehensive patient population database by
all variables thought to affect the outcomes of interest. It remains possible,
however, that unanticipated confounders could have influenced the results.
Although we found a difference of 15% in overall survival at 3 years, the study
failed to reach statistical significance. This lack of statistical power is due to
premature termination of the trial due to an unexpectedly high rate of
pneumonitis, with one death from ARDS.
The use of concurrent neoadjuvant chemoradiotherapy in LABC appears
to significantly improve the pCR rate and result in a trend to improved overall
survival. Given the poor outcome for LABC patients, any potential treatment
regimen that could result in a 15% increase in overall survival should be
aggressively pursued. Use of docetaxel appears to be associated with too high a
rate of pneumonitis, therefore a future phase III multicentered randomized trial
should be undertaken where the radiosensitizing benefit of taxanes can be
exploited, using for example paclitaxel [29] concurrently with locoregional
radiation as part of a full neoadjuvant chemotherapy regimen.
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CHAPTER 3

Role of Plasma Osteopontin as a Biomarker in Locally Advanced Breast
Cancer.

A version of this chapter was published, with M Brackstone as a senior coauthor: Anborgh PH, Caria LBR, Chambers AF, Tuck AB, Stitt LW, Brackstone
M. Am J Transl Res 2015, vol. 7(4): 723 –732. Reproduced with permission.
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CHAPTER 3: ROLE OF OSTEOPONTIN AS A BIOMARKER IN LOCALLY
ADVANCED BREAST CANCER.

3.1 INTRODUCTION
Locally advanced breast cancer (LABC) is considered an aggressive and
advanced stage of non-metastatic breast cancer, accounting for approximately 515% of all breast cancer cases [1-3], with a five year overall survival rate of 3042% [3-6]. Current treatment for this form of cancer is multimodal, involving
neoadjuvant chemotherapy, surgery and radiotherapy [7, 8]. Approximately 10%20% of patients achieve a clinical complete response (CR) and 50%-60% will
achieve a partial response (PR) to neoadjuvant therapy. However, only one half
to two-thirds of clinical CRs will be confirmed pathologically (pathological
complete response, pCR, defined as no residual invasive breast cancer in the
surgical specimen [1]). Response to neoadjuvant chemotherapy allows clinicians
to identify patients who may have a good outcome, as pCR remains the best
predictor for long-term survival [6, 9].
Osteopontin (OPN) is a secreted, integrin-binding phosphoprotein that is
expressed by several normal tissues and cell types [10, 11]. OPN plays an
important role in various aspects of malignancy, particularly those involved in
tissue invasion and metastasis [10, 12-18], and OPN levels have been
associated with aggressiveness in several cancer types, including breast cancer.
We, as well as other groups, have shown by immunohistochemistry that
elevated levels of OPN found in primary tumours may be correlated with a poor
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patient prognosis and tumour stage [19-21]. OPN can also be detected in the
blood of patients with various forms of cancer, including breast, prostate, colon,
lung, liver and stomach cancer and can be measured using an ELISA (enzymelinked immunosorbent assay) [22-27]. Plasma OPN levels are found to be
elevated in the majority of metastatic breast cancer patients and increased
baseline levels of plasma OPN in metastatic breast cancer patients are
associated with a worse prognosis and increased tumour burden [23, 25].
Additionally, in metastatic breast cancer patients monitored by serial OPN blood
levels, survival decreases (despite treatment) as plasma OPN levels increase
over time [23, 25].

Plasma OPN may thus have both a prognostic and a

predictive role in metastatic breast cancer, making monitoring plasma OPN levels
in metastatic breast cancer patients throughout treatment and over their disease
course potentially useful to predict aggressive tumour behavior. In contrast, we
recently reported data obtained for early breast cancer patients that failed to
show prognostic value for baseline plasma levels in those patients, although we
did find elevated plasma OPN in post-baseline samples from a subset of patients
[26].
This study is, to our knowledge, the first study to measure plasma OPN
serially in LABC patients. Serial measurement of plasma OPN levels over
treatment may potentially provide information with respect to patient response to
neoadjuvant therapy and long-term survival. The ability to more accurately
monitor response to neoadjuvant therapy may lead to better management of
these patients.
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3.2 MATERIALS AND METHODS
3.2.1 Patient Enrollment and Treatment Course
Fifty-two female patients and one male patient diagnosed with LABC,
being treated at the London Regional Cancer Program in London, Ontario,
Canada, were enrolled during 2007-2011 into this study, which was approved by
the Western University Health Sciences Research Ethics Board. All patients had
a histologically confirmed clinical stage III breast cancer and were eligible for
neoadjuvant therapy, excluding inflammatory breast cancer or patients with
distant metastases. Patients with any prior history of invasive cancer or prior
chemotherapy or radiotherapy were excluded. All patients provided written
informed consent to participate in this study. No eligible patients declined
participation. Standard patient treatment included neoadjuvant chemotherapy,
modified radical mastectomy and adjuvant regional radiation. Patients received
one of two standard neoadjuvant chemotherapy regimens: AC-T (Doxorubicin
60mg/m2 and cyclophosphamide 500mg/m2 IV q3 weekly x 4 cycles followed by
docetaxel 100mg/m2 IV q3 weekly x 4 cycles) or FEC-D (5-fluorouracil 500mg/m2,
epirubicin 100mg/m2 and cyclophosphamide 500mg/m2 IV q3 weekly x 3 cycles
followed by docetaxel 35 mg/m2 qweekly x 9 cycles). The patients receiving FECD received their regional external beam conformal radiotherapy (45 Gy in 25
fractions plus 5.4 Gy in 3 fractions or 9 Gy in 5 fractions depending on disease
burden) concurrent with docetaxel therapy in the neoadjuvant setting versus
identical radiotherapy in the adjuvant setting for AC-D patients. This was followed
in all patients by modified radical mastectomy to remove the breast and axillary
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lymph nodes, which were examined pathologically. All surviving patients were
followed for at least 2.5 years. All patients, with the exception of the male patient
who died unexpectedly of aspiration-induced respiratory arrest following
chemotherapy cycle 2, completed the treatment course. Three female patients
became metastatic during neoadjuvant therapy. Patient characteristics as well as
tumour characteristics and subsequent occurrence of metastases during or after
neoadjuvant therapy are listed in Table 3.1. All patients were followed
prospectively and none were lost to follow-up.

3.2.2 Plasma Sample Collection and OPN Analysis
Blood samples for OPN measurement were collected in tubes with EDTA
anticoagulant and processed as previously reported [22]. OPN was measured in
plasma samples by ELISA (Human Osteopontin EIA Kit, catalogue #ADI-900-142,
Enzo Life Sciences, Ann Arbor, MI) as previously described [27]. Samples were
collected from all patients at baseline (just prior to the first cycle of
chemotherapy) and again just prior to each subsequent chemotherapy cycle
treatment or every three weeks throughout neoadjuvant treatment for patients
receiving their docetaxel weekly. Plasma samples from a cohort of 90 healthy
women without cancer were collected and measured for OPN as described
previously [26].
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Table 3.1. Patient and tumour characteristics, and site of metastasis.

OPN
Number
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

Age at
Baseline
53
52
68
52
50
64
59
47
56
44
42
76
67
64
39
46
42
48
53
47
44
38
62
26
58
43
52
49
63
48
61
39
43
47
49
64
34
40
58
42
53
44
45
57
60
50
44
45
62
51
58
31
62

Gender

Tstage

Nstage

ER

PR

HER2

Grade

Site of Metastasis

F
F
F
F
F
F
F
F
F
F
F
M
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F
F

T3
T4a
T4b
NA
T4b
T3
T4b
T4b
T2
T3
T4b
T4b
T3
T4b
T2
T3
T3
T3
T4b
T4b
T1c
T2
T2
T2
T3
T2
T2
T3
T3
T3
T3
T3
T3
T3
T2
T3
T3
T2
T1
T2
T3
T3
T3
T2
T3
T3
T3
T3
T3
T3
T2
T2
T2

N1
N0
N1
NA
N1
N1
N1
N1
N1
N1
N1
NX
N0
N1
N1
N0
N1
N1
N0
N1
N2
N0
N1
N1
N2
N1
N2
N2a
N1
N1
N1
N1
N0
N0
N0
N2
N3
N1
N3
N0
N0
N1
N0
N0
N0
N2
N1
N1
N2a
NX
N1
N3
N3

Pos
Unk
Pos
Pos
Pos
Pos
Neg
Pos
Neg
Neg
Pos
Unk
Pos
Pos
Pos
Pos
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Pos
Pos
Pos
Neg
Pos
Pos
Pos
Neg
Pos
Neg
Pos
Neg
Pos
Pos
Pos
Neg
Pos
Pos
Pos
Pos
Neg
Pos
Pos
Pos
Pos
Pos
Pos
Pos

Pos
Unk
Pos
Pos
Neg
Neg
Neg
Pos
Neg
Neg
Pos
Unk
Pos
Pos
Pos
Pos
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Neg
Pos
Pos
Pos
Pos
Neg
Pos
Pos
Pos
Neg
Pos
Neg
Neg
Neg
Pos
Pos
Pos
Neg
Pos
Neg
Neg
Pos
Neg
Pos
Pos
Neg
Pos
Pos
Pos
Pos

Pos
Unk
Neg
Neg
Pos
Equiv
Pos
Neg
Pos
Pos
Neg
Unk
Neg
Pos
Pos
Neg
Pos
Neg
Pos
Neg
Pos
Pos
Pos
Neg
Pos
Pos
Pos
Pos
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Neg
Neg
Neg
Pos
Neg
Neg
Pos
Neg
Pos
Neg
Neg
Neg
Neg
Pos
Pos
Pos
Pos
Neg

2
1
1
3
3
2
3
3
3
3
3
2
1
1
2
2
3
1
3
3
3
3
3
3
3
2
2
2
3
2
3
2
2
2
3
2
3
1
3
2
3
2
2
3
2
3
1
2
3
2
3
3
2

0
0
0
0
Liver
0
Lung
Liver
0
0
Lung/Liver/Bone
Unk
0
Liver
Brain/Liver/Lung/Bone
0
Lung
0
0
0
0
0
Brain
0
0
0
0
0
0
0
0
Lung
0
0
Bone
Bone
0
0
0
0
0
0
0
0
Bone
Lung
0
0
0
0
0
0
0

ER, estrogen receptor; Equiv, equivocal; NA, not available; Neg, negative; Pos,
positive; PR, progesterone receptor; Unk, unknown.
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3.2.3. Pathological Assessment
Surgical specimens were sent for final pathological assessment. Tumour
response to neoadjuvant chemotherapy was sub-stratified as follows [28]:
i)

Complete pathological response (pCR) (No evidence of residual invasive

tumour in breast or axilla)
ii)

Partial response (PR) (at least a 30% decrease in residual tumour volume)

iii)

No evidence of response (stable disease) (NR)

iv)

Progression of disease (PD) (at least a 20% increase in residual tumour

volume).

3.2.4 Statistical Analysis
Repeated measures analysis of variance was used to compare OPN
levels across cycles of treatment, with Tukey’s multiple comparisons test used to
make pair-wise comparisons between cycles. The co-variates used included age,
gender, T stage, N stage, ER, PR, HER2 and grade. Student’s t-test was used to
compare data between healthy women and patients. The Kaplan-Meier
technique was used to estimate survival, comparisons were made using the logrank statistic, and the calculation of hazards ratios and evaluation of the effect of
baseline OPN as a continuous variable were done using Cox regression. The
relationship between OPN levels and response to chemotherapy was evaluated
using Fisher’s exact test. SAS 9.3 was used for all statistical analyses (SAS
Institute Inc., Cary NC).
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3.3 RESULTS
Plasma OPN levels in ng/ml for each patient over the course of
neoadjuvant chemotherapy are shown in Figure 3.1. Patient 12, who was the
only male in the study, died following the second cycle of chemotherapy from
what appeared to be treatment-related toxicity. A baseline OPN level of
69.7ng/ml was measured and at cycle two, just prior to his death, OPN level was
elevated to 141.3ng/ml. The two OPN values for this patient were not used for
the following analyses. A second patient progressed during the first 2 cycles of
chemotherapy and was, therefore, removed from the study and not included in
the analysis; the third patient died from acute respiratory distress syndrome
shortly after docetaxel/radiotherapy without surgery and was, therefore, also
excluded from analysis. The remaining 50 patients were included for analysis.
OPN values at baseline/cycle 1 were obtained for 50 patients. Mean OPN
value was 70.3ng/ml at baseline/cycle 1, while median value was 63.6ng/ml
(range 33.3 – 189.8ng/ml). We have previously measured plasma OPN levels of
90 healthy women and found a mean value of 32.0ng/ml (median value
26.3ng/ml (range 11.8-108.6ng/ml) [26]. This differs significantly from the mean
values of LABC patient plasma OPN at baseline/cycle 1 (p<0.001) (Figure 3.2).
OPN levels across 7 cycles of neoadjuvant treatment were compared for
the 34 patients for whom we had a complete set (no missed blood draw at each
chemotherapy cycle) using repeated measures analysis of variance. There was
an increase in OPN levels seen during chemotherapy cycles that was significant
overall (p<0.001). Mean patient plasma OPN levels between successive cycles
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Figure 3.1. Plasma OPN levels during neoadjuvant therapy with final
response to treatment and survival for all 53 LABC patients. At every
treatment cycle plasma samples were obtained and OPN was measured
in triplicate by ELISA. Average OPN levels are shown in ng/ml. Final
patient response is denoted as complete response (CR), partial response
(PR), no response (NR) or progressive disease (PD). Patient numbers in
black indicate patients who were alive 2.5 years post-surgery and red
numbers indicate patients who died within that period. Patients are
grouped first according to status (alive vs dead) and then according to
increasing baseline OPN, except patients for which no baseline OPN was
obtained in which case OPN at cycle 2 was used. Patient 12 is a male
patient who died following 2 neoadjuvant cycles. The dotted lines indicate
upper limit of OPN levels in a cohort of 90 healthy women (108.6ng/mL)
and median value at baseline/cycle 1 (63.6ng/mL), respectively.
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Figure 3.2. Plasma OPN levels at baseline/cycle 1 compared to OPN levels
of 90 healthy women. The boxes show OPN value between the
25th and 75th percentiles, with whiskers showing ranges; the lines
within the boxes mark the median values. OPN values from healthy
women were as reported.
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show no significant difference from baseline/cycle 1 through to cycle 5.
Significant pairwise differences exist between the mean OPN levels of cycle 1 vs
cycle 6 (p<0.001), and cycle 1 vs cycle 7 (p<0.001). Overall, all but three OPN
values at baseline/cycle 1 as well as the majority of the LABC patient samples
from cycles 2-8 have OPN values within the normal range (i.e. ≤108.6ng/ml)
based on a prior study of 90 healthy women without cancer [26] (Figure 3.1).

3.3.1 Association of OPN Values with Overall Survival
To determine the association of OPN values with overall survival, patients
were divided into 2 groups: OPN <63.6ng/ml versus OPN ≥63.6ng/ml, the
median OPN value at baseline/cycle 1. By comparison, the majority (92%) of
healthy women had OPN values <63.6ng/ml. The Kaplan-Meier survival curve
indicates that patients with baseline/cycle 1 OPN <63.6ng/ml had a significantly
improved overall survival than patients with baseline/cycle 1 OPN ≥63.6ng/ml
(Figure 3.3). The log rank test showed that this difference was statistically
significant (Chi-square=5.9; p=0.015; hazard ratio (HR) 3.3; 95% confidence
interval (CI): 1.3 – 10.4). Cox regression analysis with OPN at baseline/cycle 1
as a continuous variable produced similar result (Chi-square=10.4; p=0.001).

3.3.2 Association of OPN Values with Response to Neoadjuvant Therapy
The majority of the female LABC patients (62% or 32 out of 52) had a PR
to neoadjuvant therapy; eleven patients (21%) had a CR, four patients (6%) had
PD and four individuals (8%) had NR to treatment. Plasma OPN levels at
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Figure 3.3.

Association of plasma OPN levels at baseline with LABC
patient survival. Kaplan-Meier survival curves were constructed
after dividing the patients into two groups according to the median
OPN value at baseline/cycle 1 (63.6ng/ml) (log-rank test, p=0.011).
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baseline were compared with the final pathologic response to neoadjuvant
chemotherapy. Mean OPN value at baseline/cycle 1 for patients with CR was
60.3ng/ml, while for patients with PD or NR, mean OPN value was higher at
75.1ng/ml (Figure 3.4) however this difference was not statistically significant
(p=0.054; two-tailed). Six out of seven (86%) patients with PD or NR had OPN
values ≥63.6ng/ml at baseline/cycle 1 (for patient 18 with PD, no baseline/cycle1
value was obtained), while 4 out of 11 (19%) patients with CR or PR had OPN
values ≥63.6ng/ml at baseline/cycle 1 (p=0.066).

3.4 DISCUSSION
Tumour response to neoadjuvant treatment is an important predictor of
prognosis and overall survival for the LABC patient population. In this current
study, measuring serial plasma OPN levels was evaluated as a novel method for
monitoring tumour response to neoadjuvant chemotherapy of LABC patients. The
majority (83%) of the patients treated in this study had pCR or PR, of which pCR
is believed to be the most important current prognostic marker for survival.
Our results show that during the course of neoadjuvant treatment, as the
patients receive additional cycles of chemotherapy, a statistically significant
increase is seen in OPN levels at later cycles (6, 7 and 8) compared to earlier
cycles (1–5). Cytotoxic chemotherapies that are used for cancer treatment can
stimulate the immune system. Up-regulation of OPN expression in immune cells
allows for increased macrophage adhesion, migration, cytokine release and
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Figure 3.4. OPN levels at baseline for complete responders and nonresponders to neoadjuvant treatment. Lines indicate median
OPN value for eleven patients with pCR (55.5ng/ml) and median
OPN value for seven patients with NR or PD (75.8ng/ml) (p=0.054).
Dashed line indicates the median OPN value at baseline
(63.6ng/ml) of the entire group of patients.
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phagocytosis, all of which are important events of the immune and inflammatory
response [29, 30]. Therefore, it is possible that the increased plasma OPN levels
observed in patients over the course of neoadjuvant chemotherapy is from two
different sources:

OPN expressed by immune cells as a component of the

inflammatory response, and that secreted by the primary tumour itself [14, 19,
26]. Further work is required in order to determine the exact source of plasma
OPN detected during treatment.
We have recently reported that, in a group of 90 healthy women, plasma
OPN levels ranged from 11.8-108.6ng/ml [26]. Based on this, a level of
108.6ng/ml has been used as the upper limit of normal in the present study and
OPN levels above this value were considered elevated. We have previously
shown that in a cohort of 70 patients with metastatic breast cancer, 70% had
elevated levels of OPN [23] and patients with increased plasma OPN levels had
significantly shorter survival times. In line with this, Bramwell et al. [25] reported
that in a larger cohort of women with metastatic breast cancer, 66% had elevated
baseline OPN levels that were inversely and significantly associated with survival.
In addition, serial monitoring of OPN levels revealed that an increase of
>250ng/ml at any time was the most prognostic variable for poor survival. This
association of increasing OPN levels over time with poor prognosis supports the
use of serial monitoring of OPN levels in order to help make treatment decisions
by determining response. In contrast, in a cohort of postmenopausal women with
early breast cancer, only 4 women out of 314 (1.2%) had elevated OPN
(>108.6ng/ml) at baseline. That study found a mean baseline plasma OPN level
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of 46ng/ml (range 22.6 – 290ng/ml), which did not differ statistically from normal
levels [26] and found no evidence supporting a prognostic value of plasma OPN
for that group of early breast cancer patients.
While plasma OPN levels have thus been reported to be elevated in
women with metastatic disease but not with early breast cancer, levels for
patients with locally advanced disease had not been previously studied. This
current study showed that most LABC patients have plasma OPN levels that are
not elevated above what had been previously considered the ‘normal range’ at
baseline. However, mean OPN levels for LABC patients at baseline/cycle 1 were
significantly higher than mean OPN level for the group of 90 healthy women.
When comparing baseline OPN levels to final pathologic response,
patients who did not respond to treatment had a higher mean OPN level
compared to the eleven patients who had pCR to treatment (p=0.054). The
majority of non-responders also had OPN values ≥63.6ng/ml at baseline while
the majority of responders had OPN values ≤63.6ng/ml at baseline (p=0.066).
These differences, although not reaching statistical significance in this small
number of patients, are clinically interesting as they may help identify which
patients are likely to respond to neoadjuvant chemotherapy and are worthy of
further study.
Baseline OPN levels were significantly associated with pathological
response to treatment (p=0.015). Cox hazard ratio regression revealed that
patients with OPN levels above 63.6ng/ml were significantly more likely to die of
their disease (hazard ratio=0.3; 95% confidence interval 0.10-0.78; p=0.01), and
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overall, baseline OPN level was significantly associated with survival (p=0.001).
Therefore, OPN represents the first known predictive and prognostic plasma
tumour biomarker for overall survival in both locally advanced and metastatic
breast cancer patients.
In conclusion, LABC patients have a poor overall prognosis, due to their
high risk of tumour recurrence and development of future metastases. The study
reported here demonstrates a statistically significant difference in survival
between patients using baseline plasma OPN level. Our results strongly support
the need for prospective clinical trials to further validate the utility of measuring
plasma OPN levels in LABC patients, and to determine its role in clinical
decision-making regarding anticipated response to neoadjuvant chemotherapy.
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CHAPTER 4: RADIATION-INDUCED LUNG INJURY AFTER CONCURRENT
NEOADJUVANT

CHEMORADIOTHERAPY

FOR

LOCALLY

ADVANCED BREAST CANCER.

4.1 INTRODUCTION
Outcomes for women with locally advanced breast cancer (LABC) remain
suboptimal, with five-year survival of approximately 50%, despite aggressive
treatment with a combination of chemotherapy, radiotherapy and surgery, all
delivered sequentially [1, 2]. Achieving a complete pathological response (pCR)
to neoadjuvant therapy (defined as no residual cells in the breast or axilla) is a
major prognostic factor, as women with a pCR have a significantly longer overall
survival (OS) and disease free survival (DFS) than women without a pCR [3-6].
However, rates of pCR are low: a large meta-analysis demonstrated that 17% of
women, on average, achieve a pCR after neoadjuvant treatment [4].
For other malignancies, such as head and neck cancers, lung cancer, and
cervical cancer, concurrent chemoradiotherapy provides a survival advantage
over sequential chemotherapy and radiation therapy [7-10]. Delivery of both
modalities concurrently affords several potential advantages, including spatial cooperation, temporal co-operation, non-cross resistance, and radiosensitization
[11]. In an attempt to improve the pCR rate for LABC, a phase II trial was
launched, evaluating the efficacy of a regimen consisting neoadjuvant docetaxel
concurrent with locoregional radiotherapy. At the recommendation of the data
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safety monitoring committee, the trial closed early due to a higher-thananticipated rate of symptomatic radiation pneumonitis (RP).
In breast cancer, rates of RP after radiotherapy are usually low, often <5%,
with fatal RP being rare [12, 13]. In contrast, rates of RP after treatment of lung
are higher, affecting up to 13-37% of patients [14, 15]. Although predictors of
symptomatic RP and CT-based radiation-induced lung injury (RILI) (as measured
by Hounsfield unit density changes) have been evaluated in lung cancer patients,
and in breast cancer patients receiving radiotherapy alone [16-18], to our
knowledge no similar data exists examining patients receiving concurrent
chemoradiotherapy for breast cancer. Therefore, the goal of this study was to
evaluate predictors of symptomatic RP and CT-based RILI in a unique cohort of
breast cancer patients treated with concurrent neodajuvant chemoradiation
therapy.

4.2 MATERIALS AND METHODS
4.2.1 Patient Description
From August 2009 to June 2011, thirty-two patients with biopsy-confirmed
T3/T4 and/or N2/N3 LABC were accrued for this University of Western Ontario
Research Ethics Board approved protocol. Patients with prior malignancies,
systemic treatment within the last 5 years, or prior radiotherapy to the head, neck,
breast or thorax, were excluded. Patients with the diagnosis of inflammatory
breast cancer were also omitted.
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4.2.2 Treatment Details
Neoadjuvant chemotherapy was a standard anthracycline-based regimen.
It consisted of three cycles of intravenous 5-fluoruracil (500mg/m2), epirubicin
(100mg/m2) and cyclophosphamide (500mg/m2) administered every three weeks
(FEC). This was followed by a period of concurrent chemoradiotherapy. Weekly
IV docetaxel (35mg/m2) was given over nine weeks, with daily external beam
radiation therapy (intensity modulated radiation therapy or three-dimensional
(3D)-conformal radiotherapy, calculated using a collapsed-cone algorithm for
dose calculation) administered concurrently during the first six weeks. A dose of
45Gy in 25 fractions was given over 5 weeks, and a boost dose of either 5.4Gy in
3 fractions or 9Gy in 5 fractions was given during the sixth week if residual
disease was present. Radiation treatment was delivered on megavoltage
machines using 6MV energy or greater. Five weeks after the last dose of
docetaxel, patients underwent a modified radical mastectomy (MRM).

4.2.3 Image Registration and Lung Density Measurements
This report examines symptomatic RP and CT-based RILI. Oncologic
outcomes (pCR rates and survival) will be reported separately once the survival
data matures. All trial patients were eligible for this sub-study of symptomatic RP
and RILI. All 32 patients were scored for possible symptomatic RP using National
Institute of Health Common Terminology Criteria for Adverse Events (CTCAE)
v3.0 (CTCAE grade ≥2). The trial mandated that each patient received at least
three CT scans. The first was done prior to FEC chemotherapy, the second

93
before the start of concurrent docetaxel-radiotherapy and the third was
completed before surgery. Any additional CT scans were at the discretion of the
treating oncologists. To assess CT-based RILI, 27 out of 32 patients had at least
one follow-up CT scan available and were evaluable for that endpoint.
Radiotherapy treatment planning scans were overlaid onto their post-treatment
CT scans in order to measure changes in lung density over time (Figure 4.1).
The relationship between dose and lung density changes was assessed similarly
to previous studies [17]. Briefly, isodose levels (5Gy, 10Gy, 20Gy, 30Gy, 40Gy)
were converted into contours on the planning scan and were transferred from the
planning CT scans onto follow up scans after coregistration of the scans (MIM
Software 5.5, Ohio, USA). Deformable registration was attempted, but due to the
substantial differences between pre-radiotherapy and post-radiotherapy scans
which resulted in difficulty obtaining adequate registrations, non-deformable
algorithms were used instead. Contours were then examined and manually
adjusted

if necessary. To assess changes in lung density over time, (HU)

density changes in each ‘dose band’ (5-10Gy, 10-20Gy, 20-30Gy, 30-40Gy,
>40Gy) were generated and compared among scans. Contralateral lung
receiving <5Gy was considered unirradiated and used as a control to correct for
baseline differences between scans.

4.2.4 Statistical Analysis
Descriptive statistics were generated for baseline patient, tumour and
treatment characteristics. Univariable logistic regression analysis was performed
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Figure 4.1. Representative example of image registration with overlaid
isodose lines: (A) >40Gy, (B) 30-40Gy, (C) 20-30Gy, (D) 10-20Gy,
(E) 5-10Gy, (F) <5Gy. (a) Planning CT scan with contoured isodose
lines (b) Post-treatment follow-up CT scan with the contours from
the planning scan overlaid via rigid registration.
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for each available factor to identify predictors of symptomatic RP. T-tests and
ANOVAs (Analysis of Variance) were used to identify significant differences in
density change stratified by various combinations of: (a) RP grade (≥2 versus <2),
(b) radiation dose (5-10, 10-20, 20-30, 30-40 and >40Gy), and (c) time (0-3, 3-6,
6-12 and >12 months). Linear mixed models were generated to examine
relationships between radiological lung density changes (dependent variable),
radiation dose (fixed effect), time (fixed effect), and other potential predictors
(fixed effects). Statistical analysis was performed using SAS version 9.2 software
(SAS Institute, Cary, NC, USA) with two-sided statistical testing at the 0.05
significance level.

4.3 RESULTS
Baseline characteristics for the 31 evaluable patients are reported in Table
4.1, and radiotherapy planning parameters are reported in Table 4.2. In total, 17
(53%) patients developed symptomatic RP (CTCAE v3.0 grade ≥2). Eight
developed grade 3 pneumonitis requiring supportive oxygen, and one died of
acute respiratory distress syndrome (ARDS) associated with RP (grade 5
toxicity). Univariable logistic regression of potential predictors of symptomatic RP
is shown in Table 4.3. No treatment, patient, or tumour factors were significantly
associated with symptomatic RP. Since all patients received concurrent
chemotherapy, the effect of chemotherapy could not be assessed on logistic
regression.
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Table 4.1.

Baseline tumour, patient and treatment characteristics of all
patients (n=31).

Characteristic

All Patients
(n=31)

Age – median (mean, max)

49 (27, 64)

T stage – n (%)
T1
T2
T3
T4

1 (3.2)
4 (12.9)
21 (67.7)
5 (16.1)

N stage – n (%)
N0
N1
N2
N3
NX

9 (29.0)
11 (35.5)
6 (19.4)
4 (12.9)
1 (3.2)

Smoking History – n (%)

11 (35.5)

Left Ventricular Ejection Fraction
(LVEF) (%) – median (min, max)

64 (50, 77)

HER2/Neu status – n (%)
Negative
Positive
Equivocal
Total docetaxel dose received (mg) –
median (min, max)

17 (54.8)
8 (25.8)
6 (19.4)
522 (360, 666)

Received trastuzumab (Herceptin) – n (%)

11 (35.5)

Radiation delivery – n (%)
3D-CRT
IMRT
Tomotherapy

16 (51.6)
13 (41.9)
2 (6.5)
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Table 4.2.

Dosimetric parameters.

Parameter

Median (mean, max)

Lung V5 (%)

31.2 (25.5, 97.0)

Lung V10 (%)

27.2 (20.9, 45.4)

Lung V13 (%)

23.7 (19.4, 34.8)

Lung V20 (%)

21.0 (10.5, 31.1)

Lung V30 (%)

17.7 (7.628.8)

Lung V40 (%)

11.7 (0.7, 24.1)

Mean Lung Dose (Gy)

10.3 (8.1, 15.7)

Heart V5 (%)

29.5 (3.6, 100)

Heart V10 (%)

22.5 (0.03, 91.8)

Heart V20 (%)

11.5 (0.0, 52.5)

Heart V30 (%)

6.0 (0.0, 49.2)

Heart V40 (%)

0.7 (0.0, 38.9)

Mean Heart Dose (Gy)

8.7 (1.6, 26.9)
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Table 4.3.

Univariable

logistic

regression

models

examining

the

relationship between individual predictors of pneumonitis
grade ≥2 (n=31).

** overall analysis of effects (applicable to categorical variables only)
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In total, 79 follow-up CT scans for 27 patients were co-registered with
baseline CT scans and analyzed for RILI, with a median of three follow-up CT
scans per patient (range 1-6). Following analysis of the post-treatment scans,
linear mixed modelling showed both radiation dose and time post-treatment to be
highly predictive of CT RILI (p<0.001 and p=0.021, respectively). Overall density
changes at low dose levels (<10Gy) were minor, but a marked increase evident
with increasing dose, with regions receiving ≥20Gy exhibiting density increases
of 100 HU or more (Figure 4.2). For both 6-12 months and >12 months posttreatment, significant differences in density change were observed across all
dose bands (both p<0.001), with greater differences observed for higher dose
bands compared to lower dose bands, respectively. This trend was also
observed during the 3-6 month period, although was not found to be significant
(p=0.058).
Patients with symptomatic RP were observed to have higher rates of
density change across all dose levels (Figure 4.3), with significant differences
observed in the low-dose (5-10Gy, p=0.040) and high-dose regions (>40Gy,
p=0.024). Patients who developed RP also had significantly larger CT density
changes than patients without RP at both 6-12 months (p=0.002) and >12
months (p = 0.013) post-treatments, suggesting a sustained effect transitioning to
fibrosis.
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Figure 4.2. Estimated means (± standard error) for CT lung density
changes (in Hounsfield Units (HU)) over time (months),
stratified by radiation dose (Gy).
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Figure 4.3. Estimated means (± standard error) for CT lung density
changes (HU) relative to radiation dose (Gy), stratified by
pneumonitis grade ≥2 versus <2.
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4.4 DISCUSSION
In animal models, CT-based HU density changes after radiotherapy are
strong surrogates of RILI, and correlate with histologic evidence of radiation
injury, including the presence of inflammatory cells and infiltrative changes in the
irradiated lung [19]. In this study of taxane-based concurrent chemoradiotherapy
for LABC, more than half of patients developed symptomatic RP and one patient
sustained a grade 5 toxicity. RILI was evident even in regions areas of lung
receiving modest doses of radiotherapy, with a significant relationship evident
between radiation dose, time post-treatment, and RILI.
The extent of CT-based RILI evident in this cohort appears to be higher
than in patients who do not receive concurrent taxanes. In a cohort of 25 patients
with stage III NSCLC where CT-based RILI was measured after cisplatin-based
(non-taxane) chemotherapy with 60-66Gy of radiotherapy, there was no change
in HU density within the first 3 months after treatment at any dose level. In that
group, regions of lung receiving 40-50Gy did not show increases of more than
100 HU at any time in follow-up [18]. Similar results were seen in a mixed cohort
of 118 patients, including breast cancer, lymphoma, and lung cancer patients
treated with a variety of fractionations: relative to the lowest dose levels (0-5Gy),
areas receiving modest doses of radiotherapy (<40Gy), showed very little RILI at
3-months, and relatively minor HU increases (<50 HU) with further follow-up.
Although care must be taken in drawing conclusions from comparisons across
studies, due to differences in baseline factors and data collection, these findings
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suggest that the more profound, early HU increase seen herein (Figure 4.2) may
be related to the radiosensitizing properties of concurrent taxanes.
When

given

concurrently

with

radiotherapy,

taxanes

are

potent

radiosensitizers [20-23], a property that this phase II study attempted to exploit to
improve the pCR rate. Locoregional radiation for breast cancer is usually well
tolerated, with only <5% of patients experiencing symptomatic RP, which is
typically transient [12]. In a recent randomized trial of locoregional vs. local
radiotherapy after lumpectomy for node-positive breast cancer, the rate of RP in
the arm receiving locoregional radiotherapy was 2.3% [13]. Although the final
data on oncologic outcomes, including pCR rate and survival, will be reported
once the data matures, this interim analysis suggests that concurrent taxanebased chemoradiotherapy for breast cancer should be used with caution and
only in the context of a controlled trial. The radiosensitizing properties of taxanes
are recognized in the treatment of non-small cell lung cancer. For such patients,
a recent individual patient data meta-analysis demonstrated that the use of
taxane compared to non-taxane chemotherapy with radiotherapy was a
significant predictor for developing pneumonitis (p<0.001) [14].
Since taxanes have become incorporated into routine oncologic use for
node-positive breast cancer, the challenge of maximizing their benefits while
minimizing toxicity, namely pneumonitis, has become complex. The synergistic
interaction of taxanes and radiotherapy has shown promise with regards to
disease-free and overall survival of patients with node positive breast cancer [24,
25], yet pneumonitis remains an important cause of morbidity. Limited studies
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have been conducted for concurrent chemoradiotherapy to treat LABC, but a few
small trials have shown promise and are the basis upon which we conducted our
phase II trial [26, 27]. A retrospective review of 44 high-risk breast cancer
patients demonstrated the feasibility of concurrent radiation delivered with either
paclitaxel or docetaxel every three weeks [26]. Treatment was well tolerated with
nine (20%) patients experiencing Grade 3 skin toxicity, with higher rates of
toxicity associated with docetaxel, and no reports of pneumonitis. Another study
was conducted on 44 LABC patients who received 30 mg/m2 paclitaxel twice
weekly with concurrent radiation prior to surgery [27]. An improved pCR was
achieved, with acceptable toxicity and no cases of RP. These differences in RP
may be related to choice of taxane (docetaxel vs. paclitaxel), their dosing, or the
frequency of administration, and further research is needed to determine the
optimal, safe parameters.
The findings of this study must be considered in the context of its
strengths and limitations. The clinical data used herein was collected as part of a
rigorous, phase II trial, but the analysis of CT-based RILI was an unplanned,
retrospective analysis. The CT registration process is associated with some
inherent imprecision [28], which we attempted to correct by manually inspecting
and correcting isodose line contours. Some CT scans were done at the discretion
of the treating oncologists, which may introduce unmeasured confounding factors.
The small sample size resulted in limited power to detect predictors of RP, and
the selected nature of the study population may affect the generalizability of our
findings.
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In

conclusion,

rates

of

RP

after

concurrent

docetaxel-based

chemoradiotherapy are higher than would be expected after breast radiotherapy.
In this population, CT density changes of RILI occur earlier and appear to be
more profound than in other studies measuring RILI after thoracic radiotherapy,
suggesting a radiosensitizing effect of the docetaxel. Mature oncologic outcomes
from this study are required to fully define the therapeutic ratio, but in the interim,
concurrent taxane-based chemoradiotherapy should be used cautiously. Further
study is needed to determine optimal, safe strategies for delivery of highly active
chemotherapy with locoregional radiotherapy for patients with LABC.
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CHAPTER 5: GENERAL DISCUSSION

5.1 OVERVIEW OF RESULTS
Locally advanced breast cancer (LABC) represents a challenging
subgroup of advanced disease requiring more aggressive treatment than is
currently being provided, given its low survival. Chapter 1 of this thesis
represents an overall review of breast cancer and of the existing LABC treatment
[1]. The current guidelines for LABC patients on for Cancer Care Ontario can be
found in Appendix II [2]. Chapter 2 represents a clinical trial that was undertaken.
Thirty-two LABC patients were treated with neoadjuvant FEC-weeklyD
chemotherapy with concurrent locoregional radiation during docetaxel, reporting
the clinical outcomes of this study. The full protocol for this clinical trial can be
found in Appendix III. Chapter 3 represents a biological correlative study of the
same clinical trial, evaluating plasma osteopontin (OPN) as a tumour biomarker
and predictor of response to treatment or prognostic marker of survival [3].
Chapter 4 represents an evaluation of the radiation pneumonitis toxicity seen
during this same clinical trial, which ultimately resulted in its premature
termination [4]. In addition, other exploratory biological correlative substudies
were undertaken, and the results are reported in Appendix IV. The findings of the
studies reported in each chapter of this thesis are summarized separately below.
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5.1.1 Neoadjuvant Chemoradiation Therapy in LABC
Thirty-two LABC patients were treated with neoadjuvant FEC q3 weekly x
3 cycles followed by weekly docetaxel x 9 cycles with locoregional radiation
delivered during the first 6 of these weeks (45Gy in 25 fractions plus 5.4Gy in 3
or 9Gy in 5 fractions). All patients underwent a modified radical mastectomy five
weeks after completing treatment. These patients were matched 1:3 to a
concurrent control cohort of LABC patients treated with the standard treatment
sequence (neoadjuvant chemotherapy regimen AC-D or FEC-D) using
propensity matching, where 27 patients were successfully matched to 81 control
patients for age, stage and molecular subtype.
Patients treated with the study regimen using concurrent chemoradiation
were significantly more likely to have a pathological complete response to
treatment (i.e. no residual invasive breast cancer in the breast or lymph nodes).
There was a trend towards a 15% improvement in overall and disease-free
survival that failed to reach statistical significance to due premature termination
of the study following one treatment-related death.
Based on the results of the clinical trial reported in this thesis, and given
the poor clinical outcomes in LABC, the improvement in treatment response with
concurrent chemoradiation by exploiting the radiosensitization of taxanes should
be further explored.
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5.1.2 Osteopontin as a Tumour Marker
Osteopontin is a secreted, integrin-binding phosphoprotein found in
several tissue types, including breast cancer. Plasma OPN levels have been
demonstrated to be prognostic among metastatic breast cancer patients, where
baseline levels at diagnosis were significantly elevated in comparison to normal
healthy controls. There have been no studies to-date evaluating OPN levels
among locally advanced, but not yet metastatic, breast cancer patients.
OPN levels were measured in 32 patients with LABC treated every three
weeks during neoadjuvant q3 weekly FEC chemotherapy followed by weekly
docetaxel concurrent with locoregional external beam radiation (see Chapter 3).
These patients were added to 20 LABC patients treated with neoadjuvant
anthracycline and cyclophosphamide q3 weekly x 4 cycles followed by docetaxel
q3 weekly x 4 cycles, where OPN levels were also collected every 3 weeks. OPN
levels were measured using ELISA. The serial OPN levels seemed to
demonstrate a slight trend toward increasing over treatment, which did not
appear to be related to clinical response to treatment. Baseline pre-treatment
OPN levels were studied and contrasted to clinical outcomes, to evaluate
whether plasma OPN levels predicted treatment response. Our study
demonstrated that, when the patient population was dichotomized based on the
median value of 63ng/mL, baseline elevated OPN level significantly predicted for
overall survival, and showed a trend to predicting pathological response to
treatment [3].
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Thus, OPN appears to be a predictive marker for neoadjuvant treatment
response in LABC, as well as a known prognostic marker for metastatic breast
cancer. These findings should be validated in a larger prospective clinical trial.

5.1.3 Toxicity of the Neoadjuvant Chemoradiation Therapy
Although chemosensitization by docetaxel resulted in an increased pCR
and a trend toward improved disease-free and overall survival, it was not without
an increase in toxicity (see Chapter 4). Eight of the 32 patients experienced
grade 3 pneumonitis following docetaxel and radiation, most commonly
presenting as shortness of breath at 1-2 weeks after the completion of radiation.
One patient, who was a long-time smoker, was the only patient to require
transient oxygen therapy. All were treated with a tapering regimen of high dose
steroids (see study protocol, Appendix III), and in all but one of these cases,
patients were clinically resolved by the time surgery was done 5 weeks later. The
prior smoker remained with grade 1 shortness of breath for several months after
surgery. One patient experienced acute respiratory distress syndrome after
having been treated bilaterally with radiation using intensity-modulated radiation
therapy for bilateral locally advanced breast cancer. As a result of this death, the
study’s independent data safety monitoring committee recommended premature
termination of the study.
Radiation dosage and time to radiation were found to be predictive of
radiation-induced lung injury. Serial CT lung images of patients with pneumonitis
were contrasted to the radiation planning CT images for the 27 of 32 patients
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who had follow-up CT scans of the lungs after radiation. Lung tissue density was
found to increase with increasing radiation dosage, time and degree of
pneumonitis [4].
Radiation density was found to be higher than expected from radiation
alone, and therefore it is possible that docetaxel itself resulted in chemical
pneumonitis secondary to its known capillary leak syndrome risk. Prior studies
evaluating the use of another taxane, paclitaxel, with concurrent radiation
showed very low rates of clinical pneumonitis [5, 6]. If this concurrent
radiosensitizing chemotherapy regimen is considered for future trials, it is
recommended that paclitaxel, rather than docetaxel, be utilized in order to avoid
this toxicity while retaining its beneficial effects on improvement of pCR.

5.2 LIMITATIONS AND FUTURE DIRECTIONS
The clinical trial reported in this thesis was a prospective single arm Phase
II trial, and as such, it is prone to limitations common to all studies that are not
randomized controlled. Despite every effort being made to independently match
the patients to concurrently treated control patients by variables that could impact
on pCR or survival, it remains possible that other patient, tumour or treatment
factors were not adjusted between the two groups, and therefore impacted on the
differences in pCR rates, disease-free and overall survival rates seen. This
finding should therefore be validated in a prospective randomized controlled trial.
More needs to be understood about the relationship between regional
radiation therapy and resultant improved overall survival. An older but eloquent
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simple study done by Wallgren and colleagues in 1978 [7] randomized patients
with breast cancer to preoperative versus postoperative radiation. These patients
all received the same radiation modality, all had modified radical mastectomies
and did not receive any hormonal therapy or chemotherapy. Consequently, any
impact on overall survival can be attributed to the random assignment of
radiation timing. Patients who received preoperative radiation had a significantly
improved survival compared with postoperatively treated patients. More recent
work in the exploding field of immuno-oncology has suggested that radiation may
prime immunogenic cell death, likely by a number of mechanisms related to
antigenic T-cell activation [8]. Clearly, more research needs to be done, but
further work should focus on exploration of the tumour antigen priming effects of
radiation when delivered preoperatively in breast cancer patients. Future trials
involving preoperative radiation should all include the collection of serial tumour
samples, in order to evaluate this potential complex immunogenic effect of
radiation.
Given the toxicity seen with docetaxel, specifically resulting in pneumonitis
rates higher than expected from radiation alone or from other taxanes, such as
paclitaxel concurrent with radiation, future randomized trials should be
considered with paclitaxel using the dosage and schedule evaluated by Dr.
Formenti and colleagues [5]. It has only been studied in a sandwich regimen with
neoadjuvant paclitaxel twice weekly with concurrent locoregional radiation
followed by surgery followed by anthracycline-based chemotherapy. Therefore, a
future trial should be undertaken to exploit chemosensitizing radiation impacts on
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clinical response to treatment with a novel regimen using paclitaxel, such as
anthracycline and cyclophosphamide q2-3 weekly x 4 cycles followed by twice
weekly paclitaxel x 9 weeks with locoregional radiation during the first 6 of those
weeks. Patients should be randomized to this novel regimen versus the same
regimen delivered in the adjuvant setting. This could be followed by breast
conserving surgery for patients experiencing a good response to treatment, or
mastectomy for those with a less favourable response to treatment.
At the time that this clinical trial was undertaken, there were significant
shortages in cancer funding to hospitals, and chemotherapy chair time was at a
premium. It was, therefore, not feasible to propose a clinical trial where patients
who were currently receiving chemotherapy once every 3 weeks would instead
be coming for chemotherapy twice a week. Since that time, weekly paclitaxel and
weekly docetaxel regimens have become much more common. As a result, it is
much less of a stretch to propose a twice-weekly regimen to patients who would
otherwise be treated weekly during the taxane component of chemotherapy.

5.3 CONCLUSION
A phase II clinical trial was undertaken in LABC patients treated with a
novel neoadjuvant chemotherapy regimen, where docetaxel was given weekly
and concurrently with daily locoregional radiation. When compared to standard
treatment, chemoradiation significantly improved pCR and appeared to show a
trend in improved disease-free and overall survival. This needs to be exploited in
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future randomized clinical trials using paclitaxel, to avoid an elevated risk of
pneumonitis. Plasma OPN as a prognostic tumour biomarker can then also be
validated in this future proposed trial.

5.4 REFERENCES
1.
Mandilaras V, Bouganim N, Spayne J, Dent R, Arnaout A, Boileau JF, et
al. (2015) Concurrent chemoradiotherapy for locally advanced breast cancer-time
for a new paradigm? Curr Oncol 22(1):25-32.
2.
Brackstone M, Fletcher GG, Dayes IS, Madarnas Y, SenGupta SK, Verma
S, et al. Locoregional therapy of locally advanced breast cancer: a clinical
practice guideline. Curr Oncol 22(Suppl 1):S54-66.
3.
Anborgh PH, Caria LB, Chambers AF, Tuck AB, Stitt LW, Brackstone M
(2015) Role of plasma osteopontin as a biomarker in locally advanced breast
cancer. Am J Transl Res. 2015;7(4):723-32.
4.
Chow TL, Louie AV, Palma DA, D'Souza DP, Perera F, Rodrigues GB, et
al. (2014) Radiation-induced lung injury after concurrent neoadjuvant
chemoradiotherapy for locally advanced breast cancer. Acta Oncol 53(5):697701.
5.
Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, et al.
(2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy
followed by surgery and postoperative doxorubicin-based chemotherapy in
locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21(5):864-70.
6.
Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, et
al. (2010) Preoperative concurrent paclitaxel-radiation in locally advanced breast
cancer: pathologic response correlates with five-year overall survival. Breast
Cancer Res Treatment 124(3):723-32.
7.
Wallgren A, Arner O, Bergstrom J, Blomstedt B, Granberg PO, Karnstrom
L, Raf L, Silfversward C (1978) Preoperative radiotherapy in operable breast
cancer: results in the Stockholm Breast Cancer Trial. Cancer 42(3):1120-5.
8.
Golden EB, Apetoh L (2015) Radiotherapy and immunogenic cell death.
Sem Rad Oncol 25:11-17.

117

APPENDICES

118
APPENDIX I. RESEARCH ETHICS BOARD APPROVAL

119

APPENDIX II

Locoregional Therapy of Locally Advanced Breast Cancer:
Guideline Recommendations

A version of this chapter was published, with M. Brackstone as the first author:
Brackstone M, Fletcher GG, Dayes IS, Madarnas Y, SenGupta SK, Verma S and
Members of Breast Cancer Disease Site Group. Curr Oncol 2015, vol.
22(Suppl1): S54 –66. Reproduced with permission.

120
APPENDIX II: LOCOREGIONAL THERAPY OF LOCALLY ADVANCED
BREAST CANCER: GUIDELINE RECOMMENDATIONS

II.1 INTRODUCTION
This guideline addresses several questions related LABC as defined
previously.

In early breast cancer, breast-conserving surgery (BCS) with

adjuvant radiotherapy (RT) has been found equivalent to mastectomy (in patients
meeting BCS selection criteria) for long-term outcomes and it is preferred by
many patients for cosmetic and psychological reasons. The applicability of BCS
to LABC and the use and extent of RT after mastectomy is still a matter of debate.
Historically, LABC has had poor outcomes. Although neoadjuvant (preoperative,
induction) therapy was first introduced in an attempt to improve tumour
resectability and overall survival (OS) rate with early adjuvant treatment,
improved OS was not realized [1-5].

However, other clinically important

outcomes were observed, including disease downstaging and feasibility of breast
conservation in select cases, which form the basis for continued use of this
approach. Furthermore, neoadjuvant chemotherapy (NACT) also allows an in
vivo assessment of chemosensitivity, potentially allowing a regimen change that
would not otherwise be made with traditional postoperative adjuvant treatment.
Finally, NACT provides a platform for important biomarker and correlative studies
to enhance our understanding of this disease.
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Although BCS becomes technically feasible in some patients with LABC
with good response to NACT, there is uncertainty as to whether mastectomy or
BCS is most appropriate. Conversely, optimal treatment when LABC does not
respond to initial NACT is unclear. Sentinel lymph node biopsy (SLNB) is used in
early breast cancer as an alternative to full axillary lymph node dissection (ALND).
The role of SLNB compared with ALND in patients with LABC receiving NACT
has not been established.
NACT has expanded beyond classically unresectable LABC and it is being
used more frequently for some smaller tumours, especially certain biologic
subtypes (e.g., triple negative, HER2+). Although this document does not
evaluate effectiveness of NACT, its expanded use means that clinical trials often
cover a heterogeneous patient population (see Section III.1.2 Target Population).

II.2 METHODS
II.2.1 Guideline Development
The evidence-based guideline series developed by Cancer Care Ontario’s
(CCO’s) Program in Evidence-Based Care (PEBC) use the methods of the
practice guidelines development cycle. The core methodology used to develop
the evidentiary base for the present project was the systematic review. The
resulting evidence underpins the recommendations developed by the working
group and the Breast Cancer Disease Site Group (DSG). The systematic review
and companion recommendations are intended to promote evidence-based
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practice in Ontario. The full three-part evidence series can be found on the
Cancer Care Ontario (CCO) Web site.

II.2.2 Questions
1.

In female patients with locally advanced breast cancer with good response
to neoadjuvant therapy, what is the role of breast-conserving surgery
(BCS) compared with mastectomy?

2.

In female patients with LABC,
a.

is radiotherapy indicated for those who had mastectomy?

b.

does locoregional irradiation result in higher survival and lower
recurrence rates compared with breast/chest wall irradiation alone?

c.

is RT indicated for those achieving pathological complete response
(pCR) to NACT?

3.

In female patients with locally advanced breast cancer who receive
neoadjuvant chemotherapy is sentinel lymph node biopsy (SLNB) or
axillary dissection the most appropriate axillary staging procedure?

Is

SLNB indicated before neoadjuvant chemotherapy rather than at the time
of surgery?
4.

How should female patients with locally advanced breast cancer who do
not respond to initial neoadjuvant therapy be treated?
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II.2.3 Target Population
This guideline is pertinent to female patients with locally advanced breast
cancer (LABC). For purposes of this guideline, LABC includes Stages IIB and
IIIABC and inflammatory cancer, as defined in the AJCC Cancer Staging Manual,
6th edition [6]. Most studies in the evidentiary base (see Section 2) included
heterogeneous populations spanning Stages IIB – IIIC and sometimes included
inflammatory breast cancer. Very few studies dealt only with Stage III or specific
subgroups such as patients with T3N0 cancer. As most of the major studies did
not report results separately for patients with Stage IIB and Stage III cancers, the
evidence did not support recommendations based on a narrower definition of
LABC or subdivided by stage. Although some people do not consider Stage IIB
to be locally advanced, there is an increasing trend to treat less bulky disease
(Stage IIB) in a similar manner, including neoadjuvant therapy; therefore, the
recommendations may also be applicable to this group.

II.2.3.1 Intended Users
The intended users are surgeons and medical and radiation oncologists
specializing in breast cancer.

II.2.4 Literature Search
The full search strategy and inclusion criteria are presented in the
systematic review (Brackstone et al, 2014); only a brief summary is provided
here. The literature in the medline and embase databases (1996 to December 11,
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2013) and the Cochrane Library was searched for relevant studies. Searches of
the Web sites of Canadian and international health organizations were also
conducted to identify existing clinical practice guidelines, systematic reviews, and
health technology assessments relevant to the guideline questions. All studies
identified through the literature search were assessed against the selection
criteria by a health research methodologist from the working group (GGF), with
Cindy Walker–Dilks screening results from preliminary searches. Studies of
uncertain eligibility were discussed with the other authors.
The literature search was designed to retrieve systematic reviews, metaanalyses, randomized control trials (RCTS), cohort studies, and clinical practice
guidelines concerning locoregional therapy for LABC. Studies had to include at
least 50 patients (except for question 4), have a prospective design, and provide
a statistical comparison of the interventions of interest. Systematic reviews and
meta-analyses had to include a description of the review methods (literature
search, study selection, data extraction).
Randomized controlled trials were included if they addressed stages IIB
and IIIABC disease (including inflammatory breast cancer), as were RCTS that
addressed stage II (unspecified) and stage IIA disease, provided that stage I plus
stage IIA disease constituted fewer than half the cases or that subgroup results
for either or both of stages IIB and III were available. Studies in which the title
and abstract indicated only “early breast cancer” with no mention of stage or
other indication that patients meeting our definition of LABC might form all or part
of the population were excluded. An exception was made for RCTs located
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based on another publication about LABC (review, guideline, or RCT): in such
cases, the Methods and Results of the original RCT publication were reviewed to
determine whether the study group actually met our definition of LABC despite a
title and abstract indicating otherwise. Studies in which the cancer was described
as metastatic were excluded unless metastasis only to regional lymph nodes was
mentioned. Randomized controlled studies were the preferred publications.
Cohort studies were considered in the initial screening, but were included only if
the comparison groups were equivalent—for example, they had a similar tumour
stage distribution. Cohort studies were excluded if the patients were assigned to
treatment based on patient and disease factors instead of randomly, such that
the prognoses in the groups (before treatment) were not equivalent.
For question 2(b) about the extent of RT (whole breast or chest wall, or
locoregional), studies were excluded if they focused on partial compared with
whole-breast irradiation (for example, accelerated partial breast irradiation,
brachytherapy, intensity-modulated radiation therapy) or on intraoperative
techniques (for example, targeted intraoperative radiotherapy or intraoperative
radiotherapy with electrons), or if they compared RT techniques (dose-density,
boost, hypofractionation) or focused on simulation or treatment planning.

II.2.5. Development of Recommendations
The working group drafted recommendations based on the systematic
review. Where evidence from RCTs was limited, recommendations were based
on the authors’ professional experience, together with a consideration of current
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practice and recommendations in other guidelines. Such limitations are clearly
indicated in the key evidence and qualifying statements that follow each
recommendation.

II.2.6. Internal and External Review Process
Before submission of the draft report for external review, the systematic
review and practice guideline were reviewed by the members of the Breast
Cancer DSG and the PEBC Report Approval Panel (RAP). The latter group
consists of the PEBC director and two other members with expertise in clinical
and methodology issues. The DSG and RAP members reviewed the draft
systematic review and practice guideline and provided feedback, which was
incorporated into the guideline. The revised draft document was then distributed
for external review. External review included both targeted peer review (intended
to obtain direct feedback from a small number of content experts) and
professional consultation (intended to facilitate dissemination of the guideline to
Ontario practitioners and to provide opportunity for additional feedback). Results
of those two sources of feedback can be found in the full guideline report on the
CCO website (Brackstone et al, 2014).

II.3

RESULTS
After removal of duplicate citations, the searches in Medline and embase

resulted in 42,138 publications. After application of the inclusion and exclusion
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criteria, 143 publications of trials, 18 clinical practice guidelines, and 27
systematic reviews or meta-analyses remained. Most studies included a mix of
cancer stages. The full systematic review (Brackstone et al. 2014) provides
details of the methodologic characteristics and clinical outcomes of the included
trials.
No studies meeting the inclusion criteria were located for question 1 (BCS
vs. mastectomy after good response to NACT). Several RCTs dealt with question
2(a) (RT after mastectomy), with some studies including patients receiving
anthracycline-based chemotherapy, but not taxanes. For question 2(b) (extent of
RT), one prospective nonrandomized study [7] met the inclusion criteria. Three
RCTs were relevant (two published only as abstracts), but they included both
early cancer and LABC and therefore did not meet the threshold of 50% or more
of the patients having stage IIB–III cancer. A large number of studies compared
the technical feasibility of SLNB and ALND, but they did not compare long-term
survival outcomes. Data for question 4 were also very limited.

II.4. DOCUMENT REVIEW PROCESS
II.4.1. Internal Review
During the internal review by DSG members (other than those of the
working group), 16 approved the document, 1 had strong concerns about the
inclusion of stage IIB in the guideline and did not approve, and 1 abstained
because the document was outside his area of expertise. Most of the comments
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received were related to the definition of LABC. Although 1 reviewer preferred
that stage IIB be removed from the definition of LABC, the working group decided
that it was neither feasible nor desirable to redo the evidence summary, because
most studies reported a heterogeneous patient group, and few dealt specifically
with stage III cancers. As suggested by 1 reviewer, we incorporated a footnote
describing the rationale and limitations of the LABC definition into the text
describing the target population, because those aspects are essential to the
document and address some of the other comments.
There was concern that, in recommendation 1, modified radical
mastectomy was said to be the standard of care for LABC (that is, for all patients
with LABC) and that such treatment did not really apply to patients with stage IIB
breast cancer. Although the working group did not feel it appropriate to list all
situations in which bcs might be considered, recommendation 1 was modified to
clarify that mastectomy does not apply to everyone and that the judgment of the
surgeon—and patient preference—is required. A qualifying statement was also
revised to clarify that evidence for BCS in LABC is weak overall, but that
exceptions exist.
As a result of 2 comments, we included a qualifying statement for
recommendation 1 indicating that the type of surgery offered (for example, skinsparing mastectomy with immediate reconstruction) continues to evolve, but that
such advancements are beyond the scope of the guideline.
A comment about question 4 suggested that some patient groups (for
example, estrogen receptor–positive, lobular histology) do not respond as well to
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chemotherapy. The working group believes that recommendation 4(b) (consider
second-line chemotherapy, hormonal therapy if appropriate, RT, or immediate
surgery) is sufficient. A separate guideline on lobular cancer could be useful, but
addressing that variant in the current guideline is not feasible.
The RAP members had several suggestions that were addressed in the
revised document. The key evidence and qualifying statements were edited to be
less narrative and more succinct; the reader should review the evidence
summary8 (literature review) for more details. The description of the study
selection

criteria

was

reworded

to

be

clearer

to

the

reader.

The

Recommendations and Key Evidence and Literature Search sections were both
revised to ensure that studies for question 2(b) are clearly understood to have
been conducted in a broad group of patients with stages I–III cancer and not
specifically LABC. Those studies do not meet the inclusion criteria of
approximately 50% or more LABC cases in either the full study or a reported
subgroup analysis; however, two studies were reported only as abstracts and
might include subgroup data relevant to LABC when fully reported. Adverse
effects had been included in the recommendations during the development
process; additional details for some questions were added to the Discussion
section of the systematic review.

II.4.2. External Review
Responses were received from 7 targeted peer reviewers (2 surgical
oncologists, 3 radiation oncologists, 2 medical oncologists) considered to be

130
clinical experts on the topic of the guideline. The documents and a brief
questionnaire were also distributed to professions in our database with an
interest in breast cancer. During the latter professional consultation, 28
responses were received: 10 from medical oncologists, 4 from pathologists, 6
from radiation oncologists, 5 from surgeons, and 3 from surgical oncologists.
Most reviewers considered the guideline to be of high quality and said that they
would make use of it in their practice. Most comments were related to choice of
wording or unclear phrasing, and revisions were made accordingly. Some
reviewers wanted further or more specific recommendations, but available RCT
data would not allow for that. Other queries related to items outside the scope of
the questions and the literature review. Detailed comments and responses from
the authors are reported in the full evidence document8

II.5 RECOMMENDATIONS
II.5.1 Preamble
Communication between physicians, surgeons, and pathologists is
essential. A multidisciplinary case conference is the recommended forum for
discussion of cases.
Any prior use of neoadjuvant therapy should be indicated when specimens
are submitted for pathologic examination.

Clinical details often affect the

pathologic examination and interpretation, whereas details of pathology reports
will determine appropriate treatment. Prior therapy (including neoadjuvant
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therapy) can change the nature of the specimen and what should be reported.
The experience of the authors is that use of neoadjuvant treatment is frequently
not indicated when submitting specimens.
It is recommended that surgical clips marking the original (pretreatment)
tumour location be inserted before administration of neoadjuvant therapy.
Neoadjuvant therapy may result in change in the extent or distribution of tumour,
or complete disappearance (clinically or pathologically complete response). The
consensus reached at the Canadian Consortium for Locally Advanced Breast
Cancer (COLAB) in 2011 [8] was that clips should be inserted at the time of
diagnosis to mark tumour location and this should be considered the standard of
care. Use of clips allows more accurate identification of the original tumour site
(especially if there is complete response), resection of all (previously) cancerous
tissue with adequate margins, pathologic diagnosis of the most appropriate area
of specimens, and better accuracy of molecular analyses.

II.5.2 Recommendation 1
For most patients with LABC, modified radical mastectomy should be
considered to be the standard of care.
BCS may be considered for some patients with non-inflammatory LABC
on a case-by-case basis when the surgeon deems the disease can be fully
resected and there is strong patient preference for breast preservation.
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II.5.2.1 Key Evidence
No randomized controlled trials (RCTs) that directly compared BCS with
mastectomy in patients with LABC were found in the literature review.
Evidence in early breast cancer is that BCS plus radiation is equivalent to
mastectomy alone [9, 10].

There is a continuum in breast cancer stage, as

opposed to a sharp cut-off between early and locally advanced (see Target
Population).

The Cancer Care Ontario/Program in Evidence-Based Care

(CCO/PEBC) guideline [10] included all of Stage I and II, although the Early
Breast Cancer Trialists’ Collaborative Group (EBCTCG) defined early as “breast
cancer in which all clinically apparent disease can be removed surgically” [11].
Therefore, at least some cancers defined as LABC in the current guideline (e.g.,
Stage IIB) are covered in the recommendations of these other guidelines.
Guidelines by the American College of Radiology (ACR) [12], National
Comprehensive Cancer Network (NCCN) [13], and the Consensus Conference
on Neoadjuvant Chemotherapy in Carcinoma of the Breast [14] indicate BCS is
appropriate for some patients with LABC after NACT. This may include small
N2/N3 tumours with nodal response, or large (T3N0 or T3N1) tumours with good
response. NCCN recommends patients initially Stage IIIABC (except T3N1) with
good response be treated with mastectomy or consider lumpectomy (plus ALND
plus radiotherapy). We endorse the criteria for BCS as outlined in the ACR [12]
and Consensus Conference guidelines [14] and The International Expert Panel
on Inflammatory Breast Cancer [15].
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II.5.2.2 Qualifying Statements
Patients should be informed that for LABC as a whole the data are
insufficient to recommend BCS as a rule; however, there may be some
exceptions that can be considered on a case-by-case basis.
The extent of surgery, including BCS, should be determined after full
discussion between the patient and the treating oncologist, taking into
consideration the patient’s values and the lack of direct evidence regarding the
relative benefit of BCS versus mastectomy in this particular situation.
When considering between mastectomy and BCS (for those meeting
selection criteria), benefits and harms must be weighed. BCS is considered to
have generally better cosmetic effects, and for some female patients may have
less impact on body image, self-esteem and sexuality than complete breast
removal by mastectomy.

With BCS there is usually no need for additional

reconstructive surgery and the operation may be less complex. In some cases of
BCS, there may be positive margins requiring re-excision. In cases of recurrence
after BCS, further surgery may be needed, and some patients may wish to
eliminate this possibility by having mastectomy as initial treatment.
Wide excision of the remaining tumour in the region of the original preneoadjuvant treatment tumour bed plus RT is recommended for patients with
LABC who strongly desire BCS.
BCS is not advised in inflammatory breast cancer because the extent of
tumour involvement cannot be reliably ascertained.
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There is continuing evolution in the type of surgery offered (e.g., skinsparing mastectomy with immediate reconstruction), but these are beyond the
scope of this guideline.

II.5.3 Recommendation 2(a)
Radiotherapy following mastectomy is recommended for patients with
LABC.

II.5.3.1 Key Evidence
The EBCTCG meta-analyses [16] found radiotherapy (RT) reduced
recurrence rates and increased survival rates in high-risk patients (15-year breast
cancer mortality rate 44.6% vs 49.5%, p<0.00001; overall mortality rate 51.4% vs
55.2%, p=0.0002).
In patients with node-positive breast cancer who had mastectomy plus
axillary clearance (ALND) there was improvement in 5-year local recurrence risk
(5.8% vs 22.8%, p<0.00001), 15-year breast cancer mortality risk (54.7% vs
60.1%, p=0.0002), and 15-year overall mortality rate (59.8% vs 64.2%,
p=0.0009). There were significantly increased survival rates in patients with 1-3
positive nodes or ≥4 positive nodes, for all T groups, and for patients receiving
systemic therapy.
The benefit of RT in reducing breast cancer recurrence and mortality rates
appears to be offset by adverse effects in older trials (primarily cardiovascular
and lung adverse effects) especially in female patients with low risk of recurrence.
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The ratio of breast cancer mortality rate to other mortality rates was strongly
affected by nodal status, age, and decade of follow-up. The absolute benefit still
favoured RT overall, but not necessarily in subgroups with particularly low risk of
recurrence. More recent reviews found that the effectiveness of RT is increased
and cardiopulmonary adverse effects are greatly reduced with modern RT
planning and technique; therefore, the non-cancer mortality rate data in the
EBCTCG meta-analyses may not be relevant to current practice.

II.5.3.2 Qualifying Statements
The use of three-dimensional (3D) treatment planning is important to
minimize the dose to the lung and heart to ensure improvements in breastcancer-specific survival rates are not offset by non-breast cancer mortality rates.
Treatments provided should conform to accepted standards with respect to
tissue coverage and dose. Techniques such as gated RT or active breath-hold
are used in some centres to reduce cardiotoxicity, although these were not
evaluated in this guideline series.
Radiotherapy after BCS was not part of this review, however guidelines for
early breast cancer recommend radiation following BCS [9, 10] and this is the
current standard of care. In the absence of RCTs to the contrary, it is logical that
radiation be used following BCS for LABC as well. Radiotherapy following BCS
for LABC is the current standard of care.
The EBCTCG meta-analysis found RT improved recurrence and survival
rates in the subgroup of patients with systemic treatment, and improved
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recurrence rates (but without significant improvement in survival rate) in patients
without systemic treatment. RT significantly improved the local recurrence rate in
patients receiving anthracycline-based chemotherapy but there was no effect on
survival rate.

Several of the studies used older regimens such as

cyclophosphamide + methotrexate + fluorouracil (CMF). Whelan et al [17] also
found RT reduced mortality in patients with node-positive breast cancer who
received systemic treatment. No studies were included in the systematic review
using taxane-based chemotherapy.

Newer chemotherapies and targeted

therapies may reduce the absolute benefit of RT for some patients, although in
the absence of RCTs, RT is still recommended.
Patients should be informed that improvements in recurrence and
disease-specific survival rates have not necessarily translated into advantages in
OS, possibly related to radiation-induced adverse effects in older studies. This
may be especially relevant to patients with low risk of recurrence. RT reduced
the recurrence rates in all groups reported, but the absolute benefit in patients
with very low risk of recurrence due to disease characteristics and systemic
therapy may be small, and some may consider the incremental benefit of RT,
although statistically significant, to be clinically unimportant.
Lymphedema is more likely when surgery includes ALND or/and when RT
includes the nodal areas. Decreased shoulder mobility, decreased strength, arm
weakness, and paresthesia/hypesthesia have also been reported.

The

Bundesministrium für Forshung und Technologie (BMFT; German Breast-Cancer
Study Group) 03 study [18] found that 25% of RT patients had acute skin
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reactions, and 28% had long-term skin alterations (1-2 years after RT).
Radiation pneumonitis has been reported in approximately 4% of patients [19,
20], although this increased to 23% (p=0.008) when RT and anthracycline
chemotherapy were both used. In some older RT regimens there was a
significant increase in contralateral breast cancer and non-cancer mortality rates,
primarily from heart disease and lung cancer [16, 21]. Careful treatment planning
is likely to reduce (but not eliminate) risks other than lymphedema and skin
effects.
The benefit of post-mastectomy radiotherapy (PMRT) in patients with
node-negative LABC (T3-4, N0) is less clear because they have not been
reported in isolation. The fourth cycle of EBCTCG [16] revealed that patients
with T3-4 cancer experienced a 5.7% reduction in mortality rate (70.1% vs 75.8%,
p=0.20), whereas patients with node-negative cancer (primarily early cancer) had
a 4.2% increase in mortality rate (42.4% vs 38.2%, p=0.0002). Patients with
T3N0 cancer remain a group with limited data and should be discussed
individually with regards to risks and benefits.

II.5.4 Recommendation 2(b)
It is recommended that patients with LABC receive locoregional radiation
encompassing the breast/chest wall and local node-bearing areas following
breast-conserving surgery or mastectomy.
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II.5.4.1 Key Evidence
The recommendation for breast/chest wall irradiation is based on several
RCTs as summarized in the EBCTCG meta-analyses [11, 16, 22-25] and is
discussed in Question 2a.
A prospective nonrandomized study [26] in high-risk patients with Stage IIIII breast cancer found improved disease-free survival (DFS) rates at median 77
months follow-up (73% with internal mammary (IM) node RT vs 52% without,
p=0.02), whereas OS was 78% vs 64%, p=0.08. Subgroups at higher risk of
recurrence may have greater benefit, as has been reported for patients with
positive nodes.
A meta-analysis of the role of RT to regional nodes included three trials
(two abstracts and one full publication) in patients with early/LABC [27] and
concluded that regional RT to IM and medial supraclavicular (MS) nodes
improves DFS, OS, and distant metastasis-free survival (DMFS) in Stage I-III
breast cancer. This analysis did not meet our inclusion criteria because only
approximately 36% of patients had LABC; therefore, the results need to be
confirmed when the trials are fully published including subgroup data.
The recommendation to include local node-bearing areas is consistent
with current practice and other clinical practice guidelines. The NCCN guideline
[13] recommends that if IM lymph nodes are clinically or pathologically positive,
RT should be administered to the IM nodes; otherwise, treatment to the IM nodes
should be strongly considered in patients with node-positive and T3N0 cancer.
NCCN also states that RT to the infraclavicular region and supraclavicular area is
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recommended for patients with ≥4 positive nodes and should be strongly
considered if 1-3 nodes are positive, and considered for patients with T3N0
cancer (especially if inadequate axillary evaluation or extensive lymphovascular
invasion).
The American College of Radiology [28] recommends PMRT for T1-2N2+
and T3-4N+, usually including ipsilateral supraclavicular fossa for patients with
positive nodes. There is more variation for IM nodes, but IM RT is considered for
patients at risk of IM involvement such as those with medial or centrally located
tumours and positive axillary lymph nodes.

PMRT treatment of T1-2N1 and

T3NO is controversial and should be individualized.

II.5.4.2 Qualifying Statements
Locoregional treatment (compared with breast/chest wall alone) increases
the risk for cardiovascular/pulmonary adverse effects. The additional fields are
more technically complex to administer. The use of 3D treatment planning is
important to minimize the dose to the lung and heart to ensure improvements in
breast-cancer-specific survival are not offset by non-breast cancer mortality.
The risk of long-term adverse effects from locoregional radiation should be
weighed against the potential benefits in patients with lower-risk disease,
particularly those with left-sided tumours. Ideally, such patients should be
discussed in a multidisciplinary setting.
In light of the incomplete data, any recommendations regarding the role of
extended radiation in LABC are significantly limited. Although some studies
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attempted to isolate the role of irradiation to the IM nodes [29, 30], others
included additional radiation to the MS nodes [31-33] or all locoregional nodes
[34, 35].
The additional benefit of regional nodal RT is small, but significant for the
overall patient groups studied in RCTs (early cancers plus LABC combined).
The incidence and/or severity of lymphedema is higher with locoregional
RT. Especially in patients with lower-risk disease, the risk of long-term adverse
effects from locoregional radiation should be weighed against the potential
benefit of reduced recurrence rates and increased survival rates.
Patients with T3N0 cancer (verified to be N0 pre- and post-neoadjuvant
therapy) remain a group with limited data and should be discussed individually
with regards to risks and benefits. An updated EBCTCG analysis on mastectomy
patients [36] was published in March 2014 (after the literature review). A
comparison of the effect of RT in female patients with node-negative cancer who
had axillary sampling or ALND found RT significantly reduced recurrence only in
those with axillary sampling. Patients with ALND had significantly worse overall
mortality with RT than without (RR=1.23, p=0.03), whereas in patients with
axillary sampling RT had no significant effect (RR=1.00, p>0.1). Although this
does not separate the effect of locoregional from chest wall RT, it suggests that
RT to the axilla is necessary when there is not full ALND.
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II.5.5 Recommendation 2(c)
It is recommended that postoperative radiotherapy remains the standard
of care for patients with LABC who have pathologically complete response to
neoadjuvant therapy.
II.5.5.1 Qualifying Statements
No prospective randomized studies were found in the literature review
(see Section 2) that compared treatment with vs without RT in female patients
with pathologically complete response (pCR) to neoadjuvant therapy.

The

consensus of the authors is that postoperative RT should therefore remain the
standard of care.
When examining the evidence, it is important for the clinician to be aware
of the various definitions for pCR that have been used in clinical studies. These
range from no microscopic evidence of viable tumour cells, only residual necrotic
or nonviable tumour cells, or only residual intraductal tumour cells in the resected
specimen. The MD Anderson Cancer Center requires the added disappearance
of axillary lymph node metastasis for a pCR.
Randomized trials such as those planned by the Athena Breast Cancer
Network [37, 38] and the NSABP B51/RTOG 1304 trial may provide data to reevaluate the recommendation for specific subgroups in the future.
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II.5.6 Recommendation 3(a)
It is recommended that axillary dissection remain the standard of care for
axillary staging in LABC, with the judicious use of SLNB in patients who are
advised of the limitations of current data.

II.5.6.1 Key Evidence
The median sentinel lymph node (SLN) identification rate (SLN ID rate)
was 93% in patients with cN0 cancer and 85% in patients with clinically positive
nodes. SLN ID rates depend on the experience of surgeons and the techniques
used.
The ACOSOG Z1071 trial [39, 40] conducted with patients with positive
nodes (>85% LABC) is one of the largest and most recent studies. It found a
93% SLN ID rate for cN1 cancer and 89% for cN2 cancer. The false negative
(FN) rate is not dissimilar to the recommended FN rates for early breast cancer
surgery [41].
Although the studies indicate that SLNB is technically feasible in both
early and locally advanced breast cancer, a small percentage of patients will be
understaged using SLNB alone.

This risk needs to be weighed against the

increased adverse effects of ALND.
This recommendation is based on the authors’ valuing potentially
increased survival rates with use of ALND over increased postoperative
complications. Given the results of the Z0011 and EBCTCG studies for early or
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operable cancers, some patients may decide that for less advanced LABC (e.g..
Stages 2b-3a) the adverse effects of ALND are greater than the benefits.

II.5.6.2 Qualifying Statements
Although the SLNB technique in patients (mostly with LABC) receiving
NACT is comparable to that in early breast cancer, the clinical implications of a
FN SLNB is not known in these patients.
The benefit of ALND is that more nodes are removed and examined,
giving more accurate staging for some patients. Provided that locoregional RT is
to be administered in all patients, as recommended in Questions 2a and 2b, the
staging may have no impact on treatment. However, some patients may value
the additional prognostic information. If a patient is not going to receive
locoregional RT, then ALND is recommended.
There may be a secondary treatment benefit of ALND in that involved
nodes are removed and, therefore, will not metastasize further.
More than 80% of female patients undergoing ALND have at least one
postoperative complication in the arm and psychological distress is common [42].
In the Z0011 trial [43, 44] ALND added to SLNB resulted in more wound
infections, axillary seromas, paresthesias, and subjective reports of lymphedema
than SLNB alone.
The NCCN guideline [13] (not specifically on NACT) indicates “in the
absence of definitive data demonstrating superior survival [with axillary lymph
node staging], the performance of ALND may be considered optional in patients
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who have particularly favourable tumours, patients for whom the selection of
adjuvant systemic therapy is unlikely to be affected, for the elderly, or those with
serious comorbid conditions”. They recommend that cN0 plus SLN negative
(including T3N0) need no further ALND. However, the authors of the current
guideline note that most patients with LABC are pathologically node positive
before neoadjuvant therapy, even those considered clinically negative; therefore,
a high portion may still be pathologically node positive after neoadjuvant therapy.
None of the studies included inflammatory breast cancer; therefore, these
findings cannot be extrapolated to that cohort of patients.

II.5.7. Recommendation 3(b)
Although SLNB before or after NACT is technically feasible, there is
insufficient data to make any recommendation regarding the optimal timing of
SLNB with respect to NACT. Limited data suggests higher SLN ID rates and
lower FN rates when SLNB is conducted before NACT; however, this must be
balanced against the requirement for two operations if SLNB is not performed at
the time of resection of the main tumour.

II.5.7.1 Key Evidence
Only three of the studies in Table 6 of the evidence summary [45-47]
compared timing of SLNB (before or after NACT) and one additional study
(abstract only) performed SLNB before neoadjuvant therapy [48]. The rest of the
studies performed SLNB and ALND after completion of NACT. Before NACT the
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SLN ID rate was 98-99%, whereas after NACT it was a median of 93% in
patients with clinically node-negative cancer and 88% overall. The studies also
suggest FN rates are lower when SLNB is conducted before NACT.
The SENTINA study [45] did not conduct ALND if the SLNB before NACT
was negative so FN rates could not be determined for this subgroup. Arm B of
the SENTINA trial included patients initially cN0 with a positive SLN (pN1SN)
before NACT and conducted a second SLNB plus ALND after NACT. SLN ID
rate was 76% in the second SLNB and the FN rate based on the second SLNB
was 61% compared with a SLN ID rate of 99% in patients with cN0 cancer when
SLNB was performed before NACT. This suggests that SLNB should not be
performed both before and after NACT.

II.5.7.2 Qualifying Statements
It is often considered that adjuvant treatment should be based on the initial
stage as determined before any treatment, although the extent of surgery
depends on the size/extent of the tumour immediately before surgery (i.e., after
any neoadjuvant treatment).

Some studies suggest NACT often eliminates

cancer from the SLN but not all the other nodes. For these reasons, there is
theoretical justification for performing SLN biopsy before NACT. The very limited
data would support this, but is considered insufficient at this time to make a
strong recommendation due to the trade-off required in risk and inconvenience of
needing to perform two separate operations (one for SLNB and one to remove
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the main tumour) compared with the normal procedure of removing the tumour
and SLN (or ALND) in one operation.

II.5.8 Recommendations 4(a) and 4(b)
II.5.8.1 Recommendation 4(a)
It is recommended that patients receiving neoadjuvant anthracyclinebased therapy whose tumours do not respond or where there is disease
progression be expedited to the taxane portion of the anthracycline-taxane
regimen.

II.5.8.2 Recommendation 4(b)
For patients who fail to respond or who progress on first-line NACT, there
are several therapeutic options to consider including second-line chemotherapy,
hormonal therapy (if appropriate), radiotherapy, or immediate surgery (if
technically feasible).

Treatment should be individualized considering tumour

characteristics, patient factors and preferences, and risk of adverse effects.
Management of patients who do not respond to initial neoadjuvant therapy
should be individualized through discussion at a multidisciplinary case
conference.

II.5.8.3 Key Evidence (Recommendations 4(a) and 4(b))
Anthracycline-taxane is a standard therapy, with the taxane administered
either concurrently or consecutively. The NSABP B-27 trial [49-51] found AC
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followed by docetaxel gave significantly improved clinical and pathological
response and lower rates of local recurrence compared with neoadjuvant AC
alone. Because most patients were not LABC and patients were not randomized
based on response, the trial is not included in the evidence review of Section 2.
The GeparTrio study [52] and a trial by Qi et al [53] evaluated early
switching to second-line chemotherapy after nonresponse to two cycles of firstline chemotherapy and demonstrated conflicting findings: the first demonstrated
no improved response to treatment but better tolerability and the second
demonstrated some improved response but worse adverse effects and treatment
delays. There is therefore insufficient evidence to switch chemotherapy midtreatment.
The recommendations are based on current practice and are consistent
with the guidelines by NCCN [13], Health Canada [54], and the Consensus Panel
for Neoadjuvant Chemotherapy [14].

II.5.8.4 Qualifying Statements (Recommendation 4(b))
There is a body of literature including patients with locally advanced and
metastatic disease (mostly single-arm case series, small pilot studies, or
retrospective studies) that supports a variety of second-line single agent and
multi-agent NACT and/or RT regimens to improve response (including
pathologically complete response) and, thus, operability or survival. Although the
data are limited and not within the rigorous inclusion criteria of the literature
review, Table 8 of Section 2 lists some of these studies as examples of regimens
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in the medical literature that have been tried in this clinical scenario. These data
are not systematically reviewed nor of quality sufficient to make a
recommendation as to preferred regimens.

It is advised that oncologists

individualize the choice of therapy based on the patient and risk of adverse
effects.

II.6 FUTURE RESEARCH
Prospective RCTs designed for patients with LABC who fail to respond to
NACT are needed so that more definitive treatment recommendations can be
developed.
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APPENDIX III. LABC CLINICAL TRIAL PROTOCOL

III.1

PATIENT ELIGIBILITY

III.1.1 Eligibility Criteria
•

Biopsy proven LABC, Locally advanced breast cancer. (operable or nonoperable)

•

Any T3/T4 or N2, N3 Clinical TNM stage breast cancer without metastases

•

Adequate renal function, as evidenced by a measured or calculated creatinine
clearance ≥50 ml/minute. If calculated, the following formula must be used:
Calculated creatinine clearance (ml/min)=
(140-age) x weight (kg) x 1.04
Cr (µmol/l)

•

Adequate hematologic reserves, as evidenced by an absolute neutrophil
count ≥1.5 x 109/L, platelets ≥100 x 109/L

•

Adequate hepatic function as evidenced by a total bilirubin ≤1.5 x the
upper limit of normal (ULN), and AST ≤2.5 x ULN.

•

ECOG Performance Status of 0, 1 or 2.

•

Patients should be able to comprehend the Letter of Information and be
capable of giving informed consent.

•

Female age ≥18 years old

•

Negative serum pregnancy test

•

Adequate wall motion study results (LVEF ≥50%)
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•

Patients with other prior malignancies will be considered eligible if they are
felt to be beyond risk of recurrence of the previous malignancy (generally
>5 years after diagnosis, with no evidence of recurrence).

There are no

restrictions on time from a basal cell or squamous cell carcinoma of the
skin or a carcinoma in situ of the cervix
•

Adequate baseline pulmonary function studies must be confirmed prior to
consent for radiation or radiation treatment planning. FEV1 should be
equal to or greater than 1.0 litre.

III.1.2 Ineligibility Criteria
•

Inflammatory cancer (as defined by clinical evidence of dermal-lymphatic
tumour involvement.)

•

Patient refuses modified radical mastectomy

•

No patient may have received prior systemic treatment for disease within
last 5 years, no prior radiotherapy given to head and neck, breast, or
thoracic site.

•

Previous ipsilateral breast cancer diagnosis.

•

Pregnant or lactating females are ineligible.

•

Female patients of reproductive potential who decline to employ an
adequate contraceptive method are ineligible.

•

Participation in any concomitant trials.
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III.2

REGISTRATION PROCEDURES
All eligible patients enrolled on the study will be entered into a patient

registration log located at London Regional Cancer Program (LRCP). This will
provide a serial number for that patient which should be used on all
documentations and correspondence.
All registration will be carried out by LRCP and will be obtained by calling
the LRCP Clinical Research Unit at 519-685-8623. At the time of calling, a
completed eligibility and signed consent must be available. There will be no
exceptions to the eligibility/ineligibility criteria.

III.3

OVERAL TREATMENT PLAN

III.3.1 Concurrent Neoadjuvant Chemotherapy and Radiation (CNCR)
III.3.1.1 Initial Chemotherapy
CNCR treatment will begin within 6-8 weeks of their diagnosis of LABC
(study enrollment) and will consist of 3 cycles of intravenous FEC chemotherapy
(5-fluoruracil

(500mg/m2),

epirubicin

(100mg/m2)

and

cyclophosphamide

(500mg/m2)) q3 weekly. The FEC chemotherapy will be followed by additional
chemotherapy using docetaxel, concurrent with radiation. Adverse events from
chemotherapy and radiation therapy as well as grading of any developed toxicity
will be assessed by the oncologist as per National Cancer Institute. Any dose
delays or dose reductions will be reported to the principal investigator, but dose
reductions to 80% prescribed dose or one week dose delay will be acceptable for
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this study. Patient tolerability will be assessed every 3 patients, and any grade 4
toxicities or treatment delays will be reviewed by an independent clinical review
board and will be reported to the Health Sciences Research Ethics Board at the
University of Western Ontario.

III.3.1.2 Radiation Concurrent with Chemotherapy
Docetaxel (35mg/m2) will be given IV weekly with radiation treatment daily
during the first 6 weeks of docetaxel. Concurrent radiation therapy will start
during the first day of week one of docetaxel chemotherapy. Radiation therapy
will consist of external beam therapy for a total dose of 45Gy in 25 fractions over
5 weeks. A reduced volume boost of 5.4Gy in 3 fractions to 9Gy in 5 fractions will
then be given to residual gross disease in the breast or regional lymph nodes
during the sixth week. The patient is to be placed in the supine position on an
angle board with straight spine and the ipsilateral arm raised and supported by
an armrest and the chin extended with appropriate headrest.

All treatment

planning will be performed on the Phillips Pinnacle workstation. All radiation
treatment will be delivered on megavoltage machines using 6MV energy or
greater with the following procedures/variables:
Treatment Interruption: any treatment delay of less than one week,
radiation should be completed to prescribed dose. Any treatment delay of greater
than one week, radiation should be completed to prescribed dose at the
discretion of the treating radiation oncologist. All treatment delay causes and the
length of the delay shall be reported.
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Dose and Fractionation:

Phase I – the dose will be 45Gy in 25 daily

fractions over 5 weeks. 95% of the PTVs should receive 95% of this dose. Dose
variation within the breast should be no more than plus 7% and no less than
minus 5 percent.
Phase II – the boost dose will be 5.4Gy in 3 daily fractions to 9Gy in 5
daily fractions over 1 week. If there is concern that the residual gross tumor
volume is too extensive, the boost will be limited to 5.4Gy in 3 fractions over 1
week. Any gross residual in the supraclavicular area will be limited to a boost of
5.4Gy in 3 fractions.
Prescription Point: For the tangents, this will usually be the point at a
depth of two-thirds of the distance from the overlying skin contour to the posterior
tangents at mid-separation. The normalization point is placed away from the
underlying lung. For the supraclavicular and axillary fields, the prescription point
is at midplane.

III.3.1.3 Surgery
Chemotherapy with radiation will be followed by modified radical
mastectomy 5 weeks after the last dose of docetaxel, which would give 8 weeks
of radiation recovery preoperatively. The patient will receive a single dose of
preoperative antibiotic 30 minutes prior to commencement of the surgery. The
modified radical mastectomy will be performed in the standard fashion, resecting
the breast parenchyma through an elliptical incision in order to allow for primary
skin closure. Through the same wound, a complete level I and II axillary
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dissection will be performed. A 19 Blake drain will be place beneath the skin flaps
and secured through a stab incision with Prolene suturing, and the skin flaps will
be reapproximated with buried subdermal 3-0 monocryl sutures and the
epidermis closed with a running subcuticular 4-0 monocryl suture and the wound
covered with steri-strip dressings. Homecare nursing will be arranged for daily
wound assessment and drain care, which will be removed when the serous
drainage falls below 30ml per day.

III.3.1.4 Translational Research Components
Plasma OPN – blood will be drawn for plasma osteopontin at the same
time blood is drawn for CBC or biochemistry. The blood will be labelled with the
patient ID # and sent to the 4th floor laboratory at the LRCP for storage and
analysis.
Sesta MIBI SPECT/CT – each patient will have 3 CTs done. The first CT
will be performed just prior to the start of FEC chemotherapy. Second CT will be
done just prior to the start of the Docetaxel chemotherapy. The third CT will be
done just prior to surgery. CT scans will be performed by the nuclear medicine
department at LHSC.
Core Needle Biopsy – at the time of your diagnostic biopsy procedure, you
may have agreed to participate in a biopsy evaluation study and have signed a
separate consent and letter of information. If you have participated in that study,
the additional samples taken will also be used as the first set of tumour samples
for this current study. If you have refused to participate in the biopsy evaluation
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study, it does not affect your participation in this study. If you were NOT invited to
participate in a research study at the time of your diagnostic biopsy procedure,
you will be asked to undergo another ultrasound-guided biopsy procedure, where
three extra pieces of tumour tissue will be taken. Taking extra pieces will not
change the ability of doctors to diagnose or treat your cancer, and will not change
the outcome of the treatment. It is important to be able to test whether the ability
of the cancer cells to grow and spread changes over the duration of the
treatment. This study involves having 3 sets of biopsies IN TOTAL to be used for
the research study only – at the baseline as described above, at the half-way
point of chemotherapy (after 9 weeks), and when you are having your surgery
(after completing chemotherapy and radiation) (when you are already asleep for
your surgery, to avoid any discomfort to you). Each biopsy will take
approximately 3-5 minutes. These biopsies will be performed at St. Joseph’s
Health Centre.
Ex Vivo Tumour Invasion Model – the serial tumour biopsy samples will be
collected fresh in phosphate-buffered saline and delivered to Dr. Costello’s
laboratory, where these samples will be dissected into 1mm tumour plugs. One
of these will be immediately stored in RNA Later and kept frozen at -80oC for
later analysis. The remaining samples will be placed in individual culture wells
and incubated in fresh bovine Type I collagen at 37oC for five days after each
row of wells has been treated with the chemotherapies used in the trial according
to CPS maximum allowable IV dosage (FEC and D). Half of the wells will be
radiated at 0.8Gy once. At the completion of 5 days, optical spectroscopy will be
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used to determine the maximal diameter of tumour cell invasion into the matrigel.
Half of the tumour plugs in these wells will be formalin fixed and paraffinembedded, and the other half will be flash frozen at -80oC. This will be performed
by Dr. Costello’s company titled Oncoscreen®. The laboratory will be completely
blinded to patient identifiers or treatment response of any patient.
RNALater Samples – the samples frozen in RNALater will be shipped
frozen to Sudbury Ontario to be processed by RNA Diagnostics Inc. under the
supervision of Dr. Amadeo Parissenti. The RNA integrity will be assessed and
quantified. Samples will be de-identified so that the analysis will be completed
prior to any information regarding patient identifiers or individual treatment
response. If sufficient RNA quality is identified in a given tumour sample, its DNA
and RNA will be extracted. DNA copy counts of proteins felt to be involved in
treatment resistance will be measured and full genomic RNA array analysis will
be performed using micro-array technology. The remaining sample products will
be kept for

potential micro-proteomic analysis if required to quantify tumour

proteins felt to be involved in treatment resistance.
Immunohistochemical Protein Expression Analysis: Samples which are
paraffin-embedded will be analyzed using immunohistochemical (IHC) staining
for the proteins involved in drug or treatment resistance or apoptosis.
Laser Cytometric Analysis of Cancer Stem Cells – samples which are
flash-frozen will be analyzed for cancer stem cell population counts per 0.4µm
slide using immunofluorescence for markers of breast cancer stem cells including
CD24, CD44 and ALDH and measured by computerized cell count analysis.
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III.3.2 Chemotherapy Treatment
The planned regimen is 3 cycles of FEC (5-fluorouracil 500mg/m2,
epirubicin 100mg/m2 and cyclophosphamide 500mg/m2 intravenously) every 21
days to be followed by concurrent daily radiation with once weekly docetaxel
35mg/m2 IV for 6 weeks. Upon completion of the concurrent treatment, subjects
will continue on with weekly docetaxel for an additional 3 weeks. In the study of
concurrent radiation with bi-weekly paclitaxel, although all women were able to
complete the 6-week course of chemoradiation, over 90% of subjects required
more than the planned 2 weeks for skin recovery from completion of treatment to
surgery. The additional chemotherapy will allow time for tissue healing
preoperatively, as well as give a complete course of systemic treatment. This will
be followed by primary surgery 5 weeks after completion of chemotherapy.
Women with Her2/neu positive breast cancer will receive neoadjuvant
trastuzumab as per standard of care.

The trastuzumab will be initiated with

docetaxel at the start of chemoradiation. Although trastuzumab is associated
with a small risk of cardiotoxicity, the updated results of adjuvant studies do not
demonstrate any increased risk, even when trastuzumab is administered
concurrently with radiation or taxanes. Monitoring for cardiac toxicity of
trastuzumab will be done as per institutional standard at the London Regional
Cancer Program with wall motion study performed every 3 months while on
therapy. Dose modification will be made as per international and institutional
guidelines for Trastuzumab-associated cardiac dysfunction. Trastuzumab will be
continued for a total duration of 1 year as per standard of care.
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Women with estrogen receptor positive breast cancer will receive
endocrine therapy according to their menopausal status.

This will be initiated

after completion of their systemic chemotherapy.

III.3.2.1 Administration of Chemotherapy
G-CSF not routinely given, but could be given as per LRCP standard.
Timetable of administration of FEC is as follows:
•

standard prophylaxis with antinausea and antiemetics

•

0min – start hydration using 500ml/hr 0.9% NaCl for a total of 500ml

•

15min – Fluorouracil 500,mg/m2 IV push then Epirubicin 100mg/m2 IV
push by chemo suite nurse over 5-10min

•

20min – Cyclophosphamide 500mg/m2 IV infusion, full dose over 40min

•

60min – flush with 0.9% NaCl and disconnect the patient

Docetaxel will be given weekly for 9 weeks. Her2/neu positive breast
cancer will receive trastuzumab with docetaxel at the start of chemoradiation and
the protocol is as follows:
•

week 1 – start trastuzumab, over 90min, 1hr observation

•

week 4 – start trastuzumab, over 60min, 30min observation

•

week 7 – start trastuzumab, over 30min, 30min observation

•

week 11 – start trastuzumab, over 30min, no observation

165
On the evening prior to chemotherapy, dexamethasone (8mg tablet) will be taken
by the patient. Docetaxel administration during week 1 and week 2 will be as
follows:
•

0min – start hydration using 500ml/hr 0.9% NaCl for a total of 500ml

•

patient receives another 8mg dexamethasone from chemo suite nurse

•

15min – docetaxel 35mg/m2 in 250 ml of 0.9% NaCl infused as:
o ¼ rate for first 15 minutes, then BP check by nurse
o ½ rate for next 15 minutes, then BP check by nurse
o ¾ rate for next 15 minutes, then BP check by nurse
o full rate for remaining 60 minutes, then BP check by nurse
Patient is then taken to radiation suite to receive daily regional breast

radiation (IMRT) for first 2 weeks. On the evening of chemotherapy,
dexamethasone (8 mg tablet) is taken by the patient.
During week 3 to 9 (if patient tolerates the docetaxel without significant
hypotension), dexamethasone (8mg tablet) is taken by the patient on the evening
prior to chemotherapy; docetaxel administration will be as follows:
•

0min – start hydration using 500ml/hr 0.9% NaCl for a total of 500ml

•

patient receives another 8mg dexamethasone from chemo suite nurse

•

15min – docetaxel 35mg/m2 in 250 ml of 0.9% NaCl infused at full rate for
60 minutes, then BP checked by nurse.

Patient is then taken to radiation suite to receive daily regional breast
radiation (IMRT) for first 2 weeks. On the evening of chemotherapy,
dexamethasone (8mg tablet) is taken by the patient. During all infusions of
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docetaxel, patient is wearing ice mitts and ice slippers to minimize toxicity to nail
beds.
In the event of toxicity, the doses of FEC and docetaxel will be adjusted
according to the guidelines shown in the dose delays/modifications table (Table
III.1). If an adverse event is not covered in this table, doses may be reduced or
held at the discretion of the investigator for the subject’s safety.

Dose

adjustments for hematologic toxicity are based on the blood counts obtained in
preparation for the day of treatment.
No dose reductions will be made for any hypersensitivity reactions. All
patients receiving docetaxel will also receive dexamethasone (8mg PO) night
prior, 1hour prior and immediately prior to docetaxel administration. If, despite
pre-treatment, the patient experiences a hypersensitivity reaction, treatment
should be as indicated in Table III.2.

III.3.2.2 Side Effects – FEC Chemotherapy
These side effects, occur in 25%-50% of patients taking the chemotherapy
used in this study:
• Nausea, vomiting, fatigue
• Lowered white blood cell count (may lead to infection), lowered red blood
cell count (may lead to anemia, tiredness, shortness of breath)
• Irregular or permanent stoppage of menstrual cycles, inability to get
pregnant
• Complete hair loss
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Table III.1

Rules for dose and schedule adjustments in LABC patients.

FEC x 3 cycles (wk 1-9)
Grade

Treatment Modification

Myelosuppression:
9

Asymptomatic NP

<1.5 x 10 /L

Defer 1 week
If defer >1wk:dose-reduce all agents
of FEC by 20% subsequently

Febrile NP

<1.5 x 10 /L
Temp ≥ 38.5ºCor
38.3ºC at least 1hr apart

Asymptomatic TCP

Platelets ≤75x 10 /L

Hold FEC until platelets
9
>75x 10 /L.

All other toxicities
(except alopecia)

Grade 3/4

Hold until resolve to ≤ Grade 1

Dose reduce all agents of FEC by
20% subsequently

9

9

Weekly docetaxel with concurrent radiation (wk 10-15)
Myelosuppression:
9

Defer 1 week
If defer >1wk:dose-reduce by 20%
subsequently

9

Dose reduce by 20% subsequently

Asymptomatic NP

<1.5 x 10 /L

Febrile NP

<1.5 x 10 /L
Temp ≥ 38.5ºCor
38.3ºC at least 1hr apart

Asymptomatic TCP

Platelets ≤75x 10 /L

Hold FEC until platelets
9
>75x 10 /L.

Fluid Retention:

Grade 1-2

No adjustment mandated; diuretics
discretionary.

Grade 3

Diuretics
mandatory.
If
lifethreatening despite optimal medical
management: OFF PROTOCOL

9

Hypersensitivity
Reactions:
Hepatic Dysfunction:

No dose adjustment.
Anaphylaxis: OFF PROTOCOL
Total Bili
AST
AlkPhos
Normal >1.5xULN >2.5xULN
Normal

2.5-5xULN

--

Dose Reduce
25%
25%
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Normal

Skin Reactions:

All other toxicities
(except alopecia)

>5xULN

--

50%

26-43µmol/L

--

--

50%

>43µmol/L

--

--

75%

Acute Gr 1-2

No modifications

Gr ≥3

See section on Radiation Toxicity

Grade 3/4

Hold until resolve to ≤Grade 1

Weekly docetaxel (wks 16-18)
Myelosuppression:
9

Defer 1 week begin G-CSF (if
assessable) if deferred >1wk then
dose reduce by 20% subsequently

9

Defer 1 week begin G-CSF (if
assessable) if deferred >1wk then
dose reduce 20% subsequently

Asymptomatic NP

<1.5 x 10 /L

Febrile NP

<1.5 x 10 /L
Temp ≥ 38.5ºCor
38.3ºC at least 1hr apart

Asymptomatic TCP

Platelets ≤75x 10 /L

Hold until platelets >75x 10 /L

Fluid Retention:

Grade 1-2

No adjustment mandated; diuretics
discretionary.

Grade 3

Diuretics
mandatory.
If
lifethreatening despite optimal medical
management: OFF PROTOCOL

9

9

Hypersensitivity
Reactions:
Hepatic Dysfunction:

Skin Reactions:

All other toxicities
(except alopecia)

No dose adjustment.
Anaphylaxis: OFF PROTOCOL
Total Bili
AST
AlkPhos
Normal >1.5xULN >2.5xULN

Dose Reduce
25%

Normal

2.5-5xULN

--

25%

Normal

>5xULN

--

50%

26-43µmol/L

--

--

50%

>43µmol/L

--

--

75%

Acute Gr 1-2

No modifications

Gr ≥3

See section on Radiation Toxicity

Grade 3/4

Hold until resolve to ≤Grade 1
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Table III.2

Management of hypersensitivity reaction in LABC patients
enrolled in the clinical trial.

Mild symptoms:
Localized cutaneous
reactions such as mild
pruritus, flushing, rash

Consider decreasing the rate of infusion until recovery
from symptoms, stay at bedside and monitor patient.
Then, complete docetaxel infusion in the initial planned
rate.

Moderate symptoms:
Any symptom that is not
listed above (mild
symptoms) or below
(severe symptoms)
such as generalized
pruritus, flushing, rash,
dyspnea, hypotension
with systolic blood
pressure >80mmHg.

1. Stop docetaxel infusion
2. Given diphenhydramine 50mg iv with or without
Hydrocortisone 100mg IV; monitor patient until
resolution of symptoms
3. Resume docetaxel infusion after recovery of
symptoms; depending on the physician's assessment
of the patient, docetaxel infusion should be resumed at
a slower rate, then increased incrementally to the
initial planned rate, (e.g. Infusion at an 8hr rate for
5min, then at a 4hr rate for 5min, then at a 2hr rate for
5min, then finally, resume at the 1hr infusion rate)
4. Depending on the intensity of the reaction observed,
additional oral or iv premedication with an
antihistamine should also be given for the next cycle
of treatment, and the rate of infusion should be
decreased initially and then increased back to the
recommended 1hr infusion, (e.g. infuse at an 8hr rate
for 5min, then at a 4hr rate for 5min, then at a 2hr rate
for 5 min, and finally, administer at the 1hr infusion
rate).

Severe symptoms:
Any reaction such as
bronchospasm,
generalized urticaria,
systolic blood pressure
≤80mmHg, angioedema

Stop docetaxel infusion.
Give diphenhydramine 50mg iv with or without
hydrocortisone 100mg iv and/or epinephrine as
needed with physician order: monitor patient until
resolution of symptoms.
The same treatment guidelines outlined under
moderate symptoms (ie. 3rd and 4th point) should be
followed. If severe reaction recurs despite additional
premedication, the patient will go off protocol
treatment.

Anaphylaxis
(Grade 4 reaction)

OFF PROTOCOL TREATMENT
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• Temporary red-coloured urine following chemotherapy (not blood)
• Time away from work
• Hot flashes (in premenopausal women)

These side effects occur in 10-24% of patients taking the chemotherapy in this
study:
• Sores in mouth and/or throat, infection
• Taste changes
• Skin and nail changes, including discolouration and peeling
• Pain at the site where chemotherapy is administered

These side effects occur in 3-9% of patients taking the chemotherapy in this
study:
• Diarrhea, constipation, loss of appetite
• Low platelet count, leading to increased bruising or bleeding
• Headache, abdominal pain, skin rash/itching, muscle pain, eye irritation
• Darkening of the soles of the feet or palms of hands
• Thickening of the walls of the veins used for chemotherapy
• Blood in the urine
• Fever
• Fever with a low white blood cell count
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Rare but serious side effects that occur in less than 3% of patients taking the
chemotherapy used in this study include:
• Decreased ability of the heart to pump blood. If severe, you could have
shortness of breath and other symptoms of heart failure. (If mild, you may
not have any symptoms.)
• Skin damage (due to leakage of the drug)
• Acute leukemia (cancer of the blood cells)
• Lung damage
• Lowered red blood cell count severe enough to require red blood cell
transfusion; lowered platelet count severe enough to require a platelet
transfusion
• Severe infection
• Blood clots
• Changes in blood test results that indicate possible liver injury
• Allergic reaction including itching, hives,rash, flushing, hypersensitivity,
shortness of breath, wheezing, chest tightness, fever, chills, muscle
stiffening, severe breathing problems

III.3.2.3 Side Effects – Docetaxel (Taxotere)
These side effects occur in 25% -50% of patients receiving docetaxel:
• Hair loss, nausea, vomiting, taste changes
• Weakness/loss of strength, fatigue
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• Hot flashes (in premenopausal women), Irregular or permanent stoppage
of menstrual cycles (periods), inability to become pregnant
• Skin and nail changes, including discoloration and peeling
• Lowered white blood cell count (may lead to infection), lowered red blood
cell count (may lead to anemia, tiredness, shortness of breath)
• Time away from work

These side effects occur in 10-24% of patients receiving docetaxel:
• Diarrhea, constipation, loss of appetite
• Mouth sores, infection
• Pain in muscles, bones, or joints
• Headache
• Fluid retention (bloating or swelling)
• Numbness, tingling, prickling, and burning in the hands and feet

These side effects occur in 3-9% of patients receiving docetaxel:
• Ulcers in the stomach or bowels
• Darkening of the soles of the feet or palms of the hands
• Peeling of the skin (including hands and feet)
• Lowered number of platelets (which may lead to increased bruising or
bleeding)
• Eye irritation, blurred vision
• Dizziness
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• Changes (high or low) in blood pressure
• Hardening of the walls of the veins used for chemotherapy
• Reversible changes in blood test results that show possible liver injury
Symptomatic lung damage generally occurs in fewer than 3 percent of
patients secondary to docetaxel alone.

Symptomatic lung damage from

locoregional radiation alone for breast cancer occurs in 5 percent or fewer
patients, with severe shortness of breath restricting activities of daily living (grade
3 or greater) occurring in a subset of patients. The combination of docetaxel and
locoregional radiation for breast cancer may increase the frequency and severity
of symptomatic lung damage.

These side effects occur in less than 3% of patients receiving docetaxel:
• Liver failure
• Gastrointestinal problems (such as bleeding, blockage, or perforation
[opening of a hole] in the stomach or bowel)
• Lowered red blood cell count severe enough to require red blood cell
transfusion
• Skin and tissue damage in the area surrounding the catheter where the
chemotherapy drugs are injected
• Acute leukemia (cancer of the blood cells)
• Blood clots that may be life-threatening
• Heart damage, lung damage
• Severe infection
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• Inflammation of the pancreas causing abdominal pain
• Allergic reaction including itching, hives, skin rash, flushing, shortness of
breath, wheezing, chest tightness, fever, chills, severe shivering, sinus
congestion, or swelling of face, especially eyelids
• A group of symptoms which may include a blister-like rash that may be
severe; fever; inflamed eyes; redness, swelling and painful sores on lips
and in mouth (If this occurs, you may need to be hospitalized and have IV
fluids and medicines.)

III.3.3 Radiation Therapy
Concurrent radiation therapy will start during the first day of docetaxel.
Radiation therapy will consist of external beam therapy for a total dose of 45Gy in
25 fractions over 5 weeks. A reduced volume boost of 5.4Gy in 3 fractions to 9Gy
in 5 fractions will be given to residual gross disease in the breast and/or regional
lymph nodes. Gross disease in the high axilla or supraclavicular area will be
limited to 5.4Gy in 3 fractions maximum boost. If treatment is delivered using
IMRT, gross disease will be limited to 5.4Gy concomitant boost

(total dose

50.4Gy in 28 fractions to gross disease and 45Gy in 28 fractions to uninvolved
breast, axilla, IMC, and supraclavicular volumes).

III.3.3.1 Patient Position and Immobilization
Patient is to be placed in the supine position on an angle board with straight
spine and the ipsilateral arm raised and supported by an armrest and the chin
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extended with appropriate head rest. Patient is to be instructed to breathe quietly
in order to minimize respiratory motion during scanning and treatment. A
radiopaque breast wire will be placed around the ipsilateral clinical breast mound.

III.3.3.2 Scanning Protocol
Serial CT is to be collected utilizing Philips Brilliance large bore CT scanner
(or equivalent technology). Three-millimetre thick slices at 3 mm intervals will be
scanned from the level of the lower jaw to L1 (in order to encompass the whole
lung volume).

For the single isocenter technique, the junction between the

breast portals and the regional nodal portals is placed at the level of the inferior
and medial ipsilateral clavicle. The junction line is marked by tattoos. Intravenous
contrast is optional but may help with the delineation of gross residual tumor and
the regional blood vessels.

III.3.3.3 Treatment Planning
All treatment planning will be performed on the Phillips Pinnacle
workstation. In general one of the following three treatment techniques will be
used:
a) Single isocenter technique: The single isocenter is located at the level
of inferior border of the medial head of clavicle. The affected breast and
ipsilateral internal mammary chain are treated using medial and lateral deep
tangents with half beam blocking of the superior borders to create a nondivergent match with the supraclavicular and axillary fields. The tangents can be
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non-opposed, if necessary, to create a non-divergent deep/ posterior border
which can reduce underlying lung in the high dose volume. Both medial and
lateral shielding should be checked to verify maximum sparing of normal tissues
and also adequate coverage of any gross disease. The ipsilateral axillary and
supraclavicular nodes are treated with anterior and posterior oblique fields with
half beam blocking of the inferior borders to create a non-divergent match with
the deep tangents. The medial field borders should fall along the medial border of
the ipsilateral sternomastoid muscle with gantry rotation to avoid the spinal cord
(usually 8 to 12 degrees gantry rotation to the contra lateral side for the anterior
supraclavicular - axillary field). The gantry angle for the posterior supraclavicularaxillary field can be rotated such that the medial border creates a non-divergent
match with the medial border of the anterior supraclavicular-axillary field. The
superior border of the supraclavicular fields is usually at the level of the upper
thyroid cartilage. The ipsilateral larynx, acromio-clavicular joint, and the upper
one half to two-thirds of the humeral head should be shielded. If the ipsilateral
lung volume receiving 20Gy exceeds 40 percent and /or if total lung volume
receiving 20Gy exceeds 25 percent, the following alternative treatment
techniques should be considered.
b) Intensity modulated radiation (IMRT) for the involved breast with half
beam blocking of the superior borders to match the supraclavicular-axillary fields
described above. This option is especially useful when the supraclavicularaxillary fields do not encompass much lung but the deep tangents would include
too much lung. Usually, four or five field step and shot IMRT will reduce dose to
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lung compared to the preceding technique but more detailed contouring will be
necessary. Guidelines for treatment planning are in the treatment planning
module. For this approach, the supraclavicular-axillary fields will receive 45Gy in
25 fractions over five weeks. The uninvolved breast and lower axilla within the
IMRT volume will receive 45Gy in 28 fractions (no BED correction) over five and
a half weeks while gross disease will receive 50.4Gy in 28 fractions over five and
a half weeks (concomitant boost). If feasible, the uninvolved breast and lower
axilla and gross disease will be treated, using IMRT, to a dose of 45Gy in 25
fractions. A reduced volume boost of 5.4Gy in 3 fractions using 3-D conformal
radiation or IMRT boost is allowed.
c) IMRT for the entire volume, including the ipsilateral breast, axilla,
supraclavicualr area, and internal mammary chain. This approach is useful when
both deep tangents and supraclavicular-axillary fields encompass too much lung.
Treatment planning requires detailed contouring of normal structures as well as
target volumes. The ipsilateral breast, the right and left lungs, the heart, the
larynx and trachea as an organ at risk (OAR) should all be contoured. The target
volumes will also be contoured as defined below.
The uninvolved breast, IMC, axilla, and supraclavicular area will receive
45Gy in 28 fractions. Gross disease will be treated to 50.4Gy in 28 fractions

III.3.3.4 Treatment Delivery
All radiation treatment will be delivered on megavoltage machines using
6MV energy or greater. Calibration of all radiation treatment machines will be
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under the supervision of the Department of Radiation Physics at the London
Regional Cancer Program.

III.3.3.5 Critical Structure Dose Constraints
Maximum spinal cord dose shall be 45Gy. In the lung, maximum 30% of
total normal lung volume is to receive less than or equal to 20Gy. While V20Gy to
total lung under 30 percent is acceptable, V20Gy under 20 to 25 percent is
preferred. In the heart, maximum dose to 25% of the heart volume will be less
than or equal to 25Gy. For the ipsilateral humeral head, maximum dose to 50%
will be less than or equal to 30Gy.

III.3.3.6 Treatment Interruption
Any treatment delay of less than one week, radiation should be completed
to prescribed dose. Any treatment delay of greater than one week, radiation
should be completed to prescribed dose at the discretion of the treating radiation
oncologist. All treatment delay causes and the length of the delay shall be
reported. Any treatment delay of greater than two weeks will result in the patient
being discontinued from protocol.

III.3.3.7 Deviations in Radiation Protocol
Prescription Dose: Minor – between 6-10 % difference between protocol
and prescription dose; major – greater than 10 % difference between protocol
and prescription dose.
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Dose Uniformity: Minor – either (-10% to -5%) or (+7% to +10%) variation
in dose target volume homogeneity; major – dose variation to target greater than
± 10%.
Volume: Minor – margins are less than specified or fields excessively
large; major – transecting tumour of lymph node bearing areas.

III.3.3.8 Radiation Planning
Target volumes are as follows:
•

Ipsilateral Breast: This is defined as the clinical breast volume harbouring
malignancy plus any gross clinical tumor extension beyond the ipsilateral
breast. During treatment planning, it should be marked with a radiopaque
wire around its periphery. The breast will be the volume bounded by the
radio-opaque wire, excluding the chest wall and the overlying 5mm of skin.

•

PTVBREAST: This is the expansion of the BREAST plus 7mm.

•

PTVEVALBREAST: This is the PTVBREAST as defined above minus
overlying 5mm of skin.

•

GTVPRIMARY: –This is the volume of gross disease in the breast at
defined at the time of CT simulation and any other available diagnostic
information including clinical exam.

•

CTVprimary: - GTVPRIMARY plus 1.5cm margin in all directions but
limited to the anterior aspect of the pectoralis major muscle (if no muscle
invasion) and to 5 mm or more deep to the skin contour of the breast (if no
direct skin extension). The deep border of the CTV primary should include
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the muscle to rib interface if there is pectoralis muscle involvement; the
superficial border should include the skin surface if there is skin
involvement.
•

PTVprimary – CTVprimary plus 1cm.

•

PTVevalprimary – PTVprimary constrained to within 5 mm of overlying
skin, if no skin involvement, or to the skin surface if skin involvement. The
deep boundary will be the rib to lung interface.

•

GTVNODESBOOST – these are nodes considered to be grossly involved
in the ipsilateral supraclavicular and axillary area and measuring 7mm or
more in short axis at the time of planning CT scan. Pretreatment CT scan
showing the same nodes to be larger can be used to identify significant
nodes.

•

CTVnodesBOOST – This is the GTVNODESBOOST plus 1cm in all
directions but limited to the nearest surface of the adjacent muscles
(pectoralis major or minor, serratus, lattisimus, sternomastoid) and to 5mm
or more deep to the overlying skin. It should also lie within the CTVAXSC.
The superficial border should include the skin surface if there is skin
involvement.

•

PTVNODESBOOST – this is CTVnodesBOOST expanded by 7 to 10mm
(use 7mm except in large patients).

•

PTVEVALNODESBOOST – this is PTVNODESBOOST minus the
overlying 5mm of skin and minus any underlying lung.
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•

CTVIMC – this is the contour of the ipsilateral IMC vessels expanded
medially to touch the ipsilateral border of the sternum at the level of the
first, second, and third intercostal spaces. Any visible lymph nodes at
these 3 levels should be contoured and expanded by 7mm. The CTVIMC
should include the visible nodes plus the 7mm expansion.

•

PTVIMC – this is the CTVIMC expanded by 7mm.

•

PTVEVALIMC – this is the PTVIMC minus underlying lung and heart.

•

CTVAXSC: This volume encompasses the axillary and supraclavicular
lymph nodes at risk. The inferior level is usually at the level of the fifth rib
in the mid-axillary line or at least 1cm below any grossly visible lower
axillary lymph nodes. The lateral border is at least 1cm lateral to any
visible lymph nodes in the low to mid axilla (level 1 and 2 nodes) and
usually lies within a line drawn from the lateral edge of pectoralis major
and the lateral edge of the latissimus muscle. At the level of the high axilla
(level 3 nodes), the lateral border is medial to the coracoid. At the level of
the supraclavicular area, the lateral border is at the mid-clavicular line.
The medial border, anterior, and posterior borders of the axilla are formed
by the nearest surfaces of the adjacent muscles (pectoralis, serratus,
lattissimus). The supraclavicular fossa is bounded medially by the lateral
margin of the sternomastiod muscle. Inferiorly, contouring may continue
deep to the medial clavicle where the subclavian crosses the lung apex at
the level of the first rib posteriorly to join the internal jugular. Care should
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be taken to avoid extending the volume medially towards the thyroid and
the larynx, unless there is gross supraclavicular adenopathy.
•

PTVNODES – this is CTVAXSC and CTVIMC expanded by 7mm.

•

PTVEVALNODES – this is PTVNODES minus 5mm of overlying skin and
minus lung and heart.

Beam arrangement will be as follows: Phase I – the target volume is the
ipsilateral breast plus tumour extension, the ipsilateral supraclavicular and
axillary regions, the PTV primary, and the PTV nodal. Phase II – the target
volume is any gross residual disease remaining at the time of CT simulation.
Repeat CT simulation may be required if there has been more than a 2cm
shrinkage in the surface contour secondary to tumor shrinkage. If feasible, gross
residual tumor in the breast and or regional nodes can be boosted with direct
electrons and clinical setup. For gross tumor more than 5cm deep to overlying
skin, reduced volume boosts using multiple photon fields may be necessary
(parallel pair in axilla, reduced tangents in breast, or 3 or 4 field techniques could
be used).
Dose and Fractionation will be as follows: Phase I – the dose will be 45Gy
in 25 daily fractions over 5 weeks. Ninety-five percent of the PTVEVALs should
receive 95% of this dose. Dose variation within the breast should be no more
than +7% and no less than -5%. Phase II – the boost dose will be 9Gy in 5 daily
fractions over 1 week. If there is concern that the residual gross tumor volume is
too extensive, the boost will be limited to 5.4Gy in 3 fractions over 1 week. Any
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gross residual in the supraclavicular or high axillary area will be limited to a boost
of 5.4Gy in 3 fractions Patients receiving concomitant boost with IMRT will
receive 45Gy in 28 fractions to uninvolved areas and 50.4Gy in 28 fractions to
grossly involved primary tumor and nodes.
Beam modifiers, such as shielding, multi-leaf collimators, wedges and
compensators are allowed.
Prescription point: for the tangents, this will usually be the point at a depth
of two-thirds of the distance from the overlying skin contour to the posterior
tangents at mid-separation. The normalization point is placed away from the
underlying lung. For the supraclavicular and axillary fields, the prescription point
is at midplane.
Bolus (0.5cm thickness) will be placed to cover and gross skin extension
of tumor or skin ulceration as

well as any inflammatory skin involvement (note:

patients with inflammatory breast cancer are not part of this protocol). Bolus
should extend 1 to 2cm beyond the visible skin involvement.

III.3.3.9 Radiation Toxicities
These include the following:
•

Radiation pneumonitis: symptomatic pneumonitis from radiation alone
occurs in 1 to 5 percent of patients and can range in severity from a dry
cough to severe shortness of breath requiring medical management
(including admission to hospital, use of oxygen, steroids, and inhalers) but
is almost always self-limited. The combination of chemotherapy and
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radiation for breast cancer may increase the frequency and severity of
symptomatic lung injury from treatment. The clinical course of such lung
injury has not been well documented and there is the potential risk of
permanent shortness breath secondary to treatment. Treatment for
symptomatic acute pneumonitis is typically oral corticosteroids. Initiate
prednisone at 50mg orally for one to two weeks. Reduce the dosage by
fifty percent every 3 to 5 days based on patient symptomatic improvement.
A more gradual taper of steroids may be appropriate for some patients.
The majority of patients with pneumonitis recover. Progressive symptoms
requiring oxygen or hospitalization are uncommon.
•

Brachial plexopathy: this complication occurs in one percent or less of
patients at doses of 50 to 54Gy in 2Gy or 1.8Gy fractions, respectively.
Transient plexopathy can occur within the first few months post radiation
but later plexopathy can be permanent.

•

Rib fractures: this occurs in 2 percent or less of patients

•

Lymphedema: upper limb edema of any degree can occur in 10 to 20
percent of patients but moderate to severe lymphedema occurs in 5
percent or less of patients. Lymphedema can be permanent.

•

Cardiac toxicity: the risk of fatal MI from radiotherapy is estimated at 1
percent or less. Acute pericarditis is also uncommon (less than 1 percent).

•

Second malignancies: there are reports of increase in lung cancer post
radiotherapy for breast cancer. Skin cancers and rare sarcomas rarely
occur post radiotherapy.
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•

Wound dehiscence requiring surgery: the rate of this complication is
expected to be less than 5%.

Any of the above toxicities graded by NCIC/CTC v3.0 at grade 4 will be
assessed by the PI, radiation oncologist and medical oncologist together to
determine whether to stop radiation or docetaxel. There is concern that acute
skin toxicity will be increased by the combination of chemotherapy and radiation
but it is expected that most patients will complete the full regimen. It is common
with locoregional radiation alone for patients to develop patches of moist
desquamation in areas of skin folds like the axilla, infra-mammary crease, and
medial neck. These acute skin reactions alone will not require treatment
modification. General acute radiation skin toxicity management guidelines and
treatment modifications during radiation are as follows:
(a) Grade 3 or greater (moist desquamation other than skin folds) acute skin
reaction affecting more than 25 percent of the breast surface (excluding
areas of direct skin involvement by tumor) or more than 25 percent of the
supraclavicular skin surface: Hold both radiation and docetaxel up to one
week until healing visible and then re-start docetaxel and radiation with no
dose modifications.
(b) Grade 3 or greater acute skin reaction of onset earlier than fraction 16 of
radiation (start of week 4): Hold both radiation and docetaxel up to one
week until healing visible and then re-start docetaxel and radiation with no
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dose modifications. Consider the possibility of acute cellulitis and manage
with antibiotics as well, if index of suspicion high.
(c) Grade 3 or greater acute skin reaction as in 1 or 2 above but requiring
more than one week but less than 2 weeks to show signs of healing: Restart radiation alone and discontinue docetaxel.
(d) Grade 3 or greater acute skin reaction as in 1 or 2 above but with no
healing within 2 weeks treatment break: Discontinue both docetaxel and
radiation.

Management of grade 3 or greater acute skin reaction includes flamazine
applied topically 2 to 3 times a day (polysporin triple could be considered in
patients allergic to flamazine). If superimposed acute cellulitis is suspected,
antibiotic management for cellulitis can be initiated as well. Grade 4 radiation skin
toxicity will be treated symptomatically in keeping with best clinical practice as
already decided by the breast multi-disciplinary team regarding this protocol.
Early experiences with the first ten patients going through this treatment
protocol have raised concern about increased incidence and severity of radiation
pneumonitis. Toxicity on this protocol is being monitored by an independent data
safety monitoring committee. Clinical shortness of breath secondary to radiation
typical develops after radiation treatment is completed and usually one to four
months post radiation. Among the first ten patients, clinical shortness of breath
developed within the first few weeks after radiation and docetaxel. Shortness of
breath was grade 3 in 3 of ten 10 patients and, in 2 of the 3 patients, was felt to
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be definitely treatment related. In all 3 patients shortness of breath responded
quickly to steroids and all 3 went on to definitive surgery without any delay. Only
1 of the 3 women has residual shortness of breath grade 2. This patient had a
significant history of smoking and continued to smoke throughout treatment.
Complete pathologic response occurred in 5 of the first 10 patients, well above
the 20% reported in the literature for chemotherapy alone.

The breast

multidisciplinary team decided that an acceptable incidence of grade 3
pneumonitis that does not improve to grade 1 or less within 8 weeks from the end
of radiation or prior to surgery date as per protocol is five percent or lower.

As

well grade 3 or greater shortness of breath attributed to treatment that does not
improve to grade 1 or less within 8 weeks from the end of radiation or prior to
surgery date as per protocol is five percent or lower.
Pneumonitis assessment and management are as follows:
(a) all patients should have baseline pulmonary function studies;
(b) clinical considerations in evaluating a patient with shortness of breath during
or after docetaxel and radiation include pulmonary, emboli, infection, cardiac
dysfunction, and treatment related pneumonitis;
(c) in addition to clinical assessment, patients reporting worsening shortness of
breath at any time during radiation should have a complete blood count with
differential and a chest x-ray. Respirology referral is appropriate if the patient has
fever, neutropenia less than 1.0, or is not responding to medical treatment of
pneumonitis;
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(d) patients reporting grade 3 shortness of breath during or after completing
radiation should have a CT scan of the thorax. Repeat CT scans of the thorax will
be done as clinically indicated in patients who initially presented with grade 3 or
greater shortness of breath felt to represent treatment related pneumonitis. It is
recommended that CT thorax be obtained at 3 to 6 months post docetaxel and
radiation in patients who initially present with grade 3 or greater pneumonitis,
especially if there is residual shortness of breath;
(e) medical management of docetaxel and radiation related pneumonitis:
•

Medical management is individualized.

•

Grade less than or equal to 2 shortness of breath: follow up only is
appropriate.

•

Grade 3 or greater shortness of breath: Initiate prednisone at 50mg
orally daily for one to two weeks.

Reduce the dosage by fifty

percent every 3 to 5 days based on patient symptomatic
improvement. A more gradual taper of steroids may be appropriate
for some patients. If the patient is not responding to treatment,
respirology consultation is appropriate. Pentoxifylline 400mg orally
three times a day could be considered in patients who are still quite
symptomatic

despite

steroids

for

more

than

two

weeks.

Pentoxifylline has been tested in a double blind, randomized clinical
trial versus placebo but was given throughout radiation.
(f) stopping rules for treatment related pneumonitis: a data safety monitoring
committee review will be held if the number of patients with incidence of grade 3
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pneumonitis (attributed to treatment) does not improve to grade 1 or less within 8
weeks from the end of radiation or prior to surgery date as per protocol;
exceeds 2 of the first ten patients, 3 of the first twenty patients, 4 of the first 30
patients, or 5 of the first 40 patients (Table III.3). Toxicity profiles, risks and
benefits, and the study protocol will be reviewed by the data safety monitoring
committee. Protocol modifications will be discussed and reviewed by the breast
multidisciplinary team. The revised study protocol will be approved by the data
safety monitoring committee and the ethics review board before continuing.

III.4

MEASUREMENT OF EFFECT
For the purposes of this study, patients should be evaluated every 3

weeks during active treatment by caliper or ruler measurement. Where feasible,
the caliper measurement is to be done by the same investigator.
Response and progression will be evaluated in this study using the new
international criteria proposed by the Response Evaluation Criteria in Solid
Tumors

(RECIST)

Committee.

Changes

in

only

the

largest

diameter

(unidimensional measurement) of the tumor lesions are used in the RECIST
criteria. Note:

Lesions are either measurable or non-measurable using the

criteria provided below. The term “evaluable” in reference to measurability will not
be used because it does not provide additional meaning or accuracy.
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Table III.3.

Stopping rules for treatment-related pneumonitis in the
experimental treatment protocol in LABC patients.

Largest acceptable value

First non-acceptable value

N

# Cases (%)

Exact 95% CI

# Cases (%)

Exact 95% CI

10

2 (20%)

2.5% - 55.6%

3 (30.0%)

6.7% - 65.3%

20

3 (15.0%)

3.2% - 37.9%

4 (20.0%)

5.7% - 43.7%

30

4 (13.3%)

3.8% - 30.7%

5 (16.7%)

5.6% - 34.7%

40

5 (12.5%)

4.2% - 26.8%

6 (15.0%)

5.7% - 29.8%
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III.4.1 Definitions
III.4.1.1 Measurable Disease
Measurable lesions are defined as those that can be accurately measured
in at least one dimension (longest diameter to be recorded) as ≥20mm with
conventional techniques (CT, MRI, x-ray) or as ≥10mm with spiral CT scan. All
tumor measurements must be recorded in millimeters (or decimal fractions of
centimeters).

III.4.1.2 Non-Measurable Disease
All other lesions (or sites of disease), including small lesions (longest
diameter <20mm with conventional techniques or <10mm using spiral CT scan),
are considered non-measurable disease. Bone lesions, leptomeningeal disease,
ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory
breast disease, abdominal masses (not followed by CT or MRI), and cystic
lesions are all non-measurable.

III.4.1.3 Target Lesions
All measurable lesions up to a maximum of five lesions per organ and 10
lesions in total, representative of all involved organs, should be identified as
target lesions and recorded and measured at baseline. Target lesions should be
selected on the basis of their size (lesions with the longest diameter) and their
suitability for accurate repeated measurements (either by imaging techniques or
clinically).

A sum of the longest diameter (LD) for all target lesions will be
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calculated and reported as the baseline sum LD. The baseline sum LD will be
used as reference by which to characterize the objective tumor response.

III.4.1.4 Non-Target Lesions
All other lesions (or sites of disease) should be identified as non-target
lesions and should also be recorded at baseline. Non-target lesions include
measurable lesions that exceed the maximum numbers per organ or total of all
involved organs as well as non-measurable lesions. Measurements of these
lesions are not required, but the presence or absence of each should be noted
throughout follow-up.

III.4.2 Guidelines for Evaluation of Measurable Disease
All measurements should be taken and recorded in metric notation using a
ruler or calipers. All baseline evaluations should be performed as closely as
possible to the beginning of treatment and never more than 4 weeks before the
beginning of the treatment. Tumor lesions that are situated in a previously
irradiated area must not be the only site of measurable disease.
The same method of assessment and the same technique should be used
to characterize each identified and reported lesion at baseline and during followup. Imaging-based evaluation is preferred to evaluation by clinical examination
when both methods have been used to assess the antitumor effect of a treatment.
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III.4.2.1 Clinical Lesions
Clinical lesions will only be considered measurable when they are
superficial (e.g., skin nodules and palpable lymph nodes). In the case of skin
lesions, documentation by colour photography, including a ruler to estimate the
size of the lesion, is recommended.

III.4.2.2 Chest X-ray
Lesions on chest x-ray are acceptable as measurable lesions when they
are clearly defined and surrounded by aerated lung. However, CT is preferable.

III.4.2.3 Conventional CT and MRI
These techniques should be performed with cuts of 10mm or less in slice
thickness contiguously. Spiral CT should be performed using a 5mm contiguous
reconstruction algorithm. This applies to tumors of the chest, abdomen, and
pelvis. Head and neck tumors and those of extremities usually require specific
protocols.

III.4.2.4 Ultrasound (US)
When the primary endpoint of the study is objective response evaluation,
US should not be used to measure tumor lesions. It is, however, a possible
alternative to clinical measurements of superficial palpable lymph nodes,
subcutaneous lesions, and thyroid nodules. US might also be useful to confirm
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the complete disappearance of superficial lesions usually assessed by clinical
examination.

III.4.2.5 Endoscopy and Laparoscopy
The utilization of these techniques for objective tumor evaluation has not
yet been fully and widely validated. Their uses in this specific context require
sophisticated equipment and a high level of expertise that may only be available
in some centers. Therefore, the utilization of such techniques for objective tumor
response should be restricted to validation purposes in reference centers.
However, such techniques may be useful to confirm complete pathological
response when biopsies are obtained.

III.4.2.6 Tumour Markers
Tumor markers alone cannot be used to assess response. If markers are
initially above the upper normal limit, they must normalize for a patient to be
considered in complete clinical response. Specific additional criteria for
standardized usage of prostate-specific antigen (PSA) and CA-125 response in
support of clinical trials are being developed.

III.4.2.7 Cytology and Histology
These techniques can be used to differentiate between partial responses
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor
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types, such as germ cell tumors, where known residual benign tumors can
remain).
The cytological confirmation of the neoplastic origin of any effusion that
appears or worsens during treatment when the measurable tumor has met
criteria for response or stable disease is mandatory to differentiate between
response or stable disease (an effusion may be a side effect of the treatment)
and progressive disease.

III.4.3 Response Criteria
III.4.3.1 Evaluation of Target Lesions
The definitions are as follows:
•

Complete Response (CR): Disappearance of all target lesions;

•

Partial Response (PR): At least a 30% decrease in the sum of the longest
diameter (LD) of target lesions, taking as reference the baseline sum LD;

•

Progressive Disease (PD): At least a 20% increase in the sum of the LD
of target lesions, taking as reference the smallest sum LD recorded since
the treatment started or the appearance of one or more new lesions;

•

Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor
sufficient increase to qualify for PD, taking as reference the smallest sum
LD since the treatment started.

III.4.3.2 Evaluation of Non-Target Lesions
The definitions are as follows:
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•

Complete Response (CR): Disappearance of all non-target lesions and
normalization of tumor marker level;

•

Incomplete Response/Stable Disease (SD): Persistence of one or more
non-target lesion(s) and/or maintenance of tumor marker level above the
normal limits;

•

Progressive Disease (PD): Appearance of one or more new lesions and/or
unequivocal progression of existing non-target lesions.
Although a clear progression of “non-target” lesions only is exceptional, in

such circumstances the opinion of the treating physician should prevail, and the
progression status should be confirmed at a later time by the review panel (or
study chair). Note: If tumor markers are initially above the upper normal limit,
they must normalize for a patient to be considered in complete clinical response.

III.4.3.3 Evaluation of Best Overall Clinical Response
The best overall response is the best response recorded from the start of
the treatment until disease progression/recurrence (taking as reference for
progressive disease the smallest measurements recorded since the treatment
started) (Table III.4). Patients with a global deterioration of health status requiring
discontinuation of treatment without objective evidence of disease progression at
that time should be classified as having “symptomatic deterioration.” Every effort
should

be

made

to

document

discontinuation of treatment.

the

objective

progression,

even

after
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Table III.4.

Evaluation of best clinical response in LABC patients
undergoing clinical trial experimental protocol.

Target Lesions

Non-Target Lesions

New Lesions

Overall Response

CR

CR

No

CR

CR

Incomplete
response/SD

No

PR

PR

Non-PD

No

PR

SD

Non-PD

No

SD

PD

Any

Yes or No

PD

Any

PD

Yes or No

PD

Any

Any

Yes

PD
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III.4.4 Confirmatory Measurement of Pathological Response
The final assessment of tumour response will be made by one and the
same independent pathologist (confirmed by an unbiased secondary assessment
by a second pathologist) based on the pathological assessment of the entire
surgical specimen, according to current standards accepted by the Canadian
Association of Pathologists, examining the entire specimen and taking
representative blocks of tissue for analysis. Pathological response will be
subcategorized as follows:
pCR – pathological complete response (no residual invasive breast cancer
in the breast tissue);
pSPR – pathological significant partial response (<10 foci of microscopic
invasive tumour within breast);
pPR – pathological partial response (<30% of original invasive breast
tumour volume remaining);
SD – stable disease (30-80% of original invasive breast tumour volume
remaining);
NR – no response (81-120% of original invasive breast tumour volume
remaining);
DP – disease progression (>120% of original invasive breast tumour
volume remaining).
The baseline diagnostic breast MRI will be used to calculate the pretreatment tumour volume, as a surrogate measure for true pathological in vivo

199
tumour volume, given that it remains our most sensitive means of estimating in
vivo breast tumour volume.

III.4.4.1 Duration of Overall Response
The duration of overall response is measured from the time measurement
criteria are met for CR or PR (whichever is first recorded) until the first date that
recurrent or progressive disease is objectively documented (taking as reference
for progressive disease the smallest measurements recorded since the treatment
started).
The duration of overall CR is measured from the time measurement
criteria are first met for CR until the first date that recurrent disease is objectively
documented.

III.4.4.2 Duration of Stable Disease
Stable disease is measured from the start of the treatment until the criteria
for progression are met, taking as reference the smallest measurements
recorded since the treatment started.

III.4.4.3 Progression-Free Survival
Progression free survival is defined as the duration of time from start of
treatment to progression (as defined above), death or last contact, or last tumor
assessment before the start of further antitumor therapy.
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III.4.5 Adverse Event Reporting
The safety committee will consist of, at a minimum, the principal
investigator, a statistician, the data manager, and one independent physician.
They will meet annually and as required.
Toxicities occurring as a result of treatment should be reported to the
principal investigator and the Data Collection Centre at the Clinical Research Unit
of the London Regional Cancer Program in the manner described below. In
addition, the IRB/REB will be notified in keeping with good clinical practice
guidelines.
The investigator is responsible for the detection and documentation of
events meeting the definition of an adverse event (AE) or serious adverse event
(SAE) as provided in this section of the protocol. In order to fulfill international
safety reporting obligations, the investigator should include in his or her
assessment any SAEs resulting from study participation (e.g., complications
resulting from the taking of a blood sample).

III.4.5.1 Definition of an AE
An AE is any untoward medical occurrence in a patient or clinical
investigation subject administered a pharmaceutical product and which does not
necessarily have a causal relationship with this treatment. An AE can, therefore,
be any unfavourable and unintended sign (that could include a clinically
significant abnormal laboratory finding), symptom, or disease temporarily
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associated with the use of a medicinal product, whether or not considered related
to the medicinal product.
An AE does include a/an:
•

exacerbation of a pre-existing illness.

•

increase in frequency or intensity of a pre-existing episodic event or

condition.
•

condition detected or diagnosed after study drug administration even

though it may have been present prior to the start of the study.
•

continuous persistent disease or symptoms present at baseline (including

cancer signs and symptoms if more severe than expected) that worsen following
the start of the study.

An AE does not include a/an:
•

medical or surgical procedure (e.g., surgery, endoscopy, tooth extraction,

transfusion); the condition that leads to the procedure is an AE.
•

pre-existing disease or conditions present or detected at the start of the

study that do not worsen.
•

situations where an untoward medical occurrence has not occurred (e.g.

hospitalizations for cosmetic elective surgery, social and/or convenience
admissions).
•

the disease or disorder being studied or sign or symptom associated with

the disease or disorder unless more severe than expected for the subject’s
condition (e.g. subjects with advanced stages of cancer are expected to
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experience progression of disease including increased tumor size, new sites of
disease, malignant pleural effusion, malignant ascites, and death due to cancer).
•

overdose of either study drug or concurrent medication without any signs

or symptoms.

III.4.5.2 Definition of an SAE
An SAE is any adverse event occurring at any dose that results in any of
the following outcomes:
•

death

•

a life-threatening adverse event.

•

inpatient hospitalization or prolongation of existing hospitalization.

•

a disability/incapacity.

•

a congenital anomaly in the offspring of a subject who received study drug.

•

important medical events that may not result in death, be life-threatening,

or require hospitalization may be considered a serious adverse event when,
based upon appropriate medical judgment, they may jeopardize the patient or
subject and may require medical or surgical intervention to prevent one of the
outcomes listed in this definition.

Examples of such medical events include

allergic bronchospasm requiring intensive treatment in an emergency room or at
home, or convulsions that do not result in inpatient hospitalization, or the
development of drug dependency or drug abuse.
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Clarifications:
•

“Occurring at any dose” does not imply that the subject is receiving study

drug.
•

Life-threatening means that the subject was, in the view of the investigator,

at immediate risk of death from the event as it occurred. This definition does not
include an event that, had it occurred in a more severe form, might have caused
death.
•

Hospitalization for elective treatment of a pre-existing condition that did

not worsen during the study is not considered an SAE.
•

Complications that occur during hospitalization are AEs. If a complication

prolongs hospitalization, the event is an SAE. “Inpatient” hospitalization means
the subject has been formally admitted to a hospital for medical reasons. This
may or may not be overnight. It does not include presentation a casualty or
emergency room.
•

With regard to criteria above, medical and scientific judgment should be

used when deciding whether prompt reporting is appropriate in this situation.

Events or Outcomes Not Qualifying as SAEs: Any sign, symptom,
diagnosis, illness, and/or clinical laboratory abnormality that can be linked to the
disease under study or disease progression and is not possibly attributable to
study drug, are not reported as SAEs even though such event or outcome may
meet the definition of SAE.
•

Events that are exempt from reporting as serious adverse events include:
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•

Events emerging during the study that are part of the natural progression

of the underlying cancer (including disease-related deaths) unless more severe
than expected or not possibly attributable to study drug. For example,
hospitalization for the evaluation or treatment of signs and symptoms of disease
progression that are not possibly attributable to study drug will not be reported as
an SAE.
•

SAE that occur more than 28 days after the final dose of study drug that

are judged by the investigator to be unrelated to prior treatment with study drug.

III.4.5.3 Lack of Efficacy as an AE or SAE
“Lack of efficacy” (e.g., disease progression as documented by increased
tumor size, increased number of lesions, new sites of disease, malignant pleural
effusions, malignant ascites and death due to cancer) per se will not be reported
as an AE. The signs and symptoms or clinical sequelae resulting from lack of
efficacy should be reported if they fulfill the AE or SAE definition (including
clarifications).

III.4.5.4 Clinical Laboratory Abnormalities and Other Abnormal Assessments as
AEs and SAEs
A laboratory abnormality per se will not be recorded as an AE or SAE
unless it is serious (See definition of an SAE), represents the primary reason for
treatment or study discontinuation, or is associated with a clinical diagnosis.
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Sequelae of laboratory abnormalities (e.g., sepsis or fever in subjects with
neutropenia) will be recorded on the Serious Adverse Event page.
Findings from disease assessments (e.g., CT scans, MRI scans, X-rays,
bone scans, physical examinations or medical photographs) will not be recorded
as AEs or SAEs. Clinically significant abnormal findings or assessments (e.g.,
vital signs, electrocardiograms, physical examinations excluding disease
assessments) that are detected after study drug administration or that are
present at baseline and worsen following the start of the study are included as
AEs and SAEs.
The investigator should exercise his or her medical and scientific judgment
in deciding whether an abnormal finding or assessment is clinically significant.

III.4.5.5 Method, Frequency, and Time Period for Detecting AEs and SAEs
All adverse events and serious adverse events (except as noted above),
regardless of causality, that may occur anytime from the time of administration of
the first dose of any study drug until mastectomy will be recorded on the CRF.
Any delayed, continuing or New Toxicities related to study treatment must be
recorded until 6 months after mastectomy.

III.4.5.6 Documenting SAEs
A separate set of SAE Report form pages should be used for each SAE.
However, if at the time of initial reporting, multiple SAEs are present that are
temporally and/or clinically related, they may be reported on the same SAE form.

206
The investigator should attempt to establish a diagnosis of the event
based on signs, symptoms, and/or other clinical information. In such cases, the
diagnosis should be documented as the AE and/or SAE and not the individual
signs/symptoms. If a clinically significant abnormal laboratory finding or other
abnormal assessment meets the definition of an SAE, then an SAE form must be
completed. A diagnosis, if known, or clinical signs and symptoms if diagnosis is
unknown, rather than the clinically significant abnormal laboratory finding, should
be completed on SAE form. If no diagnosis is known and clinical signs and
symptoms are not present, then the abnormal finding should be recorded. The
laboratory data should either be recorded on the SAE form with the reference
range and baseline value(s) or copies of the laboratory reports and reference
ranges should be sent with the SAE form pages.

The SAE form should be

completed as thoroughly as possible and signed by the investigator or his/her
designee before transmittal to the Data Collection Centre. It is very important
that the investigator provide his/her assessment of causality to study drug at the
time of the initial SAE report.

III.4.5.7 Follow-Up of SAEs
All SAEs must be followed until resolution, until the condition stabilizes,
until the event is otherwise explained, or the subject is lost to follow-up. The
investigator is responsible to ensure that follow-up includes any supplemental
investigations as may be indicated to elucidate as completely as practical the
nature and/or causality of the SAE. This may include additional laboratory tests
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or investigations, histopathological examinations, or consultation with other
health care professionals. New or updated information should be recorded on
the originally completed SAE form with all changes signed and dated by the
investigator.

III.4.5.8 Prompt Reporting of SAEs
SAEs must be reported promptly as described Table III.5, once the
investigator determines that the event meets the protocol definition of an SAE.

III.4.5.9 Regulatory Reporting Requirements
The investigator must promptly report all SAEs to the Data Collection
Centre. We have a legal responsibility to notify both the local regulatory authority
and other regulatory agencies about the safety of a drug under clinical
investigation. Prompt notification of SAEs by the investigator to the appropriate
project contact for SAE receipt is essential so that legal obligations and ethical
responsibilities towards the safety of other subjects are met.
The investigator, or responsible person according to local requirements,
must comply with the applicable local regulatory requirements related to the
reporting of SAEs to regulatory authorities and the IRB/IEC.
If new safety information (e.g., revised Clinical Investigator’s Brochure)
becomes available, the principal investigator is required to promptly notify her
local IRB or IEC.
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Table III.5.

Time frames for submitting significant adverse event (SAE)
reports.

Initial SAE Reports

Additional Information
on a Previously
Reported SAE

Type of SAE

Time
Frame

Documents

Time
Frame

Documents

Death, result of an AE
or reasonable
possibility

24/48
hrsa

SAE form

48 hrs

Updated
SAE form

Death, not result of an
AE and not a
reasonable possibility

48 hrs

SAE form

48 hrs

Updated
SAE form

Life-threatening event,
regardless of
relationship to study
drug

24/48
hrsb

SAE form

48 hrs

Updated
SAE form

Other SAEs

48 hrs

SAE form

48 hrs

Updated
SAE form

a

Initial notification should be sent within 24 hours of the investigator
learning of the death. Fully completed documents (SAE form) should be
sent within 48 hours.
b

Initial notification should be sent within 24 hours of the investigator
learning of the life-threatening event. Fully completed documents (SAE
CRF pages) should be sent to within 48 hours.
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III.4.5.10 Post-Study AEs and SAEs
Investigators are not obligated to actively seek AEs or SAEs in former
study participants. However, if the investigator learns of any SAE at any time
after a subject has been discharged from the study, and such event(s) is(are)
reasonably related to the study drug, the investigator should promptly notify the
Data Collection Centre.

III.4.6 Subject Discontinuation/Withdrawal
Patients may discontinue protocol treatment for one or more of the
following reasons/criteria:
§

Unacceptable toxicity as defined in Section III.3.2.2 and III.3.2.3.

§

Intercurrent illness which, in the opinion of the investigator, would seriously
impair the successful completion of the protocol regimen. (If protocol
treatment is stopped for his reason, every effort should be made to offer
standard therapy or similar if and when it is possible to resume treatment).

§

Tumour progression as defined using RECIST criteria in section III.4.

§

Request by the patient (In this case the patient must be informed that he/she
may be forfeiting substantial clinical benefit and even, potentially cure, and a
standard alternative should be offered).

§

If, in the judgement of the responsible investigator, the protocol is no longer in
the best interests of the patient. A suitable alternative should be discussed
with the patient.

§

Other reasons, which should be explicitly recorded.
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Every effort should be made to follow up all patients. Patients whom are
prematurely discontinue from protocol therapy, should have blood for plasma
osteopontin and survival completed according to study calendar.

If protocol

therapy is stopped prematurely, treatment is at the discretion of the investigator.

III.4.7. Statistical Considerations
Sample size: a 95% confidence interval about a proportion p is calculated
using the formula:

p ± 1.96 p(1 − p) / n
For 52 patients and an anticipated response rate of 52% a 95%
confidence interval will have bounds no greater than ±14%.

Statistical analysis: the pathological complete response rate will be
calculated and a 95% confidence interval will be constructed. The response rate
will be compared to patients who received the same regimen but without
radiation using a chi-square test.
Kaplan-Meier estimates of overall survival and the disease free interval
will be made and comparisons made with subjects on the same regimen but
without radiation using log-rank tests.
The relationship between 99Tm sestaMIBI imaging at each of the three
time points prior to surgery and response will be evaluated using logistic
regression. ROC curves may be used to further evaluate the usefulness of this
imaging technique as a marker for tumour response.

Similarly, cellular
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response/sensitivity to CNCR using the ex vivo 3D human tumour will be
evaluated as a marker for tumour response.
Toxicities and adverse events will be described.

Ninety-five percent

confidence intervals about the percentages experiencing toxicities and adverse
events will be calculated.

III.4.8 Ethical, Regulatory and Administrative Issues
III.4.8.1 Retention of Patient Records and Study Files
An Investigator shall retain records defined as essential under GCP
guidelines for a period of 2 years following the date of marketing application is
approved for the drug for the indication for which it is being investigated; or, if no
application is to be filed or if the application is not approved for such indication,
until 2 years after the investigation is discontinued.

III.4.8.2 REB Approval
It is necessary to obtain local ethics approval of the protocol, letter of
information and consent form. Annual re-approval is required as long as patients
continue to be followed on the trial.

III.4.8.3 Amendments
An amendment to a protocol is a change significant enough to require
review/approval by local REBs (and, if applicable, by the TTD of the HPB).
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Protocol amendments will be circulated in standard format with clear instructions
regarding REB review.

III.4.8.4 Informed Consent
The REB of an institution must approve the consent form document which
will be used at that centre prior to its local activation; changes to the consent
form in the course of the study will also required REB notification/approval.
The following elements must appear in the consent form: a description of
the purpose of the study (indicating, if appropriate, that the drug is
investigational); potential side effects; potential benefits; study design; voluntary
participation; and confidentiality. It is essential that the consent form contain a
clear statement which gives permission for information to be sent to and source
medical records to be reviewed by the other agencies as necessary.

III.4.8.5 Consent Process/Patient Eligibility
Patients who cannot give informed consent (i.e. mentally incompetent
patients, or those physically incapacitated such as comatose patients) are not to
be recruited into the study. Patients competent but physically unable to sign the
consent form may have the document signed by their nearest relative or legal
guardian. Each patient will be provided with a full explanation of the study before
consent is requested.
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III.4.9 Publications
Results of this trial will be submitted for publication in a peer review journal.

III.5
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APPENDIX IV. EVALUATION OF THE RESPONSE OF LOCALLY ADVANCED
BREAST CANCER TO A NOVEL NEOADJUVANT
CHEMORADIATION THERAPY PROTOCOL:
BIOLOGICAL STUDIES.

IV.1 INTRODUCTION
Locally advanced breast cancer (LABC) represents 10-15% of all new
breast cancers, with a 5-year survival of 50% using standard treatment that
includes neoadjuvant chemotherapy, surgery and adjuvant radiation [1]. LABC is
traditionally defined as stage IIB (T3N0) and Stage IIIA/B from the TNM
classification [2]. Clinically, these tumours are greater than 5 cm in size and/or
extend beyond the breast tissue into the surrounding skin or muscle, with/without
matted axillary lymph nodes (N2), internal mammary nodes (N2) or ipsilateral
supraclavicular lymph node involvement (N3).
However,

a

small

subset

of

women

who

receive

neoadjuvant

chemotherapy and achieve a pathologic complete response (pCR), (defined as
no microscopic residual invasive breast cancer following neo-adjuvant treatment)
have a vastly improved 5 year disease free survival rate of 87% [3] and 5-year
overall survival rates of 89% [3] and 90% [4]. As such, pCR rates have become a
surrogate measure for favourable long-term outcomes in trials involving
neoadjuvant treatment [5], particularly since in vivo assessment is the only
method by which a response can be measured.
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Pathological complete response (pCR) at surgery is the best current
surrogate for overall survival [5], therefore this was the primary end-point of this
single-arm prospective Phase II trial. RNA Integrity Number (RIN), previously
demonstrated to predict treatment response to neoadjuvant chemotherapy in
NCIC MA-22 trial, has been validated as a predictive marker of pCR [6].
In order to improve survival from breast cancer, novel cytotoxic agents
have been tested following, or concurrently with, anthracycline chemotherapy,
notably taxanes [7, 8]. Docetaxel is a microtubule-stabilizing agent that induces
cell-cycle arrest at mitosis and apoptosis [9, 10]. Based on its activity in the
metastatic setting, docetaxel has been tested in randomized trials in early stage
breast cancer, and demonstrated superior survival when added to anthracyclinebased regimens compared to these regimens alone. FEC-D (fluorouracil
500mg/m2 IV, epirubicin 100mg/m2, cyclophosphamide 500mg/m2 IV every 3
weeks x 3 cycles, followed by docetaxel 100mg/m2 IV every 3 weeks x3) remains
a commonly employed regimen in the adjuvant post-operative setting [11-15]. In
spite of the improved outcomes associated with the addition of taxanes to
neoadjuvant chemotherapy regimens, the gains in achieving pCR have been
modest. The most striking pCR rates have been in Her2+ breast cancers with the
use of neoadjuvant trastuzumab (Herceptin), where pCR rates may exceed 5060%, however this is only true for a minority of patients [16].
It is well known that no two cancers are alike in their response to
chemotherapy [6, 17]. Cancers of the same subtype, grade, stage and
immunohistochemistry often respond quite differently to the same chemotherapy
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regimen, very likely due to differences in tumour phenotype and genotype [18].
Despite this well-documented heterogeneity in response to chemotherapy,
chemotherapy selection decisions continue to be based on large adjuvant
randomized clinical trials, which have a “one for all” approach to chemotherapy
drug selection. Since chemotherapy for breast cancer is usually delivered in the
adjuvant setting, there is no clinical opportunity to assess in vivo response (or
resistance) to the selected regimen. The tumour is deemed to have been
resistant only when disease recurs, usually as distant metastases, which are no
longer curable. Therefore it would be a significant clinical asset to develop early
measures of chemotherapy sensitivity for any individual proposed regimen,
allowing clinicians to tailor therapies effective for each individual patient
(‘individualized medicine’). RNA integrity (RIN) has been demonstrated to be a
good predictor of response to neoadjuvant chemotherapy as evidenced through
the NCIC MA-20 clinical trial (Parissenti, Guo et al, 2015), and is therefore felt to
be a potential individualized method of testing a tumour’s likelihood of responding
well to chemotherapy early in treatment, rather than waiting until after the
completion of a potentially ineffective cytotoxic regimen. RIN represents a
quantification score of the degree of fragmentation of ribosomal RNA (rRNA), a
process that occurs during degradation. Quantifying the rRNA integrity allows for
a measure of how much degradation has occurred, and is a useful tool for
scientists to gauge the reliability of the data they have obtained in RNA studies.
The scale is from 1 (complete degradation) to 10 (completely intact RNA) [19].
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Anatomic imaging tools, such as ultrasound and MRI, are capable of
measuring size of the tumour; however, these modalities may not be as able to
detect changes in amount of viable tumour a result of response to treatment
(viable tumour in the specimen being replaced by stromal or fibrotic tissue).
SPECT-CT imaging using

99m

Tc-bound to MIBI substrate is a functional nuclear

medicine test that can show functional changes in the tumour as a response to
treatment [20-22]. This substrate, injected intravenously, is avidly taken into
tumour cells, showing a bright tumour on the initial 10min image. The substrate,
however, actively effluxes through drug efflux transmembrane protein pumps,
such as ABC transmembrane glycoprotein pumps (i.e. P-glycoprotein (Pgp),
breast cancer resistance protein (BCRP) or multidrug resistance protein (MDP))
[23, 24]. These are the same drug efflux proteins felt to contribute, in part, to
resistance to chemotherapy-induced cytotoxicity by actively effluxing the
chemotherapeutic agent. Therefore, cancer cells able to efflux MIBI efficiently
should be also able to efflux chemotherapy. As a result, if efflux pumps are
working, rapid washout of MIBI substrate should be apparent, specifically in
tumours with presumed chemotherapy resistance. It has been demonstrated that
SPECT-CT imaging may be a useful test to predict sensitivity to chemotherapy in
LABC [25, 26], but its sensitivity has not been evaluated in response to clinical
outcomes among LABC patients, and has not been studied in the setting of serial
evaluations during active treatment. We sought to evaluate whether SPECT-CT
imaging could be used at baseline to predict sensitivity to chemotherapy when
compared to pCR, the surrogate for survival. Secondarily, we sought to explore
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whether there might be any interesting relationship between pre- mid- and posttreatment MIBI SPECT-CT imaging in terms of whether chemo-resistance could
be seen to be developing over treatment in patients who then were found to be
clinically resistant to treatment.
The OncoScreen® chemosensitivity assay is based on a 3D gel assay
that was developed to examine the effects of radiation on the invasiveness of
brain cancer cells (Dr. Penny Costello, personal communication). It provides a
tissue-like environment for testing of tumour growth, invasion and response to
chemotherapeutic agents ex vivo that more closely models the clinical situation
of examining tumour growth in the context of breast cancer treatment protocols.
Typically, tumours are surgically resected, followed by adjuvant therapy (which
can include chemotherapy), radiation and other biological and hormonal
therapies. In this scenario, there would likely be no primary tumour to contend
with, only migrating cells seeking to establish themselves as new tumours. Thus,
assessing sensitivity to drugs in a migration/invasion assay may be the best
predictor of an individual tumour’s chemotherapy response at this stage of
treatment.
Most in vitro culture experiments, such as invasion assays, utilize 2dimensional monolayer cultures exposed to a variety of agents [27], 3dimensional spheroids [28, 29], or cultured cells plated in a 3-dimensional
overlay culture on matrices in order to explore tumour response to various
conditions [30, 31]; co-cultured cells in matrix and/or in transwells may be used to
evaluate tissue interactions [32]. Three-dimensional cultures have been reported
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in the literature as a tool for exploring tumour invasiveness within the stromal
microenvironment in vitro [33]. Others have also used this model to determine
breast cancer response to chemotherapeutic agents, such as rapamycin [34].
There have been three reported publications using the 3-dimensional
human

breast

cancer

invasion

assay

similar

to

the

OncoScreen®

chemosensitivity assay as method of screening for individual sensitivity to
chemotherapies [35-37]. As a result, this method was felt to represent an ex vivo
model, which could use tumour samples obtained by needle biopsy to predict
individual chemotherapeutic sensitivities prior to treatment delivery.
Given the poor prognosis of LABC, we proposed the use of an adjuvant
regimen in the neoadjuvant setting, using the taxane (docetaxel) concurrently
with radiation for radiosensitization. As an addition to a clinical trial (Chapter 2),
three separate sub-studies were undertaken to assess the response of LABC
tumours to treatment: RNA Integrity Assay (RIN), serial single photon emission
computed tomography (SPECT-CT) imaging (sestaMIBI), and serial ex vivo
studies of biopsied tumours (3D gel invasion assay) assessing the tumour
invasiveness in response to chemotherapy.

IV.2. METHODS
IV.2.1 Patients and Therapeutic Regimen
Thirty-two patients with stage III non-metastatic LABC were enrolled at a
single institution between 2009 and 2011 (see Chapter 2). They were treated
with neo-adjuvant 5-fluorouracil, epirubicin and cyclophosphamide q3 weekly for
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4 cycles followed by weekly docetaxel (35mg/m2) concurrently with regional
radiation (45Gy with 9Gy boost in 25 & 5 fractions) for the first 6 of 9 weeks.
Patients underwent serial tumour biopsy for biological substudies (14-gauge
tumour core biopsy) pre-, mid- and post-treatment and the biopsy specimen was
stored in refrigerated phosphate buffered saline for transportation to the
laboratory. One mm3 section was then taken from the biopsies, immersed in
RNAlaterTM, and stored frozen at -80°C. At the completion of the third posttreatment biopsy procedure, the patient then underwent a modified radical
mastectomy.

IV.2.2 RNA Integrity Assay
IV.2.2.1 RNA Isolation from Tumour Core Biopsies
RNA was isolated from image-guided tumour core biopsies of the patients
pre-, mid-, and post-treatment using Qiagen RNAeasy® Mini kits, as per
manufacturer’s instructions. Briefly, The biopsies were homogenized and the
lysate was then passaged at least 5 times through a 20-gauge needle (0.9mm
diameter) fitted to an RNase-free syringe. The sample was centrifuged at high
speed in a refrigerated microfuge at 4oC for 3 minutes, with transfer of the
supernatant to a new tube. One volume (500µl) of 70% ethanol was then added
to the supernatant and the sample mixed well by repeated pipetting. A maximum
of 700µl of the sample, including any precipitate, were added to an RNeasy® mini
column and placed in a 2ml collection tube. The column was washed twice in
RPE buffer and dried by centrifugation as per the manufacturer’s protocol. The
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RNA was then eluted from the column in 30µl of RNase-free water and the eluate
reapplied and eluted from the column to increase the yield and concentration of
the RNA obtained.

IV.2.2.2 Assessment of RNA Quality
The obtained RNA samples were applied to RNA 6000 Nano LapchipsTM
(Agilent Biotechnologies, Inc.) and subjected to capillary electrophoresis using an
Agilent® 2100 Bioanalyzer. The protocol followed was identical to that described
in the company’s technical brochure for the Agilent® 2100 Bioanalyzer. The
amount and quality (RIN value) of RNA from each core biopsy was then
determined by the Bioanalyzer.

IV.2.3 Serial SPECT-CT Imaging
IV.2.3.1 Sesta-MIBI Scans
99m

Tc-labelled sesta-MIBI scintimammography was performed on the

LABC patients enrolled in the study (see IV.2.1) at the following time points: at
the time of clinical diagnosis of LABC, in the middle of neoadjuvant
chemoradiation therapy with FEC-D (after FEC chemotherapy was completed
and prior to initiation of weekly docetaxel/radiation), and at 5 weeks posttreatment (immediately prior to surgery).
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IV.2.3.2 Sesta-MIBI Injection, Scanning Protocol and Analysis
Patients underwent MIBI imaging (GE Infinia GP3 Hawkeye 4 SPECT/CT
scanner) using the prone lateral imaging technique, which allows visualization of
the breast tumour without contamination by the overlaying structures [38, 39].
99m

Tc-labelled sesta-MIBI (Lantheous, Montreal QC) was injected via gauge 20

catheter placed in the patient’s arm contralateral to the breast tumour lesion.
Patients underwent IV injection of 750MBq (20mCi)

99m

Tc-labelled sesta-MIBI,

followed by 30ml saline flush. Prone lateral imaging was performed 10min after
injection, and then at 3 hours post-injection. Images of the anterior, left lateral
and right lateral positions were acquired for each patient, using a high-resolution,
low-energy, parallel hole collimator, 512x512 matrix, no zoom, 15% energy
window centered at 140keV.
To measure MIBI washout [22, 40], a second MIBI scan was performed 3
hours post-injection. Care was taken to reproduce breast positioning compared
to early image; timing of both early and late scans relative to tracer injection was
carefully noted.
MIBI images were analyzed on XELERIS station (GE) using a method
routinely used at our centre. Briefly, circular region of interest (ROI) was placed
over the tumour on axial slice, which represented a maximum count from the
tumour. Background (Bkg) counts were obtained from the same ROI/area from
the opposite breast. The same process was repeated on early and delayed
images. Count number was corrected for decay to obtain accurate calculations.
Wash-out calculation was performed using the following formula:
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Lesion-to-normal breast (L:N) ratios were used to analyze MIBI uptake.
Changes in MIBI uptake with therapy were expressed as the percentage of
baseline L:N ratio and were compared with different categories of response to
therapy. If the efflux was more than 30% of the baseline, the tumour was
classified as chemotherapy resistant (R); conversely, equal to, or less than 30%
washout led to tumour classification as chemotherapy sensitive (S) [40].
Statistical analysis was performed using SAS statistical software, with
significance level set to p<0.05.

IV.2.4 Ex vivo Tumour Studies
IV.2.4.1 Protocol Rationale and Patient Recruitment
The OncoScreen® chemosensitivity assay was selected to test whether a
3D human tumour culture tool could be used to individually predict patient
responsiveness to neoadjuvant chemotherapy. Patients were recruited as
described in Section IV.2.1 and Chapter 2. Tissue samples were obtained from
32 adult females between the ages of 35 and 88, diagnosed with invasive
mammary carcinoma and undergoing a neoadjuvant clinical trial of FEC
chemotherapy followed by weekly docetaxel concurrent with locoregional
radiation prior to modified radical mastectomy (see Chapter 2). Samples were at
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baseline (i.e. prior to all chemotherapy), mid-way through FEC regimen (but prior
to radiation), and following docetaxel and radiation, just prior to surgery.

IV.2.4.2 Tumour Tissue Sample Handling
Tissue samples were received directly from the diagnostic imaging
department where image guided biopsy samples were taken, and placed in a
sterile phosphate-buffered saline solution at 4oC, within minutes of acquisition.
The sample was transported to the laboratory where it was placed into a
dissecting dish with a small amount of sterile buffer solution to cover the tissue.
Using a scalpel and forceps, the tissue was cut into 1-3mm pieces, dissecting
away any normal or non-viable material. The pieces were then washed with
sterile saline to remove any remaining blood and debris.

IV.2.4.3 Tumour Invasion Assay
The tumour invasion of the biopsied tumour pieces was assayed using a
collagen gel system. Briefly, a single piece of tissue was placed into the center of
each well of a 48-well plate containing 0.25ml matrix mixture, ensuring the
placement of each tissue fragment as close to the center of the well as possible.
The gel was then permitted to set at room temperature, or at 37oC non-CO2
incubator. Each well was overlaid with 0.25ml tissue culture media containing
20% serum to achieve a final volume of 0.5ml per well. Collagen type I gel
(Vitrogen 100, Cohesion Technologies, Palo Alto, CA) was added to the matrix
buffer at a concentration of 1mg/ml and mixed, adjusting the pH to 7.4.
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To assess tumour invasion in response to treatment of breast cancer cells
with standard breast cancer chemotherapies, 48-well plates were again seeded
with fresh tissue from patients in six replicates. Tissues were either left untreated
(control) or treated with the following individual chemotherapeutic agents: FEC
(5-fluorouracil (5-FU), epirubicin (epi), cyclophosphamide (cyclo)) or docetaxel
(doc). The recommended intravenous therapeutic dosage for patients was used
and reconstituted into 0.5ml total, and added to each well (5-FU 10µg/ml; epi
4µg/ml; cyclo 20µg/ml and doc 3µg/ml). Plates were maintained at 37oC with 5%
CO2 for 5 days, monitoring cell movement and invasion on days 1, 3 and 5. A
screen was only deemed valid if there was cell movement or outgrowth from the
main tumour sample in at least two of the six replicate wells. This was done on
two separate 48-well plates per patient: one plate was irradiated (0.8Gy using
60

Cobalt γ-radiation) while the second plate was not, in order to mimic ex vivo the

treatment being received with concurrent chemoradiation in vivo (R-control, RFEC, R-Doc).

IV.3 RESULTS
IV.3.1

Clinical Responses and Toxicities of FEC-D Neoadjuvant
Chemoradiotherapy
While 30 of the 32 patients (94%) completed the treatment protocol

described above, patients did experience significant toxicities. Twenty-seven
patients (84%) had grade 3 or greater toxicities, including grade 3 resolving
pneumonitis (6 patients), grade 3 dermatitis (6 patients) and one treatment-
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related death. Eight of these patients (23%) exhibited a pathologic complete
response (pCR) to treatment (Table 2.3), which is approximately twice the
Ontario pCR rate for locally advanced breast cancer (10%, unpublished data)
and significantly higher than the 14% pCR rate seen in 81 matched controls (see
Chapter 2). Moreover, at three years median follow-up, the relapse-free survival
rate was 100% in the pCR cohort and 65% among partial responders (PRs).
This suggests that the regimen, while exhibiting strong toxicity, appears to
enhance the pCR and shows a trend toward a 15% improvement in disease-free
and overall survival in locally advanced breast cancer patients.
Tumours that exhibited pCRs were distributed almost equally amongst the
basal (2 of 5 tumours = 40%), Her2 (3 of 3 tumours = 100%), and luminal B (3 of
6 tumours = 50%) subtypes. No pCRs were found among the 11 patients with
luminal A tumours (0%). While the numbers are small, the data suggests that
FEC-D regimen with concurrent radiation appeared able to induce pCRs across a
variety of breast cancer subtypes, except for the luminal A subtype. This
supports existing data in the literature that pCR is a good surrogate for survival
with the exception of luminal A subtype [41].

IV.3.2

Changes in Tumour RNA Content in Response to FEC-D
Neoadjuvant Chemoradiotherapy
We then assessed whether, similar to the NCIC-CTG-MA.22 clinical trial,

changes in tumour RNA quality or quantity could be observed during or in
response to treatment and whether low RNA quality was associated with a strong
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clinical response the completion of treatment (i.e. pCR). Figure IV.1 illustrates the
RNA concentration values for all patient biopsies isolated prior to treatment, in
the middle of treatment, and post-treatment. The plot shows that there was some
significant variability in the quantity of RNA isolated from the biopsies throughout
treatment, including pre-treatment biopsies. This suggests possible variations in
the preservation of RNA in the collected biopsies and time-dependent
degradation at the time of tissue processing. In addition, the data suggests little
difference in RNA content between pre-treatment biopsies and biopsies collected
after FEC chemotherapy (mean tumour RNA concentration of 50.0±15.1 and
50.0±11.9ng/µl, respectively). In contrast, the mean tumour RNA concentration
fell significantly after the completion of the FEC-D regimen with concurrent
radiation (10.6±2.1ng/µl, p<0.05). These findings suggest that the FEC
chemotherapy alone is insufficient to induce reductions in tumour RNA content,
but upon treatment with concurrent radiation therapy and docetaxel, tumour RNA
content falls dramatically. Despite this treatment effect, no significant differences
in tumour RNA content were observed amongst patients that exhibited a
pathologic complete response post-treatment (pCR), patients that exhibited a
partial response to treatment (PR), and patients with stable or progressive
disease (SD or PD) post-treatment (Figure IV.2).

RNA Concentration (ng/µl)
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Figure IV.1. Changes in tumour RNA concentration during treatment of
locally advanced breast cancer. There was a significant decrease
in tumour RNA content in response to treatment with docetaxel
followed by radiation therapy (* signifies p<0.05).
FEC, fluorouracil-epirubicin-cyclophosphamide; D-RT, docetaxel
concurrent with radiation therapy.
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Figure IV.2. Changes in tumour RNA content (A) pre-treatment, (B) during
treatment and (C) post-treatment of locally advanced breast
cancer. No changes in tumour RNA content were observed
amongst patients exhibiting pCR, PR or NR (both SD and PD).
pCR, pathological complete response; PR, partial response; NR, no
response; PD, progressive disease; SD, stable disease.
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IV.3.3

Changes in Tumour RIN Values in Response to FEC-D
Neoadjuvant Chemoradiotherapy

To assess changes in tumour RNA content during FEC-D chemotherapy with
concurrent radiation treatment, all samples that were noted as “insufficient signal”
for mathematical analysis were omitted. As shown in Figure IV.3A, in the three
samples post-FEC chemotherapy but before docetaxel/radiation treatment (which
achieved a pCR at the end of treatment), 2 out of 3 samples demonstrated RIN
values indicative of high RNA integrity or minimal RNA degradation (RIN >7).
Only one patient sample had a very low RIN value suggestive of significant loss
of RNA integrity (RIN value = n/a or 0). In the samples from non-responding
patients (patients who did not achieve pCR post-treatment), no effect of FEC
treatment could be discriminated using RIN. These results suggest that FEC
treatment may have an effect on RNA disruption, but this effect did not appear to
be associated with a pCR post-treatment, since only 1 out of 3 adequate samples
demonstrated this effect.
When tumour RNA integrity was assessed, after both the FEC
chemotherapy and docetaxel/radiation treatment, only two samples from patients
that achieved a pCR post-treatment had sufficient RNA for mathematical analysis
(Figure IV.3B), presumably because there was no viable tumour left in the biopsy
sample from which to extract RNA, and/or that what was thought to be tumour by
image guidance actually represented only stromal fibrosis rather than residual
tumour. For these two samples, both had RIN values of n/a or zero, indicative of
very strong loss of RNA integrity. These two responders to treatment were
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Figure IV.3. Changes in tumour RNA integrity in response to treatment of
locally advanced breast cancer: (A) mid-treatment and (B)
post-treatment. Following FEC (but prior to docetaxel) and
radiation, the responders (patients achieving pCR) had a varied
RIN level similar to non-responders (patients NOT achieving pCR),
while after concurrent chemoradiation, all responders had low RIN
levels, consistent with a treatment-related effect on RNA integrity.
RIN, RNA integrity number
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strongly distinct from non-responders based on RNA concentration and RIN
values. The low RIN values are indicative of loss of normal RNA. In the nonresponders, a wide range of RIN values are noted which is indicative of a
spectrum of change in tumour RNA from highly fragmented to highly intact.
These results suggest that loss of RNA integrity occurred with radiation and
docetaxel resulting in decreased RIN values and a loss in RNA concentration.
This loss of RNA integrity correlated with a strong response to treatment (pCR).

IV.3.4 Sesta-MIBI Serial SPECT-CT Imaging of LABC Tumours in Response
to FEC-D Neoadjuvant Chemoradiation Treatment
Of 32 patients included in the study, 2 patients failed to complete the full
MIBI protocol; these were then excluded from the study. Of the remaining 30
patients, tumours of 25 patients (83%) were found to be chemotherapy sensitive
at baseline, 28 during mid-treatment (93%), and 22 out of 22 post-treatment
(100%) (Figure IV.4). Chemotherapy sensitivity is presumed when a washout
index of less than 30% is seen. With a low washout index, the cell's inability to
efflux the cytotoxic chemotherapy is expected to result in damage to the cell in
accordance with the molecular mechanism of cell death specific to whichever
chemotherapy is delivered. Of those patients who achieved a pCR response to
neoadjuvant chemoradiotherapy, pCR sensitivity was 8 out of 8 (100%). The
sensitivity of the MIBI SPECT-CT imaging in the PR/SD cohort of patients was 17
out of 22 (77%) (difference of 23%) (Figure IV.5), which was not statistically
significantly significant (p=0.287).
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Figure IV.4. The tumour sensitivity to concurrent neoadjuvant chemoradiation, as demonstrated by SPECT-CT imaging of sestaMIBI washout. At baseline, 83% of patients demonstrated
sensitivity to chemotherapy; at mid-treatment, 93% of patients were
sensitive, and post-treatment, 100% sensitivity was achieved.
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Figure IV.5. The tumour sensitivity (mean ± 95% exact confidence interval)
to concurrent neoadjuvant chemo-radiation, as a function of
pCR. Among the 8 patients who achieved a complete pathological
response, low washout index (and, therefore, chemosensitivity) was
seen in all 8/8 (100%) patients. In the remaining 22 patients who
demonstrated
chemotherapy,

a

partial
17/22

response

or

stable

(77.3%)

patients

disease

to

demonstrated

chemosensitivity by washout index (p=0.287, Fisher exact test).
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IV.3.5 Ex vivo Tumour Studies
The number of tumour samples demonstrating growth (invasive cells seen
beyond the tumour sample invading into the surrounding Matrigel®) was
significantly impacted by the in vivo treatment. At baseline, prior to chemotherapy,
100% of the 32 patients had tumours that exhibited growth using this invasion
assay. After FEC chemotherapy, 17/32 (53%) of tumour samples exhibited
growth. Following combined docetaxel and radiation, 7/23 (30%) of tumour
samples demonstrated growth using this ex vivo model. Therefore, the ex vivo
model appears to be most effective as an invasion assay when the baseline
untreated patient tumour samples are used. The pre-treatment, mid-treatment
and post-treatment mean tumour growth (as a percentage of control to account
for intra-tumoural heterogeneity) was calculated for tumour samples cultured with
FEC chemotherapy, DOC (docetaxel), R-FEC (FEC chemotherapy while also
radiated at 0.8Gy to mimic radiosensitizing chemotherapy) and R-DOC
(docetaxel chemotherapy while also radiated at 0.8Gy) (Figure IV.6). There was
wide variety of responses both within patient wells and between patients treated
with the same chemotherapy regimens, resulting in large standard error bars. As
a result, these results do not demonstrate a clear reduction in growth with any
particular chemotherapeutic agent, even when tumour growth is personalized
(calculated as a proportion of the same tumour sample cultured alone, as a
control). The only visual difference is seen in the radiated docetaxel samples,
where the mid- and post-treated samples appear to show less tumour growth
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Figure IV.6. The tumour sensitivity to concurrent neoadjuvant chemoradiation, as demonstrated by the in vivo 3D gel invasion
assay. Tumour growth sizes were obtained from core biopsies pretreatment, mid-treatment and post-treatment. While not statistically
significant, docetaxel appeared to exhibit a radiosensitizing trend.
PRE, pre-treatment; MID, mid-treatment; POST, post-treatment.
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than the pre-treated samples, perhaps demonstrating a radiosensitizing trend
with the use of docetaxel not seen with chemotherapeutic agents alone.
Using the baseline pre-treatment samples of tumours exposed to FEC,
DOC, R-FEC and R-DOC, the patients who achieved a pCR in response to the
neoadjuvant regimen were compared to the non-pCR patients treated the same
way (Figure IV.7). Of the patients that had achieved pCR, docetaxel alone
resulted in 43% of baseline tumour growth, while addition of radiation further
reduced the tumour growth to 34% of baseline. The radiated tumour samples
appear to differ in the pCR cohort from the non-pCR cohort. The tumour samples
radiated while exposed to FEC appear to have a higher growth in the pCR cohort,
which is difficult to explain. In the pCR patient cohort, the tumour growth was
much lower when exposed to concurrent docetaxel and radiation (R-DOC) than
in the non-pCR cohort (p=0.046).
The tumour growth seen in baseline untreated tumour samples exposed to
FEC, DOC, R-FEC and R-DOC were statistically analyzed using Wilcoxon Rank
Sums two-sided test to determine whether baseline growth predicted for death or
recurrence of disease. The baseline DOC growth ex vivo appeared to best
predict for recurrence or death (p=0.039), while the others did not (FEC p=0.71;
R-FEC p=0.14; R-DOC p=0.29).
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Figure IV.7. The tumour sensitivity to concurrent neoadjuvant chemoradiation, as a function of pCR, in the in vivo 3D gel invasion
assay. Tumour growth sizes were obtained from core biopsies.
Docetaxel

with radiation appeared to exhibit a radiosensitizing

trend in patients exhibiting pCR response (p=0.046).
*p<0.05 from non-pCR group
FEC, fluorouracil-epirubicin-cyclophospamide; DOC, docetaxel; RFEC, radiation with FEC; R-DOC, radiation with DOC.
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IV.4 DISCUSSION AND CONCLUSIONS
This study was the first to use a full chemotherapy regimen with radiation
in the neo-adjuvant setting for LABC. Although this regimen was not without
toxicity, concurrent chemo-radiation significantly improved the surrogate marker
for survival in this high-risk group, resulting in a much-improved outcome, even at
short-term follow-up.
Of the tumour samples that provided sufficient RNA for analysis, RIN
values appear to predict treatment response, particularly to taxane-based
chemotherapy regimens. RNA concentration was lowest in tumour samples after
concurrent chemoradiation with docetaxel. It may be that the radiosensitizing
effects of docetaxel amplifies the genomic damage induced by external beam
radiation, mimicking the improvement in clinical outcomes as a result of this
combined therapy. Unfortunately, RNA testing revealed that many samples had
undergone RNA degradation, likely as a result of prolonged transport time in PBS
prior to being placed in RNA preservative. In order to fully evaluate the impact of
RNA integrity as a predictive test for both neoadjuvant chemotherapy and
radiation, these tests should be repeated prospectively, with samples being
placed directly from the biopsy needle into RNA preservative.
The sesta-MIBI SPECT-CT imaging study demonstrated that, among the
pCR cohort, this test had 100% sensitivity in predicting patient sensitivity to
chemoradiation

treatment.

However,

because

the

sensitivity

for

partial

responders and non-responders was still high at 77%, this test does not
discriminate sufficiently whether patients will respond to systemic treatment to be

247
a clinically useful test. The serial use of sesta-MIBI SPECT-CT imaging appears
to show an increasing sensitivity to treatment over time. This is probably due to
the possibility that a maintained efflux of MIBI substrate resulting in a low
washout index over time in patients receiving chemotherapy and/or radiation may
no longer be indicative of drug efflux capacity in tumour cells, since the posttreatment sensitivity to chemotherapy was 100%, and yet only a quarter of these
patients achieved a pCR in response to chemotherapy. Perhaps it becomes
difficult to determine where to measure washout of MIBI substrate when there is
a treatment change in the imaged tumour, resulting in a falsely low washout
index as treatment progresses. Further evaluation of this functional imaging
modality would be helpful in elucidating the mechanisms around substrate and
drug washout as measured serially in breast tumours receiving neoadjuvant
treatment.
The 3D ex vivo OncoScreen® chemosensitivity assay model showed a
wide variety of growth rates in response to the regimens given to these patients
when assessed serially during treatment. As a result, there does not seem to be
any visible trend in tumour growth over time, other than an apparent reduction in
tumour growth in samples treated with docetaxel while concurrently radiated,
perhaps demonstrating a radiosensitizing phenomenon. Further studies are
required to elucidate this. The most interesting finding was that tumour growth
appeared significantly inhibited by concurrent radiation and docetaxel in the
patients who achieved a pCR compared to those who did not. Again, these are
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preliminary findings, but do suggest that more studies should be done to exploit
the radiosensitizing effects of taxane chemotherapies in breast cancer patients.
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